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Introduction to signaling 
during early embryonic 
development





The perpetuation of animal life across uncountable generations is dependent on the remarkable 
fact that from a single cell, a complex organism is formed. How is it possible that from a single cell, 
then a lump of cells, finally all these dividing cells know where to go and what to do to form a new 
viable generation?  According to Lewis Wolpert, “it is not birth, marriage or death but gastrulation 
which is truly the most important time in your life”. Indeed, gastrulation, the process of cellular 
arrangements (epiboly, internalization, convergence and extension) after an initial stage of cell 
division following fertilization is a complex event that sets the stage for further developmentin all 
vertebrates. Embryonic development is highly predictable and can be studied more easily in some 
animal models than others. Compared to mammals which develop in utero, fish embryos are 
staged and imaged easily during development [1].
Primary cell divisions
Fish development starts with a large yolk syncytium with the oocyte sitting at the animal pole. 
After fertilization, the zygote starts to divide and initially forms a large lump of cells on top of the 
yolk known as the blastoderm. The blastoderm consists of three cell layers: mesenchymal deep 
cells that will give rise to the embryo proper. The deep cells are surrounded by a protective layer 
of epithelial enveloping layer cells (EVL). The most vegetal cells of blastoderm fuse with the yolk 
to form a multi-nucleated structure known as the yolk syncytial layer (YSL). The EVL acts as a 
protective layer for the deep cells, which are tightly attached to it. Likewise, the YSL is attached to 
the EVL. Initially, messenger RNA is maternally provided, yet after 2.5 hours post fertilization 
(hpf), zygotic transcription is initiated and maternal mRNA is cleared by miR-430 at 4hpf [2].
Epiboly
At sphere stage, or four hpf, a process called epiboly causes the deep cells to move over the yolk 
towards the vegetal pole, much like a knitted hat being pulled over your head (figure 1). First, 
intercalation of the deep cells to more superficial layers cause a thinning and spreading of the 
tissue. Not only cell migration but also changes in cell shape drive this process. These initial cell 
movements cause the embryo to shape itself from a ‘sphere’ towards the ‘dome’ stage. Further 
vegetal movement of the deep cells is caused by the pulling of the YSL and the attached EVL. This 
is partially mediated by microtubuli, which are attached to an actin meshwork at the vegetal pole 
of the yolk. Additionally, massive endocytosis in the YSL vegetal of the EVL attachment also 
mediates epiboly independent of microtubuli [3]. 
Involution 
At about 50% epiboly, cells start to move inwardly in a process called internalization or emboly. 
This will form the germ ring. Notably, at the ventral and medial parts of the embryo this occurs 
via involution of sheets of cells, while at the dorsal region this occurs via the ingression of 
individual cells. These processes give rise to the different cell layers endoderm, mesoderm and 
ectoderm. The internalizing mesendodermal cells move inwardly towards the animal pole, 
forming the hypoblast. Meanwhile, the overlaying cells that do not move inwardly (epiblast) will 
form the ectoderm and continue epiboly. 
Convergence and extension
At 6hpf, cells accumulate dorsally from the lateral and ventral regions of the embryo in a process 
called convergence. Meanwhile, lengthening of the embryonic axis occurs by cells intercalating 
and moving anteriorly in a process called extension. Together, these processes are termed 
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convergence and extension (C&E) which 
mediates the anterio-posterior lengthening and 
medio-lateral thickening of the embryo forming 
the longitudinal axis. Additionally, cells moving 
inwardly at the dorsal side of the embryo form a 
thickening called the shield, which functions in a 
similar way as the Spemann-Mangold organizer 
in other vertebrates like Xenopus and mouse, 
thus calling this stage the ‘shield’ stage. 
Cells more lateral to the shield move slower than 
cells close to the shield. Several cellular 
movements can be distinguished in several 
areas of the embryo. From more ventral to dorsal 
these are: 1) vegetal pole migration in the 
ventral mesoderm, 2) slow dorsal convergence 
along irregular paths, 3) cell packing (fast and 
efficient convergence) in the lateral mesoderm, 
4) medial planar intercalations and 5) polarized 
radial intercalations in the medial presomitic 
mesoderm. Most dorsally in the axial mesoderm, 
cells show 6) anterior-directed migration and 7) 
mediolateral intercalations [4]. 
Figure 1. Schematic representation of 
zebrafish development from the Zygote 
Period to the end of the Gastrulation Period.
 
Following the brief zygote period (a/b), when the 
embryo is at the single-cell stage, the cleavage 
period (c-d) runs from the two-cell to the 64-cell 
stage (i.e. 0.75–2.25 h post-fertilization (h.p.f). (h–
p) The blastula period follows the cleavage period 
and runs from the 128-cell stage to the 50% epiboly 
stage (i.e. from 2.25 to 5.3 hpf). (e-f) Formation of 
the enveloping layer (EVL) and yolk syncytial layer 
(YSL). (g–p) The gastrula period then runs from the 
end of the blastula period at 50% epiboly (i.e. 5.3 
hpf) through to the bud stage at 10 hpf, after which 
the segmentation period begins. Cell movements 
of convergence and extension (indicated with the 













2 Signalling in gastrulation
Non canonical Wnt signalling
Convergence and extension cell movements are mediated by multiple signalling pathways that 
drive cell migration, adhesion and cell polarization. A principal pathway regulating C&E is the 
non-canonical Wnt/planar cell polarity (PCP) pathway [5]. The PCP pathway was first discovered 
in Drosophila, where mutants for components of the, then unknown, PCP pathway showed 
unorganized (unpolarized) wing epithelia. Later, disruption of the PCP pathway showed reduced 
body axis and neural tube defects in vertebrates [5]. In zebrafish, the core non-canonical Wnt/
PCP pathway consists of extracellular Wnt glycoproteins, Wnt5 and Wnt11. Mutants for these 
Wnts (pipetail and silberblick, respectively) were identified in the late 90’s [6,7] having defects in 
forebrain development and tail formation, respectively. The Wnts are able to bind the Frizzled 2/7 
and the co-receptor glypican 4/Knypek a heparan sulphate proteoglycan [4]. Binding of Wnt to 
Frizzled causes intracellular recruitment of Dishevelled by its PDZ domain. Dishevelled in turn 
recruits Daam1, which causes RhoA, a small GTPase, activation. Additionally, Dishevelled 
activates the other small GTPases Rac1 and Cdc42. RhoA and Rac1 elicit activation of other 
downstream kinases, ROCKII and Jun kinase, respectively, which cause cytoskeletal 
rearrangements while Rac1 exerts its function on protein kinase C [4]. Other non-canonical Wnt 
pathways may regulate gastrulation as well. Ror2, the tyrosine kinase receptor for Wnt5, is able 
to modulate expression of paraxial protocadherin (PAPC) in Xenopus [8]. PAPC is an important 
regulator of cell adhesion and gastrulation [9]. Convergence and extension cell movements are 
also mediated through the Src family kinases Fyn and Yes, which are controlled upstream by Csk 
[10]. Interestingly, Fyn/Yes signalling acts parallel to non-canonical Wnt signalling, both of which 
act on RhoA downstream [11]. Additionally, maternally contributed canonical Wnt signalling 
activates Stat3 on the dorsal side of developing embryos [12]. Stat3 morphant embryos show C/E 
defects without affecting cell fate. More recently, ofd1, a gene associated with oral-facial-digital 
type 1 syndrome, which is required for ciliary motility and function was shown to interact 
genetically with components of the non-canonical Wnt pathway. Loss of ofd1 results in shorter 
and wider embryos, indicating a role for cilia in C/E movements as well [13]. 
Cell-cell adhesion
Epiboly movements are severely impaired in zebrafish embryos of the E-cadherin mutant half 
baked. Cells deficient for E-cadherin are able to migrate, but are unable to undergo mesenchymal 
to epithelial transition necessary for proper intercalation movements during epiboly [14]. The cell 
adhesion molecule PAPC also regulates C/E by activation of RhoA and JNK [9]. Moreover, the 
trimeric G-proteins Gα12 and Gα13 mediate Rho activation, and mutants show C/E defects while 
their cells exhibit a rounder shape [3]. 
MAPK signalling
The Src family kinases Fyn and Yes not only control non-canonical Wnt signalling, but also control 
MAPK signalling. Mitogen activated protein kinase (MAPK) signalling is crucial for zebrafish 
development. For example, while partial knockdown of Erk1 causes convergence defects, partial 
loss of Erk2 results in extension defects, showing distinct functions of these kinases [15]. Notably, 
while more complete loss of Erk1 only mildly affects epiboly, Erk2 knockdown results in a 
developmental arrest at the onset of epiboly. Interestingly, loss of Erk1 is rescued by expression of 
Erk2, but not vice versa, indicating a prerequisite function of Erk2 during gastrulation [15]. 
Interestingly, also expression of activating forms of NRas, BRaf and Mek induce gastrulation 
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Figure 2. A Schematic representation of the Shp2, its binding sites and disease associated 
mutations. 
A) Schematic representation of Shp2 protein, indicating the N terminal (N-SH2) and C-terminal (C-SH2) 
SH2 domains (yellow and green respectively), the catalytic protein-tyrosine phosphatase (PTP) domain 
(blue) and C-terminal tail (red). Many upstream kinases phosphorylate Shp2 on its tyrosines to regulate 
its activity, including the Src family kinase Fyn, Abl and EphA2. Upstream binding sites of receptors, 
including receptor tyrosine kinases (RTKs), Integrins and G-Protein Coupled Receptors (GPCRs), bind to 
the tandem SH2 domains of Shp2 when they are phosphorylated. Of particular note are Immunoreceptor 
Tyrosine Inhibitory Motifs (ITIMs) which are tyrosine motifs that are aptly spaced for Shp2 tandem 
SH2 binding. The arginines 32 and 138 are essential for the binding properties of Shp2. SH2 dependent 
functions of Shp2 include interactions with p53 and RhoA. The catalytic cysteine 460 is essential for 
the phosphatase function of Shp2, whereby mutation of C460 to serine completely abrogates its activity. 
Known PTP substrates are ROCKII, p85, Stat3 and Gab1. The C terminus of Shp2 contains two tyrosines 
and a proline rich region (PRR). Proteins known to associate with Shp2’s C-terminus are Grb2 and Fyn. 
Activation of Shp2 is essential for downstream signaling pathways including the ERK and AKT pathways. 
Mutations associated with Noonan syndrome have been found mainly in the N-SH2 domain whereas 
LEOPARD associated mutations are found in the PTP domain, near the catalytic site. Whereas NS 
associated mutations result in enhanced PTP activity, LS mutations result in decreased PTP activity. In the 
studies described in this thesis, the NS mutations D61G and T73I, and the LS mutation A462T and G465A 
are mainly used. See text for further details.B) Crystal structure of Shp2. Structures in top and bottom 
are in similar orientations. The N- and C-terminal SH2 domains are yellow and green, respectively; the 
catalytic PTP domain is blue, and interdomain linkers (residues 104–111 and 217–220) are white in both 
panels. Top: Ribbon diagram showing secondary structure and organization of the domains. Orange, the 
side chain of Cys459 (the catalytic nucleophile); dashed lines, disordered loops. Bottom: All nonhydrogen 
atoms of SHP-2 are displayed. Although SH2 domain–bound peptides are not present in the structure, 
residues of both domains known to contact phosphopeptides are colored red. Note that peptide binding 
sites of both SH2 domains are exposed on the molecule surface. A distinct surface of the N-SH2 domain 
occupies the active site of the PTP domain. Magenta, residues of the PTP signature motif, HCSAGIGRS; 




defects [16,17]. Hyperactivation of the MAPK pathway results in C/E defects similar to knockdown 
of Erk1/2, suggesting a tight balance between activation and inactivation of this signalling 
pathway. Indeed, phenotypes resulting from hyperactive forms of BRaf and Mek are rescued 
using small molecule inhibitors of Mek, restoring the physiological levels of Erk1/2 activation 
[16,17]. What is more striking is that a treatment during a temporal window of 1 hour prior to 
shield formation is sufficient to rescue the gastrulation defect and later phenotypes. This indicates 
that, during shield stage, a tight balance between activation and inactivation of the MAPK pathway 
is important for proper development [16,17].
 4 Shp2 
Several studies have shown that the non-receptor tyrosine phosphatase SHP2 plays a fundamental 
role during gastrulation [18-20]. In zebrafish, knockdown of Shp2 results in defective gastrulation 
cell movements, without affecting cell fate specification  [18]. In Xenopus, Shp2 is required for 
mesoderm induction and completion of gastrulation [21]. A study in Shp2 homozygous mutant 
embryonic stem cells showed that Shp2 is required at the initial steps of gastrulation, and that 
Shp2 mutant cells do not properly respond to signals initiated by fibroblast growth factors [20]. 
SHP2 is encoded by the PTPN11 gene in humans. The importance of SHP2 in human genetics arose 
with the discovery that mutations in the PTPN11 gene are the main cause of Noonan and LEOPARD 
syndromes, two autosomal dominant disorders with overlapping clinical features [22,23]. Due to 
a partial genome duplication in teleosts, the zebrafish genome encodes two Shp2 genes, ptpn11a 
and ptpn11b coding for the proteins Shp2a and Shp2b. Both Shp2a and Shp2b are derived from a 
common Shp2 ancestor [24]. SHP2 consists of two Src homology 2 (SH2) domains in tandem, a 
tyrosine phosphatase domain and a C-terminal tail [25] (Figure 2). 
The SH2 domains of SHP2 are able to bind to phosphorylated tyrosines and thereby mediate 
binding of Shp2 to its target sites. Under basal conditions, Shp2 is kept in an ‘inactive’ closed state, 
whereby the N-terminal SH2 domain blocks the active site of the PTP domain to prevent 
dephosphorylation of its target sites [25]. The C-terminal SH2 domain however, is able to bind to 
tyrosyl phosphorylated SHP2-specific binding sequences and promote binding. Since SHP2 
contains two SH2 domains in tandem, most SHP2 target proteins have tandem tyrosyl 
phosphorylation sites. Once the C-SH2 domain engages the target sequence, the tandem N-SH2 
domain is prone to bind the other phosphorylation site by which SHP2 adopts an ‘open’ structure. 
Opening the structure of SHP2 causes an availability of the PTP domain, which facilitates 
dephosphorylation of its targets (Figure 3). These do not have to be the binding partner of SHP2 
itself, but may also be other proteins in the complex [26]. 
Dephosphorylation of SHP2 target proteins is one of the mechanisms whereby Shp2 activation 
exerts its activity to activate downstream signalling pathways [27]. In Xenopus, a mutational 
analysis was performed to study the role of Shp2 in mesoderm induction following basic-
fibroblast growth factor (bFGF) induction. Whereas the C-terminal SH2 domain is necessary only 
for wild-type function of Shp2, the N-SH2 domain and PTP activity are indispensable for Shp2 
function [21]. The C-terminal tail, however, appears to be dispensable for Shp2 function. 
Alternatively, Shp2 may exhibit adaptor like activity, since EGF induced PI3K activation is 
enhanced by wild type- and phosphatase dead Shp2, but not by a Shp2 mutant that is unable to 
bind to its target [28].
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Other studies suggest a role for the C-terminal domains of SHP2 [29]. The C-terminal tail of SHP2 
consists of a proline rich domain, which is able to bind a Src homology 3 (SH3) domain, flanked by 
two tyrosines (Y542 and Y580 in zebrafish), which may be bound to SH2 domains. This suggests a 
role for SHP2 as an adaptor protein, while the C-terminus has also been opted to play a role in the 
conformational ‘opening’ and ‘closing’ of the phosphatase [30]. The upstream growth factor 
signalling pathway seems to have a decisive role in Shp2-mediated signaling, since C-terminal 
phosphorylation is mediated by FGF and PDGF, but not by EGF and IGF [29].
Despite the crucial role of SHP2 during gastrulation cell movements, little is known about the 
implication of the gastrulation defects on later development. For example, knockdown zebrafish 
embryos for Shp2 show defective gastrulation cell movements at 10 hpf and craniofacial/heart 
defects at 4 dpf [18]. However, it is poorly understood if the gastrulation cell movement defects 
are the direct cause of the later developmental defects and how the aberrant behavior of cells 
during gastrulation contribute to the impairment of development of other organs. 
Figure 3. Regulation of Shp2 in the wild-type state and in Noonan and LEOPARD syndrome. 
A) In the basal state, Shp2 is largely inactive, because the backside loop of the N-SH2 is inserted into the 
catalytic cleft. This results in mutual allosteric inhibition, with the N-SH2 inhibiting the PTP domain and 
the PTP domain contorting the pTyr peptide-binding pocket of the N-SH2 on the opposite surface. Shp2 
activation starts when the two pTyr sites (pY), one that binds the C-SH2 and the other that binds the N-SH2, 
contacts Shp2. The C-SH2 is engaged first by its pTyr ligand. The resultant increase in local concentration 
of the ligand for the N-SH2 overcomes mutual allosteric inhibition, resulting in binding of the N-SH2 to its 
pTyr ligand, thus opening the enzyme into an active conformation. This mechanism of activation is strongly 
supported by crystal structure data and multiple enzymological studies [25]. Activation of Shp2 results in 
substrate dephosphorylation with release of phosphate. B) Regulation of Shp2 activity is, in part, achieved 
by an intramolecular interaction between the PTP domain of the protein and the N-SH2 domain leading to 
a "closed" protein conformation and autoinhibition. In the wild-type situation, "opening" of the N-SH2 and 
PTP domains is required for the protein to become active. NS mutations affect the interaction between the 
N-SH2 domain and the PTP domain, resulting in a protein that is in an “open” conformation and always 
active. LS mutations reside in the PTP domain and impair the catalytic activity of Shp2, resulting in a 





























Interestingly, not only knockdowns of Shp2 induce gastrulation cell movement defects, but also 
expression of mutant Shp2 with mutations that were identified in human patients with Noonan 
Syndrome or LEOPARD syndrome. These embryos show defects at later stages that are a 
phenocopy of the symptoms observed in human patients, including short stature, hypertelorism 
and cardiac defects [18]. Moreover, the contribution of Shp2 on gastrulation signaling pathways 
and its direct substrates still need to be addressed. Detailed analysis of the role of Shp2 during 
gastrulation may provide insight into the function Shp2 in Noonan and LEOPARD syndrome.  
Outline of this thesis
Recent complementary in vivo, in vitro and ex vivo experiments reveal new insights into the 
function of Shp2 in NS and LS. However, it remains unclear how GOF and LOF mutants of Shp2 
cause overlapping disease. In this thesis we investigate the role of NS and LS Shp2 using zebrafish 
as an animal model and the cellular and molecular mechanisms by which biochemically opposite 
Shp2 mutations result in two genetic disorders with overlapping features. The main theme of our 
projects was on NS and LS Shp2 in zebrafish, with Paardekooper Overman focusing more on the 
underlying molecular mechanism and Bonetti more on developmental aspects. We have indicated 
below who of the two of us is the main contributor to the different chapters.
In Chapter two (Paardekooper Overman) we describe several methods that are used to study 
phosphatases using zebrafish and techniques that we and others have developed to assess 
gastrulation defects and to assess changes in the phosphoproteome of developing zebrafish.
Chapter three (Bonetti) is an overview of the genetics of Noonan and LEOPARD syndrome and of 
molecular mechanisms that regulate these two genetic disorders. Moreover, we introduce the 
cardiac defects associated with Noonan and LEOPARD syndrome and the use of zebrafish as a 
model to study heart development.
In Chapter four (Bonetti) we study the phenotype of knock-out zebrafish embryos for both ptpn11 
genes. Shp2 has an essential role in embryonic development. Homozygous Ptpn11-/- mouse 
embryos die pre-implantation due to defective Erk activation and trophoblast stem cell death, 
precluding the possibility to study Shp2 function in differentiated cell types in adult animals [20]. 
Zebrafish embryo development occurs externally and the embryos are transparent, allowing the 
study of gene function in vivo. Due to partial genome duplication in teleosts, the zebrafish genome 
encodes two genes, ptpn11a and ptpn11b coding for the proteins Shp2a and Shp2b. We identified 
stop mutations in the N-terminal SH2 domain of each of the two ptpn11 genes and we study the 
phenotype of the single homozygous mutants and of double homozygous mutant embryos. 
In Chapter five (Paardekooper Overman) we describe the identification of Fer kinase as a 
candidate downstream factor in NS and LS signaling using a phosphotyrosine immunoprecipitation 
and mass spectrometry approach. Following that, we investigated the role of Fer kinase in the 
regulation of gastrulation and its role in the pathogenesis of NS and LS in zebrafish. 
In Chapter six (Paardekooper Overman), we identify PZR, an important binding partner and 
substrate of Shp2 involved in adhesion and cell migration, as a hyperphosphorylated protein in NS 
and LS in both mouse and zebrafish. We show that PZR is required for normal embryonic 
development in zebrafish. Moreover, we provide evidence that PZR exerts its effects by changing 
the flux of Src activation in NS and LS. 
Heart defects are the main cause of death in NS and LS patients. In Chapter seven (Bonetti) we 
investigate the role of NS and LS Shp2 in zebrafish cardiac development. We found that impaired 
heart function and morphogenesis are highly similar in NS- and LS-Shp2 expressing embryos. NS 
and LS-Shp2 both lead to up-regulation of Erk phosphorylation at the end of gastrulation, 
indicating a common biochemical pathway for NS and LS syndrome in zebrafish development. 
17
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The genetic cause of some 25% of all Noonan cases still remains to be determined. In Chapter 
eight (Bonetti and Paardekooper Overman), we describe the identification of mutations in Alpha-
2-Macroglobulin-Like-1 (A2ml1) as cause of a disorder clinically related to NS. We identified de 
novo mutations in A2ML1 using family-based whole exome sequencing of a case-parent trio with a 
clinical diagnosis of NS. Moreover, A2ML1 mutants were functionally characterized in zebrafish, 
showing that disease associated A2ml1 induces developmental defects, reminiscent of the 
developmental defects induced by a NS-variant of Shp2. 
Finally the findings and the implications described in this thesis are discussed in Chapter nine 
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Protein-Tyrosine Phosphatases (PTPs) have important roles in signaling, but relatively little is 
known about their function in vivo. We are using the zebrafish as a model to study the function of 
PTPs at the organismal, cellular and molecular level. The zebrafish is an excellent experimental 
model for the analysis of gene function. We have developed methods to quantitatively study 
effects of PTP knockdown or expression of (mutant) PTPs, particularly with respect to 
gastrulation cell movements. Moreover, we have studied the phosphoproteome of zebrafish 
embryos. In this review, we will discuss methods to manipulate the zebrafish genome and 
techniques that we have developed to assess developmental defects during gastrulation and to 
assess differences in the phosphoproteome.  
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1. Introduction
Much is known about catalysis and regulation of PTPs [1]. However, to fully understand the 
function of PTPs, their role in whole organisms in vivo needs to be addressed. Several model 
organisms have been used to investigate the function of PTPs, including the invertebrates 
Drosophila and C.elegans and vertebrate models, particularly the mouse. Many mouse knock-outs 
have been generated that provided important insight into the function of PTPs in development 
and conditional knock-outs have allowed the analysis of the function of PTPs in particular tissues 
[2,3]. Generation of mouse models can be laborious however, and in vivo imaging is difficult. We 
and others have used the zebrafish as a model for the analysis of PTP function, because of the 
many advantages that zebrafish embryos have to offer as an experimental system. Zebrafish are 
particularly amenable for genetics, intravital imaging and large scale approaches. In addition, we 
have recently developed a method to derive cell lines from single zebrafish embryos and tumors 
[4], which complements the wide range of experimental approaches in zebrafish. Here, we will 
review zebrafish as a model system in general, the genetic tools available, the approaches that we 
have used to assess PTP function in zebrafish, focusing on in vivo cell behavior and 
phosphoproteomics and we will give an outlook on approaches that may be used in the near future 
to assess PTP function in vivo. 
2.	Zebrafish	as	an	experimental	system	
The zebrafish is an excellent model system that was initially used for large scale forward genetic 
screens [5,6]. Since then, zebrafish are increasingly being used to model human diseases [7]. 
Major advantages of the zebrafish as an experimental system are that large numbers of embryos 
can be obtained easily; 100 - 200 embryos per clutch, 1 - 2 clutches per week per adult zebrafish 
pair. The embryos develop quickly and outside the mother; after 1 – 2 days most organs have 
formed. The embryos are transparent, facilitating analysis of embryonic development by (time-
lapse) microscopy. Many genetic mutants are available and transgenesis is feasible. More and 
more transgenic lines are becoming available, expressing fluorescent marker proteins under the 
control of specific promoters, which allows for intravital imaging. Overexpression of genes or 
proteins of interest can easily be achieved by micro-injection of synthetic mRNA encoding the 
protein of interest at the one-cell stage. In addition, transient knockdown of target proteins and 
target-selected gene inactivation are feasible in zebrafish (see below). Finally, chemical 
compounds can easily be administered to zebrafish embryos by simple addition to the aqueous 
embryo medium. Medium to large scale screens for bioactive compounds have been done using 
zebrafish development as read-out [8,9]. Taken together, the zebrafish is an ideal model system 
for analysis of gene function at the genetic, molecular and cellular level in whole organisms. 
3.	Zebrafish	Protein	Tyrosine	Phosphatases	
The zebrafish genome sequence is available in public databases (http://www.ensembl.org/ 
Danio_rerio/Info/Index)[10]. In general, orthologs of most human genes can be found in the 
zebrafish genome. In fact, some genes are duplicated in the zebrafish genome, due to a genome 
duplication in teleosts 320 million years ago [11,12]. In human, PTPs are divided in four classes 
i.e. classical and VH1-like dual specific protein phosphatases (DSPs) (class I), low molecular 
weight phosphatases (class II), Cdc25 phosphatases (class III) and Aspartic acid-based pTyr 
specific phosphatases (IV) (Alonso et al. 2004). Class I classical PTPs are further subdivided into 




activated protein kinase (MAPK) phosphatases (MKPs), atypical DSPs, the slingshot phosphatases, 
PRLs, CDC14s, phosphatase and tensin homologues (PTENs) and myotubularins. Since we focus 
on on classical PTPs and PTENs, these will be discussed in this review. 
The zebrafish genome encodes 51 classical PTPs and all the subtypes that have been identified in 
the mammalian genomes are represented in the zebrafish genome [13](Table 1). Fourteen PTP 
genes are duplicated in the zebrafish genome and whether these duplicated genes are all 
functional remains to be determined. Comparison of the PTP family in the genome of five distinct 
fish species led to the surprising discovery that ptpn20, which was supposed to encode little more 
than a PTP domain, actually encodes a large PTP with multiple functional domains, resembling 
PTP-BL. The human and mouse PTPN20 genes have a similar structure as zebrafish ptpn20, and 
we confirmed this by reverse transcription PCR [14]. 
To unravel the function of PTPs during zebrafish development, we have compared the expression 
patterns of all PTP genes in zebrafish by whole mount in situ hybridization using standard 
protocols [13,15]. Most PTP genes are expressed throughout development with broad expression 
patterns early on, which become more restricted later in development [13]. Interestingly, some of 
the duplicated PTP genes have overlapping spatio-temporal expression patterns whereas others 
are mutually exclusive. It is likely that the function of the latter PTPs has diverged since their 
duplication. For gene specific expression data during embryonic development we refer to [13]. 
4.	Genetic	tools	to	study	PTP	function	in	zebrafish
PTP function has been studied in zebrafish by transient, morpholino-mediated knockdown, in 
genetic loss-of-function mutants and by expression of exogenous PTP genes and mutants thereof. 
4.1 Morpholinos
Transient knockdown of target proteins by microinjection of morpholinos is widely used to study 
gene function [16,17]. Morpholinos are either directed at the start ATG to block translation of the 
target protein or at splice sites to block splicing of the target RNA (Figure 1). Morpholino-
mediated knockdown of Pez (ptpn14) results in developmental defects in the heart and somites, 
which may at least in part be mediated by impaired TGFβ3 signaling-dependent epithelial to 
mesenchymal transition [18]. Knockdown of PTPs results in accumulation of synaptic vesicles in 
the axon terminals of olfactory sensory neurons [19]. PTPs is related to the LAR receptor tyrosine 
phosphatases and these guide peripheral sensory axons to the skin in zebrafish embryos [20]. Ve-
ptp is required for vascular integrity, due to its role in adherens junctions where it regulates 
VEGFR-dependent VE cadherin phosphorylation and cell polarity [21,22]. Ptpro is structurally 
related to Ve-ptp and is required for cerebellar formation [23]. Knockdown of Shp1 (ptpn6) 
hyperactivates the innate immune system [24]. All of the studies above used transient 
morpholino-mediated knockdown of the PTP target proteins. To study the function of all classical 
PTPs in development, we have designed two non-overlapping morpholinos against each classical 
PTP gene in the zebrafish genome and assessed their effects on early development by micro-
injection at the one-cell stage. Not all pairs of morpholinos induced the same defects, suggesting 
off-target effects (van Eekelen, Runtuwene and den Hertog, unpublished results). We have 
pursued some knockdowns in detail (see below) and rescue of the morpholino-induced defects by 
co-expression of the respective target RNAs is taken as good evidence that the observed defects 
are not merely off-target effects.
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4.2 Target selected gene inactivation
Off-target effects of morpholinos are a concern and reverse genetics approaches have been 
developed to generate genetic mutants of target genes. Both mutagenesis and viral insertions are 
commonly used to disrupt target genes. Many loss-of-function mutations have been identified in 
PTP genes (www.zfin.org)(Table 1). Mutagenesis-based gene inactivation makes use of reagents 
such as N-ethyl-N-nitrosourea (ENU) to generate random single nucleotide polymorphisms 
(SNPs) in adult males. Subsequently, offspring is generated and mutations are identified in target 
genes by SNP detection or sequencing. Target selected gene inactivation by random mutagenesis 
and resequencing of the gene of interest in a large number of F1 mutants has led to the 
identification of nonsense mutations in more than 200 target genes [25] (www.zfin.org). An 
ongoing project makes use of high-throughput sequencing and is aimed at disrupting every gene 
in the zebrafish genome. So far potentially disruptive mutations have been identified in 38% of 
the zebrafish genes [26]. 
One of the first genes that was disrupted by the original target selected gene inactivation method 
was zebrafish pten. PTEN is a prominent member of the PTP superfamily, even though its catalytic 
activity is directed at lipids, rather than phosphotyrosine. PTEN is one of the most frequently 
mutated tumor suppressor genes in human cancer and is essential for mammalian development. 
We identified an early stop in the pten gene and much to our surprise, homozygous fish were 
viable. However, unlike the human genome, the zebrafish genome encodes two pten genes, ptena 
and ptenb, prompting us to disrupt the second pten gene too. Zebrafish embryos without 
functional Pten (ptena-/-ptenb-/-) display various hyperplastic/dysplastic defects and are 
embryonic lethal [27]. Genetic mutants that lack functional Ptena or Ptenb are viable and fertile, 
indicating that Ptena and Ptenb have at least partially redundant functions. Yet, adult fish that 
retain only a single wild type pten allele (ptena+/-ptenb-/- and ptena-/-ptenb+/-) develop 
hemangiosarcomas, endothelial tumors[28]. These findings illustrate that the duplication of 
genes in teleosts can be used to study gene function in a way that is not possible in mammalian 
systems. Future analysis of the pten mutants will provide new insights into Pten function in vivo. 
Figure 1. Morpholino method. Both translation initiation and splice- site blocking  morpholinos have 
been used to knockdown expression of target proteins. Gene A is transcribed and the RNA is spliced and 
translated normally. Translation initiation blocking morpholinos (ATG-MO) are targeted at the start ATG 
and will interfere with mRNA binding to the ribosome complex thus leading to impaired protein synthesis 
of Protein A. Splice-site blocking morpholinos (splice-MO) are targeted at splice-donor or –acceptor sites 
and interfere with splicing, thus leading to inclusion of introns which may contain internal stop sites or 
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4.3 Gene targeting
Specific gene inactivation by directing nuclease activity to target genes has been developed 
successfully for zebrafish as well. Zinc Finger Nuclease (ZFN) technology has been used [29,30] 
and more recently, Transcription Activator Like Effector Nuclease (TALEN) technology appears 
even more successful [31]. Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)- 
associated systems (Cas) technology has also been applied to inactivate genes in zebrafish [32] 
and holds much promise for future inactivation of target genes. All nuclease technologies are 
based on the generation of double-stranded breaks in the target gene, which are repaired by 
endogenous DNA repair mechanisms, particularly non-homologous end-joining (NHEJ). NHEJ 
frequently makes mistakes, leading to short deletions and these actually result in frame shifts 
and hence inactivation of the target genes. In principle, a template can be provided exogenously 
for DNA repair by homologous recombination, facilitating the introduction of (disease-associated) 
mutations or insertions at will. Successful homologous recombination in zebrafish using TALENs 
to introduce an exogenous restriction site or loxP sites has been reported [31]. 
5.	 PTPs	in	zebrafish	gastrulation	cell	movements.	
Several PTPs have an essential role in gastrulation cell movements, in particular convergence and 
extension (C&E) cell movements. These morphogenetic cell movements shape the developing 
zebrafish embryo [33]. Cell movements in the developing embryo were determined by in toto 
imaging using light sheet microscopy, which provides a stunning view of gastrulation cell 
movements and at the same time illustrates the strength of the zebrafish as a model for intravital 
imaging [34]. Signaling has a crucial role in gastrulation cell movements and we and others found 
that several PTPs are essential for C&E cell movements. Knockdown of Shp2 results in defective 
gastrulation cell movements, without affecting cell fate specification [35]. RPTPα and PTPε are 
also required for normal gastrulation cell movements. Transient morpholino-mediated 
knockdown of RPTPα and PTPε, but also a genetic mutant of ptpra display C&E cell movement 
defects [36]. Moreover, knockdown of RPTPψ results in defects in C&E cell movements during 
gastrulation [37]. Finally, knockdown of PTP-BL and Ptpn20 induces gastrulation cell movement 
defects [14]. Not only knockdowns of PTPs induce gastrulation cell movement defects, but also 
expression of mutant Shp2 with mutations that were identified in human patients with Noonan 
Syndrome or LEOPARD syndrome display C&E cell movement defects. These embryos display 
defects at later stages that are reminiscent of the symptoms observed in human patients, including 
short stature, hypertelorism and cardiac defects [35]. Interestingly, expression of LEOPARD 
mutant Shp2 induces defects in neural crest specification and migration [38]. It remains to be 
determined how an activating mutation (Noonan Syndrome), an inactivating mutation (LEOPARD 
syndrome) and a knockdown induce similar developmental defects in early embryonic 
development. 
PTP signaling, resulting in gastrulation cell movements, was investigated by analysis of genetic 
epistasis interactions. Particularly, we studied the role of Src family kinases, because these are 
activated by PTPs and have a role in C&E cell movements [39,40], and Rho family GTPases, 
because these are downstream regulators of gastrulation cell movements [41]. Partial knockdown 
of Shp2, RPTPα or PTPε does not affect development, nor does partial knockdown of the Src family 
kinases, Fyn and Yes, but combined partial knockdown of these PTPs and Src family kinases 
induces severe gastrulation cell movement defects [35,36], indicating a genetic interaction. RhoA, 




[39]. Constitutively active RhoA rescues Shp2, RPTPα and PTPε knockdowns [35,36], which 
provides insight into the mechanism underlying PTP signaling in gastrulation cell movements. 
Intriguingly, the PTP-BL and ptpn20 knockdowns are rescued by dominant negative RhoA, in 
contrast to the RPTPα and PTPε knockdowns. We suggest a model in which PTPs regulate cell 
polarization, which is at the basis of normal C&E cell movements during gastrulation [14]. Some 
PTPs have positive effects on cell polarization and others negatively affect polarization. Both 
effects result in decreased directed cell migration and hence to defective C&E cell movements. 
Many PTPs are essential for normal C&E cell movements, which probably reflects the high level of 
regulation of C&E cell movements. Detailed analysis of the role of each PTP in C&E cell movements 
will provide insight into the interplay between PTPs – if any – in the regulation of C&E cell 
movements. 
6. Quantitative analysis of gastrulation defects
While analyzing gastrulation cell movement defects in zebrafish embryos we developed assays to 
quantitatively determine defective cell movements, based on (1) the shape of the embryo, (2) 
molecular markers and (3) cell migration: 
6.1  Detecting oval-shaped embryos 
Defective cell movements during epiboly and gastrulation lead to oval-shaped embryos [42,43]. 
Using Image J, we have developed a semi-automated tool to determine the oval shape of embryos. 
The circumference of the embryo is detected and subsequently, the long axis and perpendicular to 
that the short axis is determined (Fig. 2A). The ratio long axis/short axis directly represents the 
extent of oval shape. Wild type non-injected embryos display a ratio of 1.1, i.e. close to 1.0, the 
perfect sphere. The ratios of embryos with epiboly defects are usually 1.3 and up, significantly 
higher than 1.1 in wildtype and control-injected embryos. Interestingly, CI-1040, a specific 
inhibitor of MEK, which acts downstream in the pathway rescues the oval shape of the embryos, 
whereas it does not affect the ratio of wildtype embryos [43]. Detecting oval shapes of zebrafish 
embryos is a straightforward method to quantitatively determine the deviation from the normal 
shape of control embryos and therefore the severity of gastrulation defects.
6.2  Molecular markers
Embryos with C&E cell movement defects are characterized by a broader body and reduced 
extension of the body axis. Cell fate is not affected by defects in C&E cell movements and all cell 
types that are normally observed in the developing embryo are detectable in embryos with 
defective gastrulation cell movements. We routinely use a panel of markers to assess that cell fate 
is not affected. These include markers for: the dorsal organizer (goosecoid, gsc), ventral cell fate 
(bone morphogenetic protein 2b, bmp2b), dorsalizing factor (chordin, chd) and mesendoderm 
(notail, ntl) at shield stage; axial mesendoderm at 70% epiboly (cyclops, cyc) and at budstage 
forebrain (six3) and mid-hindbrain boundary (pax2). Several markers have been identified that 
provide quantifiable traits of C&E cell movements in the developing embryo at early developmental 
stages. Dlx3 (currently known as dlx3b) marks the edges of the neural plate and hgg1 (current 
name ctsl1b) marks precursors of the hatching gland. Double labeling with dlx3 and hgg1 provides 
a characteristic pattern (Fig. 2B). The position of the hatching gland, relative to the anterior-most 
dlx3 staining provides a direct measure for body axis extension and the angle of the dlx3-positive 
edges of the neural plate are directly representative of convergence [36]. In embryos with 
defective C&E cell movements, the hgg1 staining is located more posteriorly and the dlx3 staining 
is significantly wider (Fig. 2B). 
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Krox20/myod double labeling at the 8-10 somite stage and subsequent flat-mounting of the 
embryos leads to a highly reproducible pattern that can be used for quantification of the width 
and length of the embryo [44](Fig. 2C). The krox20 marker stains rhombomeres 3 and 5 and myod 
marks the somites. Embryos with 8-10 somites are used, and staining of the somites provides a 
good means to determine the age of the embryos, as a new somite is added every 30 min at this 
stage. The distance from the first to the eighth somite remains identical from the 8-somite to the 
10-somite stage. The width of the krox20-positive rhombomere 3 and the length of somites 1-8 is 
directly proportional to the width and length of the embryo, respectively, and the ratio of width 
and length allows direct quantitative comparison between groups of experimental embryos. 
6.3  Cell migration
Identification of differences in the migration of paraxial mesendodermal cells between groups of 
embryos is definitive evidence for differences in C&E cell movements. Initially, we used a 
photoactivatable dye, 4,5-dimethoxy-2-nitrobenzyl (DMND)-caged fluorescein dextran (10,000 
MW; Molecular Probes, Leiden, the Netherlands) that was uncaged by local illumination with UV 
light at 6 hpf as described [45]. The fluorescent group of cells was subsequently followed using an 
Axioplan microscope, equipped with a UV light source, adjustable pinhole and 40X objective. 
Either a group of cells in the embryo proper was photo-activated, allowing assessment of 
extension, or a group of mesendodermal cells was labeled, allowing assessment of convergence. 
Pictures were taken immediately following uncaging (6 hpf), at 80% epiboly (8hpf) and at tailbud 
stage (10 hpf). As a measure for cell migration, the angles for dorsal convergence and anterior 
extension were determined using Image J software. Knockdown of Shp2 and expression of Noonan 
Syndrome mutant Shp2 induced significant defects in C&E cell movements, assessed using a caged 
fluorophore as described above [35]. We developed an alternative for these photo-activation 
experiments: time-lapse imaging of mesendodermal cells during gastrulation [36]. Briefly, all 
nuclei of a developing embryo are labeled by microinjection at the one-cell stage with fluorescently 
labeled Histone 1 protein (Histone 1 Alexa fluor 488; Molecular Probes). The embryos are 
dechorionated at 30% epiboly and mounted at shield stage in 1% low melting point agarose with 
the dorsal side against the coverslip approximately 100 µm anterior to shield position, facilitating 
visualization of the C&E cell movements of the epiblast. We use a Leica SP2 confocal microscope 
with a 40x objective and a 488 nm laser line for excitation of the fluorophore. Images are recorded 
every 2 minutes from shield stage until 1-somite stage. The timelapse images are analyzed using 
Image J software. The nuclear Histone 1 labeling is used to determine the position of individual 
nuclei in a single optical slice for each time point. Due to innate changes in intensity, size and 
shape of the fluorescent signal of the nuclei, additional image processing is needed for efficient 
tracing of the cells. The images are successively made binary, separated by a watershedding 
algorithm, eroded to a single pixel and dilated. Projection of the resulting image onto the original 
shows that the generated objects represent cell positions with a very high accuracy (> 99%) (Fig. 
2D). These objects are readily traced over time, which generates a report with the Cartesian 
coordinates for all traced objects at each time point. These coordinates represent the contribution 
of cell migration to convergence (X-axis) and extension (Y-axis) and allow for quantification of 
migration of individual cells and of groups of cells. We have used this cell tracking method to 
compare C&E cell movements between wild type and ptpra-/- mutant embryos that lack functional 
RPTPα. Ptpra-/- embryos display significantly impaired C&E cell movements [36]. The latter cell 
tracking method does not rely on the use of a caged fluorophore, but instead a general cell 
identifier can be used. We have used fluorescently labeled Histone 1 for our experiments as well 





Figure 2. Quantitative analysis of defects in gastrulation cell movements. (A) Assessment 
of oval shape, (B) the width and relative position of molecular markers, dlx3 and hgg1 (currently known 
as dlx3b and ctsl1b, respectively), (C), the length and width of the developing embryo using molecular 
markers, krox20 and myod and (D) migration of mesendodermal cells in the developing embryo can all 
be used as quantitative traits of C&E cell movements. In A-C a schematic representation is given next to 
an actual comparison of a control embryo (wildtype Shp2 injected, WT Shp2, or non-injected control, NIC) 
and an experimental embryo (Noonan Shp2 injected, NS Shp2, or ptpra morpholino-injected). In panel D 
the actual confocal image is compared to the image after processing. The right panel shows the cell tracks. 
Cell movements in the boxed areas are directly proportional to convergence (Con) and extension (Ext) cell 
movements, respectively. See text for details.
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7.	 Phosphoproteomics	in	zebrafish
The methods above facilitate the analysis of PTP function at the organismal and cellular level. 
Biochemical analyses are required to understand the function of PTPs at the molecular level. 
Whereas the zebrafish is an excellent model system to unravel genetic pathways, biochemical 
analyses are lagging behind due to ill-understood difficulties in the use of antibodies in zebrafish 
lysates, even though the epitopes of the antibodies that are being used are highly or even perfectly 
conserved. Highly abundant yolk proteins are likely to interfere with protein analyses in zebrafish 
lysates, yet some antibodies work remarkably well in immunoblots and immunoprecipitation. 
Nevertheless, phosphoproteomic analysis of zebrafish embryos by mass spectrometry has 
provided some insight into the overall phosphoproteome of zebrafish embryos and may provide 
means to analyze the function of PTPs in vivo at the phosphoprotein level. As a first step to analyze 
PTP function at the molecular level in vivo, we set out to map the pTyr phosphoproteome in 
zebrafish embryos by anti-pTyr immunoprecipitation and mass spectrometry to identify 
phosphoproteins and protein phosphorylation sites [46]. In the process, we developed a protocol 
for quantitative phosphoproteomic analyses of zebrafish embryos: First, embryos are collected 
and excess yolk proteins are removed by washing with ice-cold deyolking buffer (Figure 3). The 
deyolked embryos may be snap-frozen until a sufficient amount of sample has been collected. 
Labeling of zebrafish embryos, similar to tissue culture cells with stable isotope labeling in 
culture (SILAC) is not feasible. Therefore, in order to compare different samples with eachother, 
peptides are labeled, either using iTRAQ or using stable isotope containing dimethyl [47]. While 
iTRAQ allows for a comparison of up to eight different conditions, dimethyl labeling is cost-
effective and facilitates a comparison of up to three different samples. Purification of the sample 
is performed using either TiO2 columns which enrich for all phosphorylated peptides, or by pTyr-
specific immunoprecipitation. Note that for pTyr immunoprecipitation collection of more sample 
(preferably >6 μg, or more than 2000 zebrafish embryos) is necessary than for TiO2. In contrast 
to pTyr immunoprecipitation, TiO2 can be used to purify all phosphopeptides and to analyze the 
phosphoproteome in relatively small samples, down to a single zebrafish embryo [48]. Using the 
TiO2 approach, we successfully analyzed the phosphoproteome of Fyn/Yes knockdown embryos 
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Figure 3. Phosphoproteomics analysis of zebrafish embryos. Zebrafish embryos (control 
and/or treated) are deyolked to remove excess yolk proteins which would otherwise interfere with 
mass spectrometric analysis. Embryos are lysed and proteins are purified and digested with trypsin. 
For quantification, we have used isotopic dimethyl labeling. Samples are then combined for direct 
analysis (reference pool of all peptides) and the samples are used for further processing. To enrich for 
phosphopeptides, either anti-pTyr immunoprecipitation or TiO2 enrichment (for pSer, pThr and pTyr) are 
being used. Fractionation of peptides is performed using strong cation exchange after (pTyr IP) or prior 
to (TiO2) phosphopeptide enrichment. Mass spectrometric analysis is performed to quantify (MS) and 




phosphoproteome of PTP knockdown or knockout embryos by immunoprecipitation of pTyr-
containing peptides after proteolysis and subsequent peptide identification by mass spectrometry 
may lead to identification of direct substrates and elucidate PTP-proximal signaling.
8. Outlook 
Here we describe genetic methods to manipulate gene function in zebrafish with the emphasis on 
PTPs. We explain how zebrafish can be used to study PTP function using a variety of quantitative 
methods to study general morphology and cell migration. Furthermore, we provide an overview 
of PTP studies performed in zebrafish and the genetic mutants available. In Table 1 we show that 
several PTPs have been studied in zebrafish, however, many are yet to be investigated. 
Additionally, genetic association studies have shown a role for PTPs in several diseases. Combined 
with the availability of genetic mutants this holds a big promise for zebrafish as tools to study 
PTPs. In addition, the advent of TALEN and CRISPR technology has facilitated the generation of 
targeted genetic mutations in the zebrafish genome and many more zebrafish mutants will be 
generated in the near future in which genes encoding PTPs are inactivated or contain mutations 
at specific positions. These genetic mutations will be crossed with transgenic lines in which 
fluorescent proteins are expressed in specific cells or tissues, allowing analysis of cell behavior in 
vivo by intravital imaging, thus providing insight into the function of PTPs at the cellular/ 
organismal level. Analysis of the pTyr phosphoproteome of zebrafish embryos that lack the 
function of a specific PTP or that express mutant PTPs may result in identification of specific 
substrates and signaling pathways, thus providing insight into the function of PTPs at the 
molecular level in vivo. Using these methods, the zebrafish provides great opportunities to study 
PTP function in development and disease in vivo.  
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Noonan syndrome (NS) (OMIM:163950) is a common (1:2000) heterogeneous syndrome that is 
related to other clinical syndromes associated with the RAS-MAPK pathway, including LEOPARD 
syndrome (LS) (OMIM:151100), cardio-facio-cutaneous (CFC) syndrome (OMIM:115150), 
neurofibromatosis type 1 (NF1) (OMIM:162200) and Costello syndrome (CS) (OMIM:218040). 
Collectively, these syndromes are termed RASopathies.
1. Symptoms
Noonan syndrome is characterized by short stature, congenital heart defects, including 
pulmonary stenosis, low set ears, webbed neck, hypertelorism, low set eyelids and chest 
deformities [1] (Figure 1). Whereas these features are prominent in a large group of NS patients, 
some patients may either be of normal height, or have less prominent craniofacial features. Other 
features include scoliosis, deafness and an increased propensity to develop leukemia. Whereas 
some patients exhibit cognitive defects as well, many NS patients have normal intelligence [2]. 
Noonan patients have a higher chance of developing juvenile myelomonocytic leukaemia (JMML), 
and mice carrying the D61G NS mutation develop myeloproliferative disease [3]. Moreover, Gab2, 
a downstream effector of Shp2, is essential for the aetiology of the myeloproliferative disorder, 
since double-mutant mice lacking Gab2 are less likely to develop myeloproliferative disease than 
Shp2 D61G knock-in mice [3]. A paternal origin for de novo mutations has been observed in NS, 
with a possible link to the age of the father as well [4]. Additionally, transmission of NS is skewed 
maternally, that may be attributed to the reduced fertility in male NS patients [4]. 
LEOPARD syndrome, an acronym of Lentigines, Electrocardiographic conduction anomalies, 
Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retarded growth and 
sensorineural Deafness is clinically very similar to NS. Patients exhibiting LS are often initially 
diagnosed with NS. Only when certain ‘café au lait’ spots or lentigines appear during early 
adolescence a clinical distinction is often made between NS and LS. Whereas NS and LS share 
many common characteristics, several clinical features are unevenly distributed among NS and 
LS patients. For instance, pulmonary stenosis (PS) is more common in NS, whereas hypertrophic 
cardiomyopathy (HCM) is more prevalent in LS [5]. Additionally, craniofacial defects are more 
prominent in NS than in LS patients and LS patients exhibit less height deficits than NS. Postnatal 
growth retardation is a clinical manifestation of NS and LS patients. Approximately 70% of adults 
with NS are below the 10th percentile for height [6] and 85% of adults with LS are below the 25th 
percentile [7]. The short stature in NS patients is generally due to a decrease in responsiveness to 
growth hormone (GH), as evidenced by reduced levels of insulin-like growth factor 1 (IGF-1) [8-
11]. A Ptpn11 Noonan syndrome mouse model displays increased ERK activation in response to 
growth hormone; blocking MAPK signaling restores IGF-1 levels, thus reducing the postnatal 
growth retardation in these mice [8]. The molecular basis of growth defects in LS is less well 
understood. 
2. Genetics
Roughly 50% of all cases of NS are caused by mutations in PTPN11 while heterozygous missense 
mutations in PTPN11 are observed in up to 90% of LS cases. Other mutations have been identified 
in genes encoding for proteins along the RAS-MAPK pathway. Mutations were identified in MEK1, 
MEK2, KRAS, NRAS and in SHOC2 [12-16]. Also RAF1 and BRAF gain of function mutations were 
identified in patients with NS and LS [17,18] (Figure. 2). Mutations in CBL, an E3 ubiquitin ligase 
with tumour suppressing activity, are causative of Noonan-like syndrome [19]. Moreover, Noonan-
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like symptoms are associated with mutations in the histone methyltransferase, MYST4, resulting 
in enhanced MAPK signalling [20]. The genetic cause of some 25% of all Noonan cases still remains 
to be determined. It is evident that these patients do not have mutations in any of the known 
























Figure 1. Clinical characteristics and facies of Noonan and LEOPARD syndrome patients. 
A) Diagnosis of Noonan and LEOPARD syndrome is primarily dependent on clinical features, including 
short stature, typical face dysmorphology, and congenital heart defects. Diagnosis can be difficult due to 
the wide spectrum of clinical features, not all of which need to be present for diagnosis. Cardinal features 
of Noonan and LEOPARD syndrome include hypertelorism, ptosis, and low-set, posteriorly rotated ears 
with a thickened helix. Cardiac abnormalities most commonly associated with the two syndromes include 
pulmonary stenosis (NS) and hypertrophic cardiomyopathy (LS). Other associated features include the 
presence of a webbed neck, chest deformity, mild intellectual deficit, cryptorchidism, poor feeding in 
infancy, bleeding tendencies, and lymphatic issues. B) Photographs of families diagnosed with Noonan [81] 





Whereas mutations that cause NS all result in a phosphatase hyperactive form of Shp2, LS causing 
mutations in Shp2 all display strongly reduced phosphatase activity [21,22]. How is it possible 
that two seemingly opposite mutations cause similar clinical features? Examination of the 
structural mechanism of Shp2 revealed a gain-of-function in NS forms of Shp2, giving rise to a 
hyperactive form [23]. NS mutations predominantly reside in the interface between the N-SH2 
domain and the PTP domain, resulting in the impairment of the closed conformation and enhanced 
catalytic activity of NS-Shp2 [24,25]. By contrast, most LS mutations reside close to the active site 
and result in strongly reduced, yet detectable, catalytic activity [24,26,27] (Chapter 1). 
Phosphatase assays have shown a catalytic defect in LS Shp2 [24,26,28]. LS-Shp2 mutations are 
mostly located in the protein-tyrosine phosphatase (PTP) domain, and the local conformational 
changes induced by LS-Shp2 mutations impair the catalytic properties of Shp2 [29]. However, in 
vivo, LS Shp2 may act as a gain-of-function as well [30]. In flies, LS mutations give rise to gain-of-
function defects that cause upregulation of MAPK and require residual PTP activity of Shp2 [30]. 
LS-Shp2 displays residual phosphatase activity [26,27]. LS mutations cause loss of phosphatase 
activity and at the same time result in enhanced binding to Gab1 and PI3K [26]. Further 
investigation showed that LS, unlike NS causes activation of the PI3K-AKT pathways upon growth 
factor stimulation [31]. This is due to enhanced phosphorylation of Gab1 due to the loss of 
phosphatase activity of LS Shp2 [31]. Enhanced PI3K activation likely contributes to the 
discrepancies between NS and LS. PI3K/AKT signaling is upregulated in hearts of LS/+ knock-in 
mice [22] as well as in fibroblasts isolated from LS patients [31]. Despite these explanations it 
remains unclear how activating and inactivating mutants of Shp2 can generate overlapping 
syndromes. Most probably, NS and LS share some of their targets in order for them to generate the 
overlapping clinical features.
4. Spatiotemporal control
Cardio-facio-cutaneous (CFC) syndrome is 
one of the RASopathies, and is caused by 
mutations in BRAF, MEK1 or MEK2. Like NS, 
activating mutations give rise to short 
stature, heart defects and craniofacial 
defects arising from hyperactivation of the 
MAPK pathway. In zebrafish, NS and CFC 
induced gastrulation defects can be 
rescued by treatment with the MEK 
inhibitor CI-1040 [14,32]. Importantly, 
inhibitor treatment is only required during 
a small temporal window prior to shield 
formation [14,32]. Not only temporal 
control but also spatial control (membrane-
bound versus cytoplasmic, or lipid-raft 
versus non-lipid raft localization) of 
protein signalling is likely a vital aspect in 
the aetiology of RASopathies. SHOC2 is a 
scaffolding protein that binds RAS and 
















Figure 2. Overview of the RAS-MAPK pathway 
associated with NS/LS disorders. Syndromes caused 
by mutations in genes of RAS-MAPK signalling proteins 
are indicated.
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targeted to late endosomes and activates ERK1/2 [33]. An interesting finding was that a mutation 
in SHOC2 that causes Noonan-like syndrome with loose anagen hair results in N-myristoylation of 
SHOC2. This causes aberrant translocation of SHOC2 to the cell membrane instead of late 
endosomes, which results in enhanced MAPK activation in a cell-type specific manner [13,33]. 
Interestingly, whereas NS mutations in Shp2 and SHOC2 are additive [34], NS and LS mutations in 
Shp2 are not [28]. Moreover, NS associated mutations in RAF1 cause enhanced heterodimerization 
with BRAF which also results in enhanced ERK activation [35]. More importantly, not only kinase-
impaired D486N RAF1 but also kinase-activating NS forms of RAF1 required heterodimerization 
with BRAF to enhance MEK/ERK activation [35]. Interestingly, RAF1 mutations have been found 
in NS and LS patients, suggesting a common mechanism for NS and LS [17].
Targeting of Shp2 to lipid rafts results in integrin clustering, Focal Adhesion Kinase 
phosphorylation, Rho and ERK activation, all of which are hallmarks of fibronectin attachment 
[36]. Shp2 is targeted to lipid rafts upon adhesion, and dominant negative RhoA blocks Shp2 
induced signalling. In addition, Shp2 phosphatase activity is essential for negative feedback to 
Rho [36]. The downstream target of Shp2, RhoA, also prevents apoptosis by activating the MAPK 
pathway and expression of bcl-2, in zebrafish [37]. A phosphatase independent, but SH2 domain 
dependent role for LS Shp2 was described in preventing p53 mediated apoptosis in the brain and 
neural crest, suggesting that the SH2 domain of Shp2 may be essential for RhoA activation [37,38]. 
An emerging model is that under basal conditions, Shp2 binds Abl, which activates p190 RhoGAP, 
which in turn inactivates Rho. In its active state, Shp2 inactivates p190 RhoGAP by 
dephosphorylation. In addition, Shp2 dephosphorylates an inhibiting tyrosine phosphorylation 
site on ROCKII, causing activation of the pathway [39]. It is noteworthy that NS Shp2-mediated 
activation of ROCKII causes heart defects in Xenopus [40].
Recently, a role for Ephrin signalling has been implicated in Shp2 mediated ERK activation [41]. 
Hepatic growth factor (HGF) induced ERK activation is dependent on EphA2 phosphorylating the 
C-terminal tyrosines, Y542 and Y580 of Shp2, thereby mediating prolonged Grb2 binding and ERK 
activation. Interestingly, ERK activation is independent of Shp2 phosphatase activity, since 
expression of T468M (LS) or a N308D (NS) variant enhanced ERK activation. Mutation of the 
C-terminal tyrosines in the LS background suppress ERK activation as well, suggesting an 
essential role for these tyrosines in mediating ERK activation. Comparison of Shp2 knockdown 
embryos and zebrafish embryos expressing LS-Shp2 allowed assessment of a phosphatase and 
ERK dependent role for Shp2 in zebrafish neural crest specification and cell migration [38]. 
Shp2 phosphatase activity plays a role in cell migration. IGF1, which cooperates with integrins to 
promote cellular migration and invasion [42,43] , mediates IRS1 binding to a complex containing 
FAK, paxilin and Shp2. This results in the dephosphorylation of FAK and paxilin. Interestingly, 
Shp2 phosphatase activity is essential for integrin deactivation since Shp2 C460S expressing cells 
show higher numbers of focal adhesion contacts [44]. This is likely independent of ERK activation 
since treatment with a MEK inhibitor did not attenuate this effect [44]. Shp2 also mediates 
activation of Fyn kinase at focal adhesion sites in a catalytic activity independent manner, where 
Shp2 binds to a6b4 integrin via its N-SH2 domain and to Fyn with its C terminal tyrosine Y580, 
thereby acting as a docking protein [45]. Additionally, Fyn phosphorylates Shp2 Y542, thereby 
providing a positive feedback loop [45]. Also Src kinase is known to be activated by, and bound to 
Shp2 in a catalytically independent manner [46]. Whereas the SH3 domain of Src was essential for 
this binding, a specific Src binding site has not yet been identified in Shp2 [46]. Other kinases also 




phosphorylation of target sites in Shp2 that are located at or near residues often mutated in NS 
and LS respectively, namely Y63 and Y279 [47]. Phosphorylation of Y279 caused a decrease in 
growth factor mediated ERK activation [47]. Other pathways than the Rho, MAPK and Src 
pathways are also controlled by Shp2, like the JAK/STAT pathway. In contrast to these other 
pathways, Shp2 plays an inhibiting role [48]. Interestingly, down regulation of Stat3 by activating 
variants of Shp2 may contribute to pulmonary stenosis in NS and myeloproliferative disorder in 
JMML [49]. Indeed, phosphorylated Stat3 is inhibited by active Shp2, and expression of active 
Stat3 rescues the activating Shp2 defects in bone marrow cells [49]. 
Several attempts have been made to find an inhibitor for Shp2 for treatment and use in biochemical 
assays [50]. One of these, NSC-87877 binds to the catalytic site of the PTP domain and is able to 
inhibit Shp2 mediated, growth factor induced ERK activation [50]. In addition, 
phenylhydrazonopyrazolone sulfonate (PHPS1) was identified by an in silico screen, and further 
tested in vitro for its phosphatase inhibitory capacity [51]. PHPS1 was able to inhibit HGF induced 
cell scattering that is mediated by Shp2 phosphatase activity [51]. However, these compounds 
only target the phosphatase dependent function of Shp2, while Shp2 also exhibits phosphatase 
independent mechanisms. 
Thus, Shp2 is involved in a plethora of signalling mechanisms and one can imagine that 
biochemical changes in the enzyme may result in widespread defects. In LS patient derived 
induced pluripotent stem (iPS) cells, several downstream proteins are hyper- or hypo-tyrosyl 
phosphorylated [52]. Interestingly, although LS Shp2 is thought to result in a decreased ability to 
activate the ERK pathway following growth factor stimulation due to its loss of phosphatase 
activity, basal levels of MEK are upregulated in these cells [52]. Gene expression profiling of NS 
and Noonan-like syndrome patients show that many alterations are present on the transcriptional 
level and that NS-specific gene expression signatures are distinguished [53]. NS Shp2 expressing 
cells show enhanced expression of Src family kinase substrates, indicating that these proteins 
may play an essential role in the aetiology of Shp2 induced NS [53].  
5. Cardiac defects associated with NS and LS
Noonan and LEOPARD patients share several clinical manifestations, including scoliosis, facial 
dysmorphic features, short stature and congenital heart defects. Despite those clinical 
similarities, the heart defects are quite distinct between Noonan and LEOPARD patients. The 
most common cardiac defect in NS is pulmonary stenosis (PS) resulting from dysplastic valve 
leaflets, but stenosis of mitral valve, atrial, ventricular, and atrio-ventricular septal defects, or, 
rarely, double-outlet right ventricle are also seen [54,55]. Moreover, hypertrophic cardiomyopathy 
(HCM) has been found in few NS patients without Shp2 mutations [56] and genotype-phenotype 
correlation studies show that only 8% of Shp2-associated NS patients present with HCM [57]. 
HCM is most commonly present in NS patients with mutations in RAF1 [58]. Electrocardiogram 
(ECG) of NS patients often shows a characteristic pattern, with a left axis deviation, abnormal R/S 
ratio over the left precordium, and an abnormal Q wave. These ECG features are characteristic for 
NS and they are not related to a specific cardiac defect (PS or HCM) [59]. In contrast, the most 
common cardiac defect in LS is HCM, but similar valve anomalies to NS are also observed [60].
Although Shp2 is a major player in cardiac disease, its function in heart development in NS and LS 
remains poorly addressed. Several animal models have been used to investigate the role of Shp2 
in NS and LS. The injection of the most prevalent human NS Shp2 mutations into Xenopus results 
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Figure 3. Stages of cardiac development. 
A) At 5 h post fertilization (hpf) cardiac progenitor cells are positioned bilaterally in the lateral marginal 
zone of the blastula. Atrial progenitor cells (pink) are located more ventrally than the ventricle progenitor 
cells (light blue). During gastrulation, the cardiac progenitor cells move dorsally towards the mid-line to 
end up in the anterior later plate mesoderm (ALPM). At 17 hpf, the future ventricle and atrial myocardial 
cells differentiate because of the expression of cardiac myosins (blue/red). The bilateral heart fields fuse at 
the mid-line (22hpf), forming a cardiac disc structure with the ventricular myocytes internally and atrial 
myocytes externally of the disc. Cardiac morphogenesis transforms the cardiac disc into a cardiac tube. At 
28 hpf, the linear heart tube has formed. At 36 hpf, cardiac looping has started, with a displacement of the 
ventricle towards the mid-line. The heart tube continues to loop and forms an S-shaped loop (48 hpf).
B) Cartoon in which the migration, rotation and involution of the cardiac tissue during heart tube 





in hearts that failed to complete looping or undergo chamber formation coupled with a delay or 
arrest of the cardiac cell cycle in M-phase [40]. Similarly, the overexpression of NS and LS Shp2 
mRNA in zebrafish embryos at the 1-cell stage result in heart displacement defects at 24 hpf [28]. 
Moreover, NS and LS Shp2 induce convergence and extension cell movement defects at the end of 
gastrulation, followed by the development of craniofacial defects and reduced body axis length at 
4dpf [28]. 
The mouse model expressing the NS-associated mutant D61G develops short stature, craniofacial 
abnormalities and multiple cardiac defects, including pulmonary stenosis and double outlet of the 
right ventricle (DORV). Their endocardial cushions show an increased Erk activation. When 
homozygous, the D61G mutant is embryonic lethal [61]. Similarly the knockin mice harboring the 
LS Ptpn11 mutation Y279C recapitulates the human disorder, showing short stature, craniofacial 
dysmorphia, and HCM. LS/+ mice also exhibit increased Akt/mTOR activity and the inhibition of 
mTOR signaling with rapamycin completely normalized and reversed the LS cardiac defects [62]. 
Conclusively, LS models support the conclusion that excessive AKT/mTOR activity, not MAPK, is 
essential for the development and maintenance of HCM. 
6.	Zebrafish	as	a	model	to	study	heart	development.
The role of NS and LS Shp2 variants in the development of cardiac defects is still unclear. Zebrafish 
has become a powerful model to study cardiac development in recent years [63,64]. Moreover, the 
transparency of zebrafish embryos facilitates time-lapse analysis of the onset and nature of the 
cardiac defects in vivo. The heart is the first organ to form and function during zebrafish embryo 
development. Heart development begins with the specification of myocardial and endocardial 
progenitor cells. Before gastrulation, 5 h post fertilization (hpf), the heart progenitor cells are 
formed and placed in the ventral and lateral regions of the embryo. Atrial progenitor cells are 
located more ventrally in the lateral marginal zone when compared with ventricular progenitor 
cells [65]. By 14 somites (17hpf), the cardiac progenitors cells appear as two bilateral pools on the 
lateral plate mesoderm (LPM) [66]. Next, by 22 somites (22 hpf), these pools combine at the LPM 
to form the heart disk. This disk moves anteriorly and to the left and forms the heart tube (24-28 
hpf). Afterwords, by 30 hpf, ventricular and atrial chambers form. By 36 hpf, the heart undergoes 
looping morphogenesis and, by 48 hpf, functional valves are formed (Figure 3A)[66]. Up to 22 
somites, the heart morphogenesis is a symmetrical process because there are no morphological 
differences between the left and right cardiac fields. However, after the cardiac disc formation, 
the myocardial tissue originating from the right cardiac field involutes ventrally and moves 
towards the anterior/left (Figure 3B). In this way, the left–right organization of the cardiac disc 
change into a dorsal–ventral organization of the cardiac tube.  Four-dimensional confocal 
miscroscopy and the automated cell tracking showed that co-occurring with right-field involution, 
the myocardial disc rotates in a clockwise direction [67-69]. As a consequence of these moviments, 
the cardiac tube is created, with its venous pole located at the left side and its arterial pole located 
at the mid-line. Breaking of the heart symmetry is initiated by a transient ciliated organ called 
Kupffer’s vesicle that is derived from the dorsal forerunner cells (DFCs) [70,71]. Cilia within the 
KV rotate in a counter-clockwise direction, thus generating a fluid flow in the same direction 
[72,73]. The directional fluid flow in the KV induces asymmetric expression of two conserved L/R 
signaling genes pitx2 (a bicoid-related transcription factor) and southpaw (spaw, a Nodal-related 
gene) in the LPM. The bilateral expression of spaw/nodal starts around the KV at the 4 somite 
stage and its expression resides in the perinodal area [74]. At around the 10–12 somite stage, 
spaw/nodal expression starts in the LPM. The left-sided spaw/nodal expression moves to the 
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anterior part of the embryo [74]. At late somite stages, the leftward expression of southpaw 
overlaps with the left-sided expression of other genes, such as lefty2. Spaw/nodal is proposed to be 
a significant player in the diffusion of the asymmetric expression in the left LPM, together with 
the activation of its own antagonists, Lefty1 and Lefty2 [75]. In particular, Lefty1 has the function 
to block the nodal expression on the right-side of the LPM. Lefty1 expression acts in the midline as 
physical barrier to avoid the diffusion of asymmetric signal in the LPM to the right side, preventing 
the right LPM to acquire a left-sided identity [76]. Impairment of the L/R patterning determination 
can cause either a randomized positioning of organs (situs ambiguus) or a mirror-image 
duplication of organs (situs inversus). In humans, clinically significant laterality defects occur in 1 
in 10,000 births [77]. The mortality associated with laterality defects is always ascribed to 
complex congenital heart defects. In fact the heart morphogenesis is very susceptible to 
impairments in the left-right (LR) body plan. The heart tube undergoes looping morphogenesis 
quite early in vertebrate development and before the heart tube has completed its formation. 
Because cardiac looping is a highly conserved process, the directionality of the heart loop can 
predict the body situs [78]. As the heart tube proceeds in the elongation, it develops a dextral loop 
(“d” loop).  The process of looping and the directionality of the loop are important for normal 
heart development. Because most cardiac structures originate from cells derived from more than 
one area of the heart tube, the significant function of looping is to rearrange regions of the heart 
tube so they are appropriately positioned for proper formation and alignment of chambers, 
valves, and septa. Thus, the directionality of looping establishes once the left ventricle underlies 
the left atrium, and the right ventricle beneath the right atrium [79]. The heart shows an atrio-
ventricular (A-V) concordance only when the position of the ventricles is correct. Moreover, L/R 
chambers division is fundamental for the functions of the heart and if L/R asymmetry is abnormal, 
one or more congenital defects may arise. These defects range from atrial septal defects (ASD) or 
ventral septal defects (VSD) to the double outlet of the right ventricle (DORV) and transposition of 
the great arteries (TGA). It is noteworthy that laterality disease is frequently associated with 
congenital heart defects (CHD) [80]. However, cardiac defects associated with laterality diseases 
are also reported in Shp2-D61G knock-in mice. A proportion of the heterozygous Shp2-D61G mice 
displays septal defects and DORV [61]. However, laterality defects are not the only cause of 
septation defects or DORV. Hence, it remains to be determined whether laterality defects have a 
role in human NS and LS. Overall the zebrafish model is becoming a very powerful model to study 
cardiac development. By evolving new and more specific assays, the zebrafish model can be used 
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The PTPN11 (protein-tyrosine phosphatase, non-receptor type 11) gene encodes SHP2, a 
cytoplasmic PTP that is essential for vertebrate development. Mutations in PTPN11 are associated 
with Noonan and LEOPARD syndrome. Human patients with these autosomal dominant disorders 
display various symptoms, including short stature, craniofacial defects and heart abnormalities. 
We have used the zebrafish as a model to investigate the role of Shp2 in embryonic development. 
The zebrafish genome encodes two ptpn11 genes, ptpn11a and ptpn11b. Here, we report that 
ptpn11a is expressed constitutively and ptpn11b expression is strongly upregulated during 
development. In addition, the products of both ptpn11 genes, Shp2a and Shp2b, are functional. 
Target-selected inactivation of ptpn11a and ptpn11b revealed that double homozygous mutants 
are embryonic lethal at 5-6 days post fertilization (dpf). Ptpn11a-/-ptpn11b-/- embryos showed 
pleiotropic defects from 4 dpf onwards, including reduced body axis extension and craniofacial 
defects, which was accompanied by low levels of phosphorylated Erk at 5 dpf. Interestingly, 
defects in homozygous ptpn11a-/- mutants overlapped with defects in the double mutants albeit 
they were milder, whereas ptpn11b-/- single mutants did not show detectable developmental 
defects and were viable and fertile. Ptpn11a-/-ptpn11b-/- mutants were rescued by expression of 
exogenous ptpn11a and ptpn11b alike, indicating functional redundance of Shp2a and Shp2b. The 
ptpn11 mutants provide a good basis for further unravelling of the function of Shp2 in vertebrate 
development.
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Introduction
The PTPN11 (protein-tyrosine phosphatase, non-receptor type 11) gene encodes SHP2, a 
ubiquitously expressed cytoplasmic protein-tyrosine phosphatase (PTP) with two Src homology 
2 (SH2) domains that is essential for normal development [1-3]. SHP2 is a positive effector of 
extracellular regulated kinase (ERK)/MAPK signal transduction, downstream of most receptor 
tyrosine kinases (RTKs) [2] [3]. Moreover, Shp2 is involved in other signal transduction processes 
as well, including Jak-STAT signaling [3] and PI3K-AKT (also known as PI3K-PKB) signaling [2]. 
Missense mutations in the PTPN11 gene are associated with the dominantly inherited genetic 
disorders, Noonan syndrome (NS) (OMIM 163950) and LEOPARD syndrome (LS) (OMIM 151100) 
[4-9]. These syndromes share several overlapping features, including facial dysmorphism, 
cardiovascular defects, hearing loss, growth retardation and scoliosis [7,10]. NS variants of SHP2 
have increased PTP activity [2]. By contrast, most LS variants of SHP2 display reduced catalytic 
activity [11-14]. NS-associated mutations in Shp2 promote Erk/MAPK signaling [2]. Yet, the role of 
LS Shp2-variants in Erk/MAPK signaling is less clear, in that both activation and inhibition of Erk/
MAPK signaling have been observed in LS [11,14-18]. Nevertheless, signaling by NS- and LS-
variants of SHP2 is distinct, because LS-SHP2, but not NS-SHP2, affects AKT (PKB) signaling 
[12,19]. The mechanism underlying how NS- and LS-variants of SHP2 induce similar defects in 
development remains to be determined. 
Shp2 has an essential role in early development in the mouse [20]. Homozygous Ptpn11-/- embryos 
die pre-implantation due to defective Erk activation and trophoblast stem cell death [20], 
precluding the possibility to study Shp2 function in differentiated cell types in adult animals. This 
problem was partially overcome with the use of conditional Shp2 knockout mice [21-23]. For 
example, mice with a Ptpn11 deletion in the cardiomyocytes show that Shp2 is required for the 
suppression of dilated cardiomyopathy [22]. Conditional deletion of Shp2 in neural progenitor 
cells results in early postnatal lethality, impaired corticogenesis, and reduced proliferation of 
progenitor cells in the ventricular zone [21]. In an aged mouse model, hepatocyte-specific deletion 
of Ptpn11 promotes inflammatory signalling and hepatic inflammation/necrosis, resulting in 
regenerative hyperplasia and spontaneous development of tumors [24]. Furthermore, a study in 
Xenopus shows that dominant-negative Shp2 mutants failed to complete gastrulation, resulting in 
severe posterior truncations [25]. In zebrafish, Shp2 knockdown embryos show a reduction of the 
body axis extension at 10 hours post fertilization (hpf) that is consistent with gastrulation 
defects. In addition, at later stages, the embryos are shorter and develop a hammerhead phenotype 
[26,27]. These data show that Shp2 is a crucial player in the development of many different 
organisms.
In our study we used zebrafish as a model to further investigate the role of Shp2. The zebrafish 
has proven to be an excellent experimental model to study gene function in vivo and to analyze 
vertebrate embryogenesis as development occurs externally and the embryos are transparent 
[28]. We identified two zebrafish ptpn11 genes (ptpn11a and ptpn11b), encoding Shp2a and Shp2b, 
respectively. We demonstrate that ptpn11a was constitutively expressed and ptpn11b expression 
increased during early embryogenesis. Ptpn11a and ptpn11b both encoded functional proteins 
with similar catalytic activity. We used target selected gene inactivation (TSGI) to identify stop 
mutations in the N-terminal SH2 domain of each of the two ptpn11 genes. Our study showed that 
ptpn11b-/- zebrafish were viable and fertile and showed no abnormal phenotype during 
development. However, single homozygous mutants for ptpn11a and double homozygous mutant 




mutants died at 5 days post fertilization (dpf). Moreover, we found that Shp2 deletion suppressed 
Erk activation in double mutant embryos, but not in embryos lacking only Shp2a or Shp2b. 
Together, our observations demonstrate that Shp2 is essential for zebrafish development, and 
that ptpn11a has a more pronounced role as the result of its higher expression level at early stages. 
Results
Characterization of zebrafish ptpn11 genes
The zebrafish genome encodes two ptpn11 genes: ptpn11a and ptpn11b [33]. The homology 
between human Shp2 and zebrafish Shp2a and Shp2b, encoded by ptpn11a and ptpn11b genes, is 
91% and 64% respectively (Figure S1). Due to the genome duplication that occurred in teleosts it 
is not uncommon for zebrafish to have two homologous copies of a gene that is present as a single 
copy in other vertebrates [34,35]. To analyze stage-specific expression of ptpn11a and ptpn11b 
mRNA in wild-type (WT) embryos, we used a reverse transcription PCR (RT-PCR) approach. 
Expression levels were analysed at 4 hpf, 10 hpf, 1 dpf, 2 dpf, 3 dpf and 5 dpf. Ptpn11a and ptpn11b 
mRNA are both expressed from 4 hpf to 5 dpf (Figure 1A). Ptpn11a mRNA was expressed at 
similar levels at all stages. By contrast, ptpn11b mRNA was hardly detectable at early stages and 
ptpn11b expression increased during development. To confirm this result, ptpn11a and ptpn11b 
expression levels were examined at 10 hpf, 1dpf, 2dpf, 3dpf and 5 dpf by quantitative PCR. Ptpn11a 
expression was constantly maintained in all the stages whereas ptpn11b gene was expressed at 
low levels at early stages and became strongly upregulated over time (Figure 1B). In situ 
hybridization experiments showed that the two zebrafish ptpn11 genes were broadly expressed 
throughout embryonic development (Figure 1C). Both ptpn11 genes were maternally expressed 
and later in development the expression was restricted to the more anterior region of the 
developing embryo. Overall, these results show that both ptpn11 genes were expressed throughout 
developing zebrafish embryos. Ptpn11a appears to be expressed at a constant level, whereas 
ptpn11b expression is low initially and is strongly upregulated over time. 
Zebrafish Shp2a and Shp2b displayed phosphatase activity 
Previously, we assessed that Shp2a is an active phosphatase and that mutant Shp2a-D61G with a 
mutation that was identified in human NS patients shows an increased phosphatase activity 
compared to wild type Shp2a [26]. To investigate if the ptpn11b gene product was functional, we 
expressed Shp2b in bacteria in parallel with Shp2a and investigated phosphatase activity. Both 
Shp2a and Shp2b displayed phosphatase activity and dephosphorylated p-nitrophenylphosphate 
(pNPP) to a similar extent. Moreover, Shp2b-D61G showed an increase in activity compared to 
WT-Shp2b, resembling the Shp2a-D61G mutant (Figure 2). These results demonstrate that both 
Shp2 proteins encoded by the zebrafish genome were functional PTPs in vitro.
Generation of ptpn11 knock-out zebrafish
We identified germline mutations in the zebrafish ptpn11 genes, using the target-selected gene 
inactivation (TSGI) strategy, developed at the Hubrecht Institute [30]. Mutant alleles ptpn11a 
hu3459 and ptpn11b hu5920 contained nonsense mutations in exon 3 of ptpn11a and ptpn11b, 
respectively (Figure 3). We denoted the homozygous mutants as ptpn11a-/- and ptpn11b-/- because 
the premature stops are well upstream of the phosphatase catalytic site and hence, no functional 
protein is produced. Ptpn11a+/- and ptpn11b+/- fish were viable and fertile and these fish were 
incrossed to generate homozygous fish. Genotypes were obtained at mendelian ratios until 5 dpf. 
Ptpn11a-/- fish did not reach adulthood. By contrast, homozygous ptpn11b-/- fish were viable and 
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Figure 1. Expression of zebrafish ptpn11a and ptpn11b mRNA during embryogenesis. (a) 
RNA was isolated from zebrafish embryos at 4hpf, 10 hpf, 1 dpf, 2 dpf, 3dpf and 5dpf. Reverse transcription 
PCR was performed to detect the indicated genes; reverse transcriptase was omitted from the reaction as 
a control (-RT). (b) Quantitative PCR for ptpn11a and ptpn11b gene expression was performed from a pool 
of wild-type embryos (n=30) collected at 10 hpf, 1 dpf, 2 dpf, 3 dpf and 5dpf. The values were normalized 
using Actin as a control and relative expression is depicted here (value at 5 dpf set to 1.0). Error bars 
indicate standard error of the mean. (c) Whole-mount in situ hybridization using ptpn11a and ptpn11b 
specific probes of 4 hpf, 10 hpf, 30 hpf, 2 dpf, 3 dpf and 5 dpf embryos. Lateral and dorsal views are given 
as indicated.
Characteristics ptpn11a-/- ptpn11b-/- ptpn11a-/-
ptpn11b-/-
Head Reduced in some 
cases
Normal Enlarged by edema. 
Prominent jaw
Heart Normal Normal Severe edema 
Swim bladder Absent Normal Absent
Length Shorter Normal Shorter
Ventral region Reduced, skinny 
appearance












Figure 2. Shp2a and Shp2b proteins 
displayed phosphatase activity. 
(a) PTP activity of pGEX, WT-Shp2a, 
Shp2a-D61G, WT-Shp2b and Shp2b-D61G 
was assayed using p-nitrophenylphosphate 
(pNPP) and quantified 
spectrophotometrically. Approximately 
1 µg purified fusion protein was used 
in the assay. Experiments were done in 
quadruplicate; averages are depicted and 
error bars indicate standard error of the 
mean. (b) Equivalent amounts of fusion 
protein that were used in the activity assays 
in (a) were run on an SDS-PAGE gel and 
stained with Coomassie blue.
Figure 3. Nonsense mutations in zebrafish ptpn11a 
and ptpn11b. 
Sequence analysis of homozygous ptpn11a and ptpn11b 
mutants. (a) A C–>T mutation in ptpn11ahu3459 resulted 
in a glutamine to a STOP mutation. (b) A T–>A mutation 
in ptpn11bhu5920 changed lysine to a STOP mutation. (c) 
Schematic representation of the exon organization and 
structural domains of ptpn11a and ptpn11b. Nonsense 
mutations upstream of the catalytic domain are represented 
by red arrows.
 incross injection (mRNA) phenotype ptpn11a-/-/total
ptpn11a+/-ptpn11b-/- - 40/199 40/199
ptpn11a+/-ptpn11b-/- ptpn11a 1/98 23/98
ptpn11a+/-ptpn11b-/- ptpn11b 5/65 12/65
 
ptpn11a+/-ptpn11b+/+ - 25/102 25/102
ptpn11a+/-ptpn11b+/+ ptpn11b 15/360 75/360
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fertile. Next, fifth generation ptpn11a+/- and ptpn11b+/- fish were incrossed and double 
heterozygous ptpn11a+/-ptpn11b+/- fish were selected. Incrosses were used to investigate zebrafish 
development in double homozygous ptpn11a-/-ptpn11b-/- embryos. Phenotypically, all genotypes 
were indistinguishable from wild type embryos up to 3 dpf (data not shown). However, at 5dpf, 
ptpn11a-/- and double mutant embryos displayed significant phenotypic changes such as reduced 
body length, malformed head, absence of swim bladder, heart edema and eye edema (Figure 4A-
D). Furthermore, these embryos were unable to move, even after stimulation. Ptpn11b-/- embryos 
were indistinguishable from wild type embryos at 5 dpf and did not display morphological defects 
(Figure 4A,C; Table 1). Ptpn11a-/- embryos and ptpn11a-/-ptpn11b-/- embryos were embryonic 
lethal. Whereas the developmental defects of ptpn11a-/- and ptpn11a-/-ptpn11b-/- embryos were 
overlapping (Figure 4 B,D), the phenotype of double mutant embryos was more severe than that 
of ptpn11a-/- embryos. 
Ptpn11a-/- and double mutants appeared shorter than wild type embryos and we measured the 
body length of wildtype and mutant embryos at 5 dpf. Ptpn11a-/- (3.33 mm ± 0.03, n = 20) and 
ptpn11a-/-ptpn11b-/- (3.28 mm ± 0.05, n = 10) embryos were significantly shorter (p < 0,001, 
Student’s t-test) than wild type embryos (3.59 mm ± 0.02, n = 21) (Figure 4E). The length of 
wildtype embryos and ptpn11b-/- embryos (3.55 mm ± 0.02, n = 15) did not differ significantly. 
Collectively, our results show that ptpn11a, but not ptpn11b, is essential for normal development. 
Yet, ptpn11b appears to be functional, because the double mutant ptpn11a-/-ptpn11b-/- displayed 
more severe defects than ptpn11a-/- by itself.
Craniofacial defects in Ptpn11a-/- and double mutant Shp2 embryos 
Patients affected by NS and LS often suffer from craniofacial defects, including positional 
anomalies of the eyes and ears and a short, webbed neck. Craniofacial defects were apparent in 
double mutant ptpn11a-/-ptpn11b-/- embryos at 5 dpf. Alcian blue staining of the cartilage revealed 
craniofacial defects that were quantified by assessment of the angle of the ceratohyal, a direct 
measure for the width of the head (Figure 5A). There was a significant difference between 
wildtype (60.72° ± 1.51, n=24) and double mutant embryos (95.14° ± 6.12, n=10) (p< 0.001, 
Student's t-test). Moreover, also ptpn11a-/- embryos (79.56° ± 5.29, n=15 p< 0.01) had a significantly 
wider ceratohyal compared to wildtype embryos, although the defect was milder. Ptpn11b-/- 
embryos (62.84° ± 5.73, n = 11) did not show a significant difference compared to wildtype 
embryos (Figure 5I). Taken together, these results show that particularly ptpn11a is indispensable 
for craniofacial development. 
Double mutant Shp2 phenotype was rescued upon ptpn11a and ptpn11b mRNA 
injections. 
To investigate if the double mutant phenotype could be suppressed by introduction of the full-
length ptpn11a and ptpn11b mRNA, we performed rescue experiments. Clutches of embryos from 
ptpn11a+/-ptpn11b-/- zebrafish were split and injected with ptpn11a or ptpn11b mRNA, or were not 
injected. The embryos were sorted based on their morphology at 5 dpf and genotyped by 
sequencing. The overall morphology of double mutant embryos is nicely distinguishable from 
Table 2. Rescue of ptpn11a mutant phenotype by injection of ptpn11a and ptpn11b. Clutches 
of embryos from ptpn11a+/-ptpn11b-/- or ptpn11a+/-ptpn11b+/+ zebrafish were split and injected with ptpn11a 
mRNA or ptpn11b mRNA. The embryos were scored based on their morphology at 5 dpf. Phenotype 
represents the number of embryos with mutant morphology/ total number of embryos. Subsequently, the 
genotype was determined by sequencing and is depicted as number of ptpn11a-/- embryos/ total number of 





wildtype embryos and 40/199 - close to the 
expected 25% - of the embryos are shorter and 
particularly the trunk and tail region is wider 
(Figure 6A). Microinjection of ptpn11a mRNA in 
offspring of ptpn11a+/-ptpn11b-/- mutants at the 
one-cell stage largely suppressed the 
morphological phenotype in double mutant 
embryos at 5 dpf (Figure6B, Table 2). Interestingly, 
injection of ptpn11b mRNA also led to rescue of the 
morphological defects (Figure 6C, Table 2), 
indicating that ptpn11a and ptpn11b have 
redundant biochemical functions. The difference 
in the function of ptpn11a and ptpn11b in 
development may be caused by the observed 
difference in expression level at early stages of 
development. To test this hypothesis directly, we 
investigated whether ptpn11b RNA was able to 
rescue the ptpn11a-/-ptpn11b+/+ phenotype. 
Ptpn11b mRNA injections at 1 cell stage indeed 
largely suppressed the ptpn11a-/- embryo 
phenotype (Figure6D,E, Table 2). These results 
show that ptpn11a and ptpn11b mRNA injections 
largely rescued the developmental defects in the 
double mutant embryos at 5 dpf and that injections 
ofptpn11b alone suppressed the ptpn11a-/- 
phenotype.
Impaired Erk/MAPK, but not Akt/PKB 
signalling in Shp2 double mutant embryos
Shp2 is required to promote the activation of the 
MAPK cascade in response to growth factors, 
cytokine receptors and integrins [3,36]. Thus, we 
examined the functional consequences of loss of 
Figure 4. Loss of Shp2 causes severe 
morphological defects at 5 dpf. 
Morphology of 5 dpf zebrafish embryos. (a) 
Representative wild-type, (b) ptpn11a-/-, 
(c) ptpn11b-/- and (d) double homozygous 
mutant are depicted. (e) The length was 
measured from nose to tip of tail at the same 
magnification. Bars show average length of 
the studied genotypes (n = 10-20). Statistics 
were determined using a student’s t-test; * 
indicates a p value < 0.05. 
Figure 5. Ptpn11a-/- and double mutant embryos exhibit craniofacial defects at 5 dpf. 
Alcian blue staining was done to visualize the cartilage. (a,e) wild-type, (b,f) ptpn11a-/-, (c,g) ptpn11b-/- 
and (d,h) double homozygous mutant. (i) Average width of the ceratohyal angle (indicated in panel a) was 
determined for each genotype (n = 10-24). Statistics were determined using a student’s t-test; ** indicates a 
p value of < 0.01, *** indicates a p value < 0.001
61
Distinct and overlapping functions of ptpn11 genes in zebrafish development
4
Shp2 on downstream signaling by investigating Erk phosphorylation in wildtype, ptpn11a-/-, 
ptpn11b-/- and double mutant embryos at 5 dpf. Immunoblotting showed that Erk activation was 
decreased in double mutant embryos compared to wild type, whereas Erk levels were not 
impaired in the single homozygous mutants (Figure 7A). Shp2 has been reported to act upstream 
of Akt/PKB signalling [12,18]. We investigated Akt signaling by immunoblotting for 
phosphorylated Akt in wild-type, ptpn11a-/-, ptpn11b-/- and double mutant embryos at 5 dpf. We 
found that Akt activation was not affected in both single ptpn11 homozygous mutants, nor in the 
double mutants (Figure 7B). Together, these data indicate that Erk/MAPK signaling, but not Akt 
(PKB) signaling is affected in mutants lacking functional Shp2. 
Discussion
In this paper we characterized the two ptpn11 genes in zebrafish, ptpn11a and ptpn11b. The 
products of these genes, Shp2a and Shp2b, respectively, are both active and exhibit comparable 
phosphatase activities. Using a TSGI approach, we identified nonsense mutations in ptpn11a and 
ptpn11b, well upstream of the catalytic site that abolished Shp2 function. In agreement with 
previous studies in mice with targeted ptpn11 [20,37], double mutant zebrafish embryos lacking 
all functional Shp2 were found to be embryonic lethal. Mouse embryos lacking functional Shp2 die 
around implantation [20,37], whereas zebrafish embryos lacking functional Shp2 survive until 
5-6 dpf. The difference in the developmental stage at which the lack of Shp2 is embryonic lethal 
between mice and zebrafish might be explained by the difference in maternal contribution of 
Shp2 in zebrafish eggs compared to mouse embryos.Whereas double mutant zebrafish embryos 
are embryonic lethal, lack of ptpn11b in homozygous single mutant fish resulted in viable and 
fertile fish without developmental defects. Yet, ptpn11a-/- single mutant embryos did not survive, 
suggesting a distinct role of the two ptpn11 genes in zebrafish development. Biochemically, Shp2a 
and Shp2b have similar catalytic activities. However, expression analyses showed that ptpn11a 
was abundant in all developmental stages whereas ptpn11b was hardly detectable at early stages. 
Ptpn11b expression increased strongly over time. This may explain why the lack of ptpn11a 
affected development and lack of ptpn11b did not. Low levels of ptpn11b in ptpn11a-/- embryos at 
early stages cannot compensate for the lack of ptpn11a. Conversely, high levels of ptpn11a in 
ptpn11b-/- embryos can compensate for the lack of ptpn11b. Ptpn11a as well as ptpn11b rescued 
developmental defects in double mutant embryos, indicating that Shp2a and Shp2b have 
redundant functions. It is noteworthy that expression of exogenous ptpn11b rescued ptpn11a-/- 
embryos, demonstrating that the difference in developmental function of ptpn11a and ptpn11b is 
mainly caused by differences in expression levels during early development. 
The developmental defects we observed in ptpn11a-/-ptpn11b-/- embryos became apparent 
relatively late during development. Only at 4-5 dpf the first morphological defects were visible. 
This is in contrast with earlier reports of morpholino (MO)-mediated knockdown of Shp2, where 
we and others observed developmental defects as early as gastrulation [26,27]. The lack of 
gastrulation defects in ptpn11a-/-ptpn11b-/- embryos may be due to maternal contribution of 
ptpn11a in the double mutants. The reduced body axis and craniofacial defects we observed in 
double mutants are comparable to the phenotypes of Shp2 knockdown embryos and of embryos 
expressing NS or LS variants of Shp2, that we and others reported earlier [26,27]. It is evident that 
Shp2 has an important role in body axis extension and craniofacial development: short stature is 
one of the most recognized symptoms in individuals with NS and LS. During the first years of life 
the body length drops below the 10th percentile for height in NS [38] and below the 25th percentile 




[40,41]. Moreover, human patients with NS or LS show 
visible craniofacial symptoms, including high forehead, 
hypertelorism, downslanting palpebral fissures, epicantal 
folds, ptosis, low-set and/or posteriorly rotated ears 
[5,42,43]. The ablation of Shp2 in neural crest cell leads to 
severe craniofacial anomalies in mice [44,45]. Similarly, 
expression of morpholino Shp2 and Noonan or LEOPARD 
Shp2 embryos, induced craniofacial defects in zebrafish at 
4dpf [26,27]. Collectively, our results showed craniofacial 
defects and body axis extension defects in mutant zebrafish 
embryos, lacking functional Shp2, that are consistent with 
defects observed in mouse models lacking functional Shp2 
in relevant cell types as well as with developmental defects 
in mouse models for NS or LS and symptoms in human 
individuals with NS or LS. 
SHP2 positively regulates (ERK)/MAPK signal transduction 
[2] and downregulation of the (ERK)/MAPK pathway, due 
to the disruption of Shp2, leads to the formation of skeletal 
abnormalities and skull defects in mice [46,47] .We show 
that at 5dpf, pERK levels are downregulated in ptpn11a-/-
ptpn11b-/- embryos, which is consistent with an essential 
role for Shp2 in Erk/MAPK signaling upstream of 
craniofacial development. However, even though in the 
ptpn11a-/- embryos pERK levels are comparable to 
wildtype, these embryos still showed craniofacial defects 
and reduced body length at 5dpf, albeit to a lesser extent 
than ptpn11a-/-ptpn11b-/- double mutant embryos. We 
cannot exclude the possibility that craniofacial development is independent of Erk/MAPK 
signaling. However, the ptpn11a-/- phenotype may be the consequence of reduced Erk/MAPK 
signaling at earlier stages, i.e. prior to 5 dpf. Ptpn11b is only expressed at low levels at these early 
developmental stages, which may not compensate for the loss of ptpn11a to sustain physiological 
levels of Shp2-dependent Erk/MAPK signaling at stages that are crucial for craniofacial 
development. At 5 dpf, ptpn11b expression is high and may compensate for the lack of Shp2a in 
ptpn11a-/- mutants with respect to Erk/MAPK signaling. To prove temporal dependence on Erk/
MAPK signaling in ptpn11a-/- mutant embryos is not trivial as it requires assessment of Erk 
phosphorylation at early developmental stages, i.e. in embryos that do not yet display 
developmental defects. Collectively, our data show that functional Shp2 is required for Erk/MAPK 
signaling at 5 dpf and whether Erk/MAPK signaling is involved in the developmental defects 
remains to be determined definitively. 
In conclusion, we characterized the two ptpn11 genes in zebrafish and found that the function of 
the two genes in development is distinct which is due to differences in their temporal expression 
patterns. The developmental defects that were observed in double mutant zebrafish embryos 
lacking functional Shp2 are consistent with developmental defects in mouse models lacking Shp2. 
The observed body axis extension and craniofacial defects are reminiscent of defects observed in 
mouse models for NS and LS, as well as the symptoms observed in human patients with NS and LS, 
underlining the importance of Shp2 for craniofacial development and body axis extension. The 
Figure 7. Impaired Erk/MAPK, 
but not Akt/PKB signalling in 
Shp2 double mutant embryos. WT, 
ptpn11a-/-, ptpn11b-/- and ptpn11a-/- 
ptpn11b-/- embryos were lyzed and 
immunoblotted with phosho-specific 
antibody for ERK and AKT; membranes 
were then reprobed for total Erk and 
Akt expression to control for loading. 
The blots were quantified and the ratio 
of phosphorylated protein/ total protein 
from three independent experiments is 
indicated below each lane. 
63
Distinct and overlapping functions of ptpn11 genes in zebrafish development
4
ptpn11 mutants that we have identified constitute a useful system to further unravel the function 
of Shp2 in development. Moreover, these mutants provide a good starting point for the 
development of genetic models for NS and LS in zebrafish that will complement other animal 
models for these syndromes. 
Materials and Methods
Ethics statement
All procedures involving experimental animals described here were approved by the local animal 
experiments committee (KNAW-DEC protocol HL05.1501) and performed according to local 
guidelines and policies in compliance with national and European law.
Zebrafish care and generation of ptpn11 mutant lines
Zebrafish maintenance, breeding and staging were performed following published protocols [29]. 
ENU mutagenesis was performed on TL males [30] and exons 1–4 of the zebrafish ptpn11a and 
ptpn11b genes were sequenced using DNA from F1 generation zebrafish. Each mutation was 
confirmed by resequencing. Genomic DNA was extracted from adult fish fin clip or fixed embryos. 
The genotyping assay for the ptpn11 mutations was performed by nested PCR with primer sets: 
ptpn11a, 5’-GCGCTGTCACACACATTAAGA, 5’-TCACAGCCAATAAAGAGAAGC; nested ptpn11a 
5’-CGACCTGTATGGTGGAGAGAA, 5’-TCCCAAATTGTCATGTAAGG; ptpn11b, 5’- 
TTCAACAACATCCTCCTAACTG, 5’-AAACAAACCACAGCTCTTCC and nested ptpn11b 
5’-GTCTGTCATCCCTCATTTCC, 5’-GCAGGATTTATTCTGTCCAC, followed by sequencing to detect 
the mutations. 
RNA isolation, cDNA synthesis and quantitative PCR
For the reverse transcription PCR (RT-PCR) experiment, thirty zebrafish embryos at various 
stages of development (4 hpf, 10hpf, 1 dpf, 2 dpf, 3 dpf and 5 dpf) were collected and homogenized 
in TRIzol Reagent (Invitrogen; Carlsbad, CA). The homogenate was centrifuged (12000g, 4ºC, 10 
min.). 0.2 ml of Chloroform were added to the supernatant, vortexed for 15 sec., incubated for 3 
min. at room temperature (RT) and then centrifuged (12000g, 4ºC, 15 min.). 0.5 ml isopropanol 
were added to the upper phase, incubated for 10 min. at RT and centrifuged (12000g, 4ºC, 15 
min.). The pellet was washed with 75% EtOH and after vortexing, centrifuged (10000g, 4ºC, 5 
min.). The pellet was then dried for 5 min. and dissolved in 100 µl MQ. After, the solution was 
incubated for 10 min. at 37 ºC, precipitated in 250 µl 100% EtOH and 10 µl 3M NaAc and stored at 
-80 ºC. 
For RT-PCR with M-MLV-RT (Promega) 1 µg of total RNA was used. PCR of cDNA was performed 
using the standard protocol of GoTaq (Promega) using oligonucleotides listed as follow; ptpn11a 
forward: 5’- ATGTGCCCAAGACTATCCAGATG, 
ptpn11a reverse: 5’- CCCACGTTCTCATAGACTCGAGA, 
ptpn11b forward: 5’- ACTGTGACATTGACATCCCAAAAA, 
ptpn11b reverse: TACTGCTGGTGGAGCCCTTTGGAT. The same primers were used for sequencing 
of the DNA fragments.
Real-time RT-PCR was performed using the IQ SYBR® Green Supermix (Biorad). Real time PCR 
MyIQ software (Bio-rad) was used to determine the amplification cycle in which product 




50°C for 2 min and pre-denaturing at 95°C for 3 min, followed by 40 cycles at 95°C for 30 sec and 
62°C for 1 min. The relative quantification was given by the CT values, determined by triplicate 
reactions for all of the samples for ptpn11a, ptpn11b and β-actin. Real time PCR Ct values were 
analyzed using the 2−ΔCT method [31].
For the quantification of ptpn11a and ptpn11b mRNA levels, the housekeeping gene actin was used 
as internal standard. ΔCT-values were calculated as follows: CT(β-actin)-CT(ptpn11)  and were 
normalized to the starting point T0 (4hpf) . 
In situ hybridization 
In situ hybridizations were done essentially as described [32]. .Digoxigenin-UTP-labeled 
riboprobes for ptpn11a and ptpn11b were synthesized from PCR products. The PCR products 
were amplified with primers containing the T7 promoter and then sequenced. Primers were 
designed as follows: ptpn11a forward, 5’- ATTTAGGTGACACTATAGGGAGCTACATTGCCACACAA, 
ptpn11a reverse: 5’- TAATACGACTCACTATAGGGTTTTTCATCTCTCGGTTTAGTCA . For ptpn11b, 
primers that attached to the 3’UTR region of the gene were designed: ptpn11b forward: 5’- 
ATTTAGGTGACACTATAGGGAACAAAACGAAGGAGAGG, ptpn11b reverse: 5’- 
TAATACGACTCACTATAGGGGCCTGCCTCATTTTTAGCTG. Embryos were cleared in methanol and 
mounted in Benzyl Benzoate/Benzyl Alcohol (2:1) before pictures were taken. 
Alcian blue staining
Morphological phenotypes were assessed at 5 dpf. Embryos were anesthesized at 5 dpf with MS-
222 (Sigma), fixed in 4% paraformaldehyde (PFA) and the cartilage was stained with alcian blue. 
Briefly, fixed embryos were washed for 10 min in 50 % ETOH in water. Next, the embryos were 
stained overnight at 4C in staining solution (0.04% alcian blue, 50mM MgCl2, 70 % EtOH). 
Embryos were washed in 0.2% of Triton X-100 in water. Pictures of lateral and ventral views were 
taken. The width of the ceratohyal angle was determined using Image J software and the ratio 
was determined as a direct measure for craniofacial defects. Averages were determined and a 
student t-test was done to determine whether the differences between the diverse conditions 
were statistically significant.
Immunoblotting
Zebrafish embryos were raised in standard conditions. At 5dpf, 5 embryos were pooled and lysed 
in buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 
1% Nonidet P-40, 0.1% sodium deoxycholate, protease inhibitor mixture (Complete Mini, Roche 
Diagnostics) and vanadate, and 40 µl lysisbuffer. Lysates were spun down and 4× sample buffer 
was added to supernatant; Samples were run on SDS-PAGE gel (10%) and transferred to PVDF 
membrane. After transfer the membrane was stained with Coomassie Blue stain to verify equal 
loading of the lysates. Subsequently the PVDF membrane was blocked with 5% BSA and then 
incubated with the corresponding antibodies targeting mouse monoclonal antibody anti-pERK, 
rabbit monoclonal antibody anti-ERK, rabbit monoclonal antibody pAKT and rabbit monoclonal 
antibody anti-AKT. All the primary antibodies were diluted 1:1000 in blocking solution and they 
were purchased from Cell-Signaling. The secondary antibodies (mouse and rabbit) conjugated to 
horseradish peroxidase (HRP), were purchased from BD bioscience Pharmaceutical and they 
were diluted 1:10,000 in TBST. The membranes were subjected to detection by enhanced 
chemiluminescence (Thermo Scientific kit).
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Phosphatase assay
We generated zebrafish ptpn11a and ptpn11b cDNA constructs and cloned them in a pGEX-4t 
vector, allowing production and purification of recombinant Shp2 proteins, fused to six histidine 
residues in their C-termini. Purified GST-fusion proteins were directly incubated in PTP assay 
buffer (20 mM MES buffer pH 6.0, 1 mM EDTA, 150 mM NaCl, 1 mM dithiotreitol, and 10 mM 
p-nitrophenylphosphate) for 45 min. at 30 °C. The reactions were quenched with 0.4 M NaOH, and 
optical density was measured with a spectrophotometer at 415 nm (wavelength).
Statistical analysis 
Statistical significance was assessed by two-tailed Student’s t-test in all experiments. Significance 
is represented in the graphs. Results are considered significant when p < 0.05 and are expressed 
as mean ± standard error of the mean. * indicates a p value of < 0.05, ** indicates a p value of < 
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Figure S1. Comparison of human 
SHP2 and zebrafish Shp2a and Shp2b 
polypeptides. The alignment was done using 
ClustalW. Identical amino acids are highlighted 
in black. The consensus sequence is shown 
underlined, on top of the rows. Amino acids are 
numbered to the right of each row.
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Noonan syndrome (NS) and LEOPARD syndrome (LS) cause congenital afflictions such as short 
stature, hypertelorism and heart defects. More than 50% of NS and almost all of LS cases are 
caused by activating and inactivating mutations of the phosphatase Shp2, respectively. How these 
biochemically opposing mutations lead to similar clinical outcomes is not clear. Using zebrafish 
models of NS and LS and mass spectrometry-based phosphotyrosine proteomics, we identified a 
down-regulated peptide of Fer kinase in both NS and LS. Further investigation showed a role for 
Fer during development, where morpholino-based knockdown caused craniofacial defects, heart 
edema and short stature. During gastrulation, loss of Fer caused convergence and extension 
defects without affecting cell fate. Moreover, Fer knockdown cooperated with NS and LS, but not 
wild type Shp2 to induce developmental defects, suggesting a role for Fer in the pathogenesis of 
both NS and LS.
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Introduction
Noonan syndrome (NS) (OMIM 163950) is a congenital disorder that manifests itself in heart 
defects, short stature, webbed neck, hypertelorism and an increase in the occurrence of juvenile 
myelomonocytic leukemia (JMML) and other malignancies. The most common causes for NS are 
mutations in PTPN11 encoding for Src-homology domain 2 (SH2) containing phosphatase 2 (Shp2) 
[1] A similar syndrome is also caused by mutations in PTPN11 and patients display similar 
symptoms as NS. An acronym of the symptoms, Lentigines, Electrocardiographic conduction 
anomalies, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retarded growth and 
Deafness gave  this syndrome its name, LEOPARD syndrome (LS)(OMIM 151100) [1]. Both NS and 
LS are part of a group of congenital syndromes caused by mutations in the RAS mitogen activated 
protein kinase (MAPK) pathway called RASopathies. Despite the similarities in the clinical 
manifestations of NS and LS, NS mutations lead to an ‘active’ form of the Shp2 phosphatase, while 
LS is thought to result from ‘inactivating’ mutations [2,3]. However, a gain-of-function for LS has 
also been described in Drosophila [4]. 
The phosphatase Shp2 consists of two N-terminal SH2 domains that are able to bind to tyrosine 
phosphorylated targets of Shp2, a protein tyrosine phosphatase (PTP) domain, and a C-terminal 
tail with a proline rich domain and two tyrosines that are able to bind Grb2 when phosphorylated. 
Under basal conditions, the N-SH2 domain blocks access of the PTP domain to its substrates, 
resulting in an inactive conformation of Shp2 [5]. In NS, mutations cause a disruption of the 
interaction between the N-SH2 domain and the PTP domain, resulting in a hyperactive form of 
Shp2 [1,2]. In LS however, mutations are mostly present in the PTP domain at the interface of the 
PTP and SH2 domain, resulting in a loss of catalytic activity. How both activating and inactivating 
mutations of Shp2 lead to similar developmental defects is largely unknown. 
Homozygous mice defective for Shp2 die in utero and have gastrulation defects, showing 
malformations of the notochord and posterior truncations [6]. Embryos lacking Shp2 also develop 
failure of neural tube closure resulting in spina bifida and secondary neural tubes resulting from 
gastrulation defects [7]. Shp2 is essential for limb formation since chimeric mice with defective 
Shp2 expressed in the mesenchyme of the progress zone showed limb bud defects [8]. More recent 
results have shown cell migration defects during gastrulation in NS and LS Shp2 expressing 
zebrafish embryos as well [9]. These convergence and extension (C&E) cell movements mediate 
the anterior-posterior lengthening and lateral narrowing of the developing embryo. C&E cell 
movements are under strict spatiotemporal control of various signaling pathways [10]. Being a 
protein proximal to many RTKs, Shp2 acts upstream of multiple signaling pathways [2]. 
As NS and LS Shp2 are thought to act biochemically opposite, yet give rise to similar clinical 
symptoms, we sought to identify potential common targets of NS and LS Shp2 in a zebrafish 
model. Pinpointing disease associated Shp2 signaling shared by NS and LS, may contribute to the 
understanding of the underlying mechanisms of NS and LS pathogenesis and the development of 
therapeutic strategies for both NS and LS. Using a comparative phosphoproteomics approach, 
phosphotyrosine (pTyr)-containing peptides of NS- and LS-Shp2 expressing zebrafish embryos 
were isolated, identified and compared to peptides of WT embryos. A peptide corresponding to 
the autophosphorylation site of Fer kinase was identified as one of the most down-regulated 
peptides in developing NS and LS zebrafish. Further investigation revealed a role for Fer in C&E 
cell movements during gastrulation. Downregulation of Fer cooperated with NS and LS to induce 






Mass spectrometric analysis identifies Fer kinase as a hypotyrosyl-phosphorylated 
protein in NS and LS zebrafish embryos.
To identify novel downstream targets of disease associated Shp2 that are affected similarly in NS 
and LS, we performed a mass spectrometric analysis on zebrafish embryos as outlined in Figure 
1A. In short, zebrafish embryos were injected with synthetic mRNA encoding wild type Shp2, NS-
Shp2 (D61G) or LS-Shp2 (A462T) which induced developmental defects at 24 hpf [9] (Figure 1B). 
Embryos were co-injected with mRNA encoding GFP, which facilitated selection of embryos that 
were injected properly. Approximately 2000 embryos per condition were lysed and combined 
prior to digestion with LysC and Trypsin. Zebrafish lysates were isotopically labeled with normal 
formaldehyle (CH2O, light) for the WT embryos, deuteroformaldehyde (CD2O, medium) for the NS 
embryos and 13C deuteroformaldehyde (13CD2O, heavy), for LS embryos. Labeled peptides were 
then combined and the mixture was processed further. The labeled peptide mixtures were 
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Figure 1. Comparative pTyr mass spectrometry on 1 day old zebrafish embryos expressing 
wild type, NS (D61G) or LS (A462T) Shp2. 
A. Work flow depicting the mass spectrometry approach. Approximately 2000 zebrafish embryos 
per condition were injected at the 1-cell stage and sorted for GFP expression. Embryos were lysed, 
trypsinised and labeled using the dimethyl labeling method. WT, NS and LS samples were combined and 
immunoprecipitated using pTyr specific antibodies. Immunoprecipitate was subjected to MS and peptides 
were identified and quantified based on MS2 and MS1 spectra, respectively. B. 1dpf zebrafish embryos 
expressing WT, D61G and A462T Shp2. Body axis length, craniofacial defects and heart edema in D61G 
and A462T Shp2 expressing zebrafish are indicated with arrowheads. C. Normalized plot of quantified 
phosphopeptides Log2 ratios. Peptide ratios with Log2 ratios  >-1 and <1 are indicated in black. Peptides 
with more that 1x Log2 difference are annotated with a-n (see Table 1 for reference). Peptides changed with 
Log2 ratios <-1 in either NS or LS are indicated in green and Log2 ratios >1 in either NS or LS are indicated 
in red. See text for further details.
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LC-MS was performed and MS1 and MS2 spectra were obtained. Ratios of light/medium and light/
heavy peptides were determined with Proteome Discoverer 1.3.0.399 using the MS1 spectra and 
normalized to the total ratio of all (non-phosphorylated) peptides as input. The input 
corresponding to the LEOPARD Shp2 expressing embryos (heavy labeled) was 2.35 fold higher 
than wild type (light labeled), whereas Noonan (medium labeled), was 1.38 fold higher than wild 
type. Whereas many peptides were identified, only a small number of phosphopeptides were 
identified and of suitable quality for quantification (see Table S1). In total, we identified and 
quantified 69 phosphorylation sites, of which 44 were pTyr sites with a pRS score of >75%. The 
other phosphorylation sites were predicted to be on serine or threonine, or the pTyr site could not 
be localized. The low abundance of tyrosine phosphorylation is likely the cause of the low number 
of identified and quantified pTyr peptides. In addition, many peptides that were identified 
corresponded to highly abundant proteins like actin, keratin and vitellogenin, a zebrafish yolk 
protein. These abundant proteins may have interfered with binding of the antibody to peptides of 
interest, leading to  reduced specificity/efficiency for the enrichment of pTyr containing peptides. 
The normalized Log2 ratios of the quantified phosphopeptides indicate that the majority of 
phosphopeptides was unaltered upon expression of NS or LS Shp2 compared to WT Shp2 (Table 1, 
Figure 1C). For clarity, the human phosphorylation sites are used in the text. A minor fraction of 
phosphopeptides was up- or down-regulated in NS and LS Shp2 expressing zebrafish embryos, 
compared to WT Shp2 expressing embryos. This fraction of peptides may represent downstream 
factors that contribute to the etiology of both NS and LS. As an internal control for the expression 
of NS and LS Shp2 compared to wild type, we confirmed similar levels of Shp2 Y63 phosphopeptide 
in the WT compared to LS. Indeed, the ‘WT’ Shp2 pY63 peptide was not observed in the medium 
labeled (NS) sample, as this peptide has a D61G substitution and was thus not identified (See 
Table 1, Figure 1B, peptides “m” and “n”).
Direct targets of Shp2 PTP activity were expected to have decreased pTyr in NS and an increase in 
LS. Surprisingly, these peptides were not abundant in our results (see Figure 1C upper-left 
quadrant). However, we identified pTyr peptide Y612 of IRS1B (peptide “k”), a known Shp2 
substrate, which was decreased (Log2: -1.18 fold) in NS but unaltered in LS compared to WT. 
Peptides that were increased in LS included a putative phoshorylation site of cell division kinase 
15 and/or 16 (CDK15/CDK16)(peptide “i”)(Log2: 1.92 fold). However, these sites could not be 
localized with a precision score of >75%. In addition, S39 of eukaryotic translation initiation 
factor 3 subunit C (EIF3C) (peptide “h”) was increased (Log2: 2.24 fold) in LS. 
Alternatively, proteins that are phosphorylated downstream of Shp2 in a phosphatase-dependent 
manner would be expected in the lower right quadrant with increased phosphorylation in 
response to NS Shp2 and decreased phosphorylation in response to LS Shp2. We identified 
phosphopeptides that were increased in NS, including Y43 of Histone 2B (H2B) (peptide “c”) 
(Log2: 1.50 fold), Y185 (Log2: 1.16 fold) (peptide “f”) and T183 (Log2: 1.18 fold) (peptide “e”) of a 
MAPK12/MAPK14 protein (zgc:171775). Additionally, we identified a phosphopeptide that was 
decreased in LS including Y666 of receptor tyrosine kinase-like orphan receptor 2 (ROR2) 
(peptide “j”) (Log2: -1.15 fold). 
Multiple peptides that were affected in a similar way (upregulation or downregulation in both NS 
and LS) were identified (lower-left and upper-right quadrant). To gain further understanding in 
how activating and inactivating mutations in NS and LS, respectively lead to similar outcomes, we 
chose to focus on this group of peptides. Two of the main hyperphosphorylated peptides in both 
NS and LS corresponded to PZR, an earlier identified target of Shp2 [19,20]. Peptides corresponding 
















Mpzl1 E7F7T2 CSSPSAPVQGPVI(pY)AQLDHSGSK Y236 Y241 2,95 1,77 a
Mpzl1 E7F7T2 MEPVV(pY)ADIR Y258 Y263 2,24 1,63 b
Histone 2B 
1/2
Q5BJA5 ESYAIYV(pY)K Y43 Y43 1,50 0,47 c
Irs1b* XP_001920152.3* TGSD(pY)MNMSPISAR Y689 Y989 1,39 1,59 d
zgc:171775 F1QHF2 HTETEM(pT)GYVVTR T181 T183 1,18 -0,02 e
zgc:171775 F1QHF2 HTETEMTG(pY)VVTR Y183 Y185 1,16 -0,09 f
Ephb3* XP_005174117.1* FLEDDPTDPTYTSSLGGK Y737** Y792** 1,04 2,90 g
wu:fc15a01 E7F486 GPLDGSL(pY)AQVK Y478 Y483 0,90 0,37





LGEGTYATVYK Y99; Y148** Y114;Y176** 0,40 1,92 i
Prpf4ba B0V1K6 LCDFGSASHVADNDITPYLV(pS)R S855 S852 0,34 0,03
Prpf4ba B0V1K6 LCDFGSASHVADNDITP(pY)LVSR Y852 Y849 0,30 0,18
Rplp; Rplp2l Q6P5K5 KEESEE(pS)DDDMGFGLFD S80 S104 0,17 0,95
Ror2 E7FCE4 WMSPEAIL(pY)GK Y668 Y666 0,13 -1,15 j
Fynrk E7F1M5 LDNGGY(pY)LSTAR Y181 Y214 0,12 0,64
Histone 2B 
1/2
Q5BJA5 ESYAI(pY)VYK Y39, Y41 Y41 0,04 -0,21
Pard3 A2BEM7 TLSP(pS)PDDHER S705 S695 0,04 0,34
Mapk14a Q9DGE2 HTDDEMTG(pY)VATR Y183 Y182 0,00 -0,06
Flo11* XP_005172506.1* TEEDHV(pY)SFPNK Y139 Y118 0,00 -0,37
Hmga1* NP_998333.1* KHPQQEASG(pS)PTPK S36 S49 -0,01 -0,32
Mapk14a Q9DGE2 HTDDEM(pT)GYVATR T181 T180 -0,03 -0,07
Fynrk E7F1M5 ELVEHY(pS)K S199 Y193 -0,06 -0,13
Dyrk2 Q5RHV3 VYT(pY)IQSR Y379 Y382 -0,07 -0,24
Krt8 Q6NWF6 NFSSLSYSGPSMSR Y29** Y25** -0,08 0,77
Mapk12b Q5RHW0 QADSEMTG(pY)VVTR Y183 Y185 -0,14 -0,22
Peak1 E7F7V3 AT(pY)TNLGQSR Y1096 Y1107 -0,17 -0,02
Dyrk1b; 
Dyrk1ab
D1L3Y5;A9QVW5 IYQ(pY)IQSR Y326; Y273 Y321 -0,19 0,00
Fynrk E7F1M5 LDNGG(pY)YLSTAR Y180 Y213 -0,19 0,08
Ybx1 A1A605 REGAE(pS)APEGEMQQQQR S159 S176 -0,20 0,48
Hipk2 Q1MTA8 AVCST(pY)LQSR Y375 Y352 -0,33 -0,09
Prkcda Q7ZUC5 RPDNNTQDVGV(pY)QDFNK Y314 Y313 -0,33 0,11
Mapk14b Q9DGE1 LTDDEM(pT)GYVATR T181 T180 -0,34 -0,18
Mapk11 Q6IQ84 QTDDEMTG(pY)VATR Y181 Y182 -0,34 -0,13
Hipk2; Hipk3 Q1LUZ7;Q1MTA8 AVCSTYLQ(pS)R S366 S355 -0,34 -0,14
Mapk12 O42376 QTDSEMTG(pY)VVTR Y183 Y185 -0,34 -0,60
Mapk12 O42376 QTDSEM(pT)GYVVTR T181 T183 -0,35 -0,58
Afap1l2 E7FH23 SSNAGGDEE(pY)I(pY)MNK Y55, Y57 Y54, Y56 -0,36 0,18
Mapk14b Q9DGE1 L(pT)DDEMTGYVATR T176 T175 -0,36 -0,16
Eppk1 I3ISA6 AVTGYTDP(pY)TGK Y1642 Y1656 -0,39 0,27
Mapk14b Q9DGE1 LTDDEMTG(pY)VATR Y183 Y182 -0,40 -0,26
Cdk1; Cdk2 Q7T3L7;Q7ZWB1 IGEGTYGVV(pY)K Y19; Y19 Y19; Y19 -0,48 0,29
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Ctnnd XP_005160310.1* YRPVDG(pY)R Y215 Y248 -0,54 0,52
Hck E7F0I7 IIEDNE(pY)TAR Y384 Y419 -0,59 -0,30
Cdk1; Cdk2 Q7T3L7;Q7ZWB1 IGEGT(pY)GVVYK Y15 Y15 -0,62 -0,21
Ptk2.1 F1QT14 YMEDS(pS)(pY)YK S579, Y580 S576, Y577 -0,69 -0,64
Keratin 4 F1QK60 GYTSQ(pS)AYAVPAGSTR S22 S51 -0,69 0,35
Chrnb1* NP_001240739.1* VADE(pY)FIR Y380 Y390 -0,70 -0,18
Abl1; Abl2 E7FDC6;B0UXN7 LMTGDT(pY)TAHAGAK Y412; Y407 Y393; Y439 -0,70 -0,20
Ptk6a F1Q7D7 ASACEPGSEL(pY)K Y111 Y13 -0,73 -0,06
Gsk2aa; 
Gsk3b
Q9YH61;Q9YH60 GEPNVS(pY)ICSR Y216 Y216 -0,78 -0,18
Ptk2.1 F1QT14 YMED(pS)SYYk S578 S575 -0,78 -0,22
Ptk6a F1Q7D7 ESV(pY)SSEDAQIPYK Y446 Y432 -0,79 -0,66
Ptk2.1 F1QT14 YMEDSS(pY)YK Y580 Y577 -0,82 -0,22
Pfn2 Q802D5 SQGGEPT(pY)NIAVGK Y99 Y99 -0,85 0,32
Abl1; Abl2 E7FDC6;B0UXN7 LMTGDTY(pT)AHAGAk T413, T408 T394; T440 -0,86 -0,24
Irs1b* XP_005157831.1* SSD(pY)MPMSPK Y584 Y612 -1,18 -0,48 k
Fer F1QBS0 QEDDGIYSSSGLK Y716** Y714** -1,91 -1,47 l
Ptpn11a F1QZU5 IQNTGD(pY)YDLYGGEK Y60 Y62 -3,74 0,35 m
Ptpn11a F1QZU6 IQNTGDY(pY)DLYGGEK Y61 Y63 -4,36 -0,05 n
respectively in NS and Log2: 1.77 and Log2: 1.63 fold, respectively in LS). A further analysis of the 
role of PZR in NS and LS is described elsewhere [21]. In addition, we identified a pTyr peptide 
corresponding to Y989 in human Insulin receptor substrate 1B (IRS1B) to be highly abundant in 
NS (Log2: 1.39 fold) and LS (1.59 fold) (peptide ”d”). A phosphopeptide corresponding to Y792 of 
EphB3 (peptide “g”) was also upregulated in NS and LS (Log2: 1.04 fold in NS and Log2: 2.90 in LS). 
At the other end of the spectrum, the most decreased phosphopeptide in NS and LS corresponded 
to Fer kinase (peptide “l”, NS: Log2 -1.91 fold, LS: Log2 -1.47 fold). The MS2 spectrum of the Fer 
phosphopeptide is given in Figure S1. Unfortunately, a reference peptide for total Fer levels was 
not identified. Thus, the reduced levels of Fer phosphopeptide may represent reduced Fer 
phosphorylation, reduced total Fer levels or a combination of both. While phosphorylation of 
serine instead of tyrosine in this peptide could not be excluded, the tyrosine in this peptide is 
found frequently in other mass spectrometry based experiments (http://www.phosphosite.org). 
In addition, the peptide was immunoprecipitated with anti-pTyr antibodies, which indicates that 
this tyrosine is likely phosphorylated. Interestingly, this tyrosine is the autophosphorylation site 
of Fer [21]. Since Fer had not been studied in zebrafish nor had Fer been implicated in NS and LS, 
we further investigated the role of Fer in these syndromes,
Table 1: Comparative mass-spectrometry of pTyr immunoprecipitated zebrafish lysates
Zebrafish embryos were injected at the 1-cell stage with synthetic mRNA constructs encoding WT Shp2, 
NS (D61G) Shp2 or LS (A462T) Shp2 and co-injected with mRNA encoding eGFP. Lysates were subjected 
to mass spectrometry as described in Materials and Methods. Normalized ratios (Log2 scale) based 
on total levels of non-phosphorylated peptides are given. * Protein name based on BLAST sequence of 
peptide. Accession numbers from BLAST hits are used for non-annotated peptides. ** pRS score <75, 
phosphorylation site could not be determined but the most commonly identified site from Phsophosite.org 




M.musculus Fer201            688 RNCLVGENNTLKISDFGMSRQEDGGVYSSSGLKQIPIKWTAPEALNYGRY 738 
R.norvegicus Fer201          688 RNCLVGENNTLKISDFGMSRQEDGGVYSSSGLKQIPIKWTAPEALNYGRY 738 
H.sapiens FER201             512 RNCLVGENNVLKISDFGMSRQEDGGVYSSSGLKQIPIKWTAPEALNYGRY 562 
G.gallus Fer201              687 RNCLVGESNILKISDFGMSRQEDDGVYSSSGLKQIPIKWTAPEALNYGRY 737 
D.rerio Fer201               689 RNCLVGENNVLKISDFGMSRQEDDGIYSSSGLKQIPIKWTAPEALNYGRY 739 
X.tropicalis Fer201          689 RNCLVGDNNALKISDFGMSRQEDDGIYSSSGLKQIPIKWTAPEALNYGRY 739 
T.nigrovirides Fer201        689 RNCLVGDNNALKISDFGMSRQEDDGIYSSSGLKQIPIKWTAPEALNYGRY 739 
T.rubripes Fer201            692 RNCLVGDNNALKISDFGMSRQEDDGIYSSSGLKQIPIKWTAPEALNYGRY 742 
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Figure 2. Fer expression in zebrafish embryos and Fer MO induced splicing defects. A. 
Alignment of zebrafish Fer kinase sequence encompassing the autophosphorylation site (black) that was 
identified by phosphoproteomics with the mammals M. musculus, R. norvegicus, H. sapiens, the avian 
G. gallus, the amphibian Xenopus tropicalis, and the fish Tetraodon nigrovirides, Takifugu rupripes and 
Oryzias latipes. B. fer expression during the first 24 hpf and at 3dpf and 4dpf was observed using in situ 
hybridization with an antisense fer probe. C. ISH with negative control sense fer probe. D. RT-PCR showing 
altered splicing of fer in MO injected embryos. Da. Model of altered splicing by Fer MO i5e6. Exons 5, 6 
and 7 are indicated in red, blue and green, respectively. Primers used for RT-PCR are indicated as arrows. 
MO is indicated in red. Due to splice blocking, intron 5 is not spliced out of the processed mRNA. Db. RT-
PCR showing gapdh control in Nacre (control) MO and Fer MO injected embryos. RT-PCR showing fer 
product in Nacre control MO and Fer i5e6 MO injected embryos, and genomic DNA as a positive control. 
Dc. Sanger sequencing showing the inclusion of intron 5 and the normal splicing of exon 6 in the RT-PCR 
product. Dd. Model of altered splicing by Fer MO e9i9. Exons 8, 9 and 10 are indicated in red, blue and 
green, respectively. Primers used for RT-PCR are indicated as arrows. MO is indicated in red. Due to 
defective splicing, exon 9 is spliced out of the processed mRNA. De. RT-PCR showing gapdh control in 
Nacre (control) MO and Fer e9i9 MO injected embryos. RT-PCR showing Fer product in Nacre control MO 
and Fer e9i9 MO injected embryos with a decrease in size of the product in e9i9 MO injected embryos. Df. 
Sanger sequencing showing the exclusion of exon 9.
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Figure 3. Fer knockdown induced craniofacial defects in zebrafish embryos.
A. Embryos were injected at the 1-cell stage with 1 ng Fer i5e6 MO, 2.5 ng e9i9 MO or 2.5 ng Nacre MO as a 
negative control. Additionally, embryos were injected with 150 ng WT Shp2 RNA, 150 ng NS Shp2 RNA or 
50 ng LS Shp2 RNA. B. Embryos were injected at the 1-cell stage with 2.5 ng Nacre control MO, 1.0 ng Fer 
i5e6 MO, 2.5ng Fer e9i9 MO or in combination with 2.5 ng P53 MO. C. Craniofacial structures were imaged 
using Tg(-4.9sox10:EGFP)ba2 embryos expressing eGFP in neural crest cells that also form the cartilage. 
Embryos were injected with Fer MO e9i9 at the 1 cell stage and imaged at 4dpf. Ceratohyal is indicated 
with a red asterisk and Meckel’s cartilage with a white asterisk. Both moderate and severe phenotypes are 




Fer kinase expression in zebrafish embryos and Fer MO induced splicing defects.
The Fujinami poultry sarcoma (fps)/Feline sarcoma ( fes) related kinase (Fer) is a widely 
expressed, 94 kDa non-transmembrane protein tyrosine kinase (PTK) that is associated with cell 
migration, tumor growth and was first described in 1986 [22-24]. Fer is involved in focal adhesion 
and cadherin signaling, as well as ERK, Akt and Stat3 signaling [22]. Fer and Shp2 share many 
signaling pathways and a requirement for both proteins has been described in synapse formation 
[25]. It is thus likely that signaling between Fer and Shp2 plays an important role in cell-cell 
adhesion, migration and morphogenesis. 
The identified peptide corresponded to tyrosine 714 (Y716 in zebrafish) which is the Fer 
autophosphorylation site, phosphorylation of which results in activation of Fer kinase activity 
[26]. Sequence alignment of the Fer kinase primary amino acid structure showed conservation of 
FER protein among vertebrates, from Homo sapiens to Danio rerio (Figure 2A), all coding for the 
conserved autophosphorylation site tyrosine. We cloned zebrafish fer from cDNA obtained from 
1dpf embryos. Sequence analysis confirmed that the fer transcript that was cloned was identical 
to ENSDART00000050957 or zebrafish fer-201 encoding full-length Fer protein. Thus, Fer and its 
autophosphorylation site are evolutionarily conserved in vertebrates, including zebrafish. 
As a first step to investigate the role of Fer kinase during development, in situ hybridization (ISH) 
was performed on zebrafish embryos, using a fer-specific probe (Figure 2B). As a negative control 
sense fer probe was used (Figure 2C). Ubiquitous expression of Fer is already apparent at the 
8-cell stage, prior to zygotic transcription, indicating maternal contribution of fer mRNA. Fer 
remained ubiquitously expressed until 10 somite stage. At later stages, fer expression was 
enriched anteriorly and in the pectoral fins. In conclusion, fer expression was ubiquitous during 
gastrulation and more restricted during later stages of development.
To investigate the role of Fer in vivo, morpholinos against Fer were injected into zebrafish embryos 
at the 1-cell stage. As a negative control, non-related Nacre MO was injected that does not induce 
developmental defects, as we have observed before [27]. We assessed Fer protein knockdown by 
immunoblotting using commercially available Fer antibodies, but unfortunately, these reagents 
did not allow detection of endogenous Fer in zebrafish embryos. Instead, knockdown of fer was 
verified by RT-PCR of knockdown embryos (Figure 2D). Injection of Fer e5i6 MO blocked splicing 
of fer intron 5, resulting in the incorporation of intron 5 and introducing multiple stop codons in 
the aberrantly spliced fer mRNA (Figure 2Da and Db). Injection of Fer e9i9 MO caused aberrant 
splicing, thereby excluding exon 9 of fer (Figure 2Dd and De). These effects of MO injections were 
verified by sequencing (Figure 2Dc and Df, respectively). 
(Figure 3 continued) suboptimal concentrations of MO (0.5 ng i5e6 MO; n=110 and 1.0 ng e9i9 MO; n=99). 
High levels of both MO’s (1.0 ng i5e6 MO; n=122 and 2.5 e9i9 MO; n=135) or low levels of both MO’s were co-
injected (n=115). Embryos were imaged at 3dpf and 4dpf and grouped by having a WT appearance (green), 
a craniofacial defect alone (yellow) a heart defect alone (orange) or both (red) at 4dpf. Relative levels of 
phenotypes are depicted. E. Embryos were injected at the 1-cell stage with normal dose of MO (1.0 ng i5e6 
MO; n=61 and 2.5 e9i9 MO; n=53), low doses of MO (0.5 ng i5e6 MO; n=57 and 1.0 ng e9i9 MO; n=50) or a 
co-injected with low doses of MO (n=70). Morphology at 4 dpf is depicted. Embryos were fixed and stained 
with Alcian blue at 4dpf and imaged laterally and ventrally. For quantification, the angle of the ceratohyal 
(F) and the ratio of the distance from the back of the head to Meckel’s cartilage and the width of the head 
was determined (G) (* indicates significance, Student’s t-test p<0.005). 
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Fer knockdown phenocopies Shp2 knockdown, NS and LS Shp2 expression in 
zebrafish.
Injection of both Fer morpholinos (i5e6 and i9e9) induced developmental defects including 
reduced body axis length, heart edema and craniofacial defects at 3dpf (Figure 3A). These defects 
were similar to the phenotypes observed in zebrafish expressing NS and LS Shp2 that were 
analyzed in parallel (Figure 3A). MOs are known to induce non-specific p53 activation and 
apoptosis [12]. To rule out that the observed phenotype is the mere result of p53 activation, co-
injection of p53 MO was performed, which is an accepted control to assess specificity of MOs. 
Knockdown of p53 did not affect the Fer knockdown phenotype, indicating that the phenotype 
was independent of p53 (Figure 3B). Taken together, two independent Fer MOs were used that 
blocked normal splicing of fer and induced developmental defects. 
The craniofacial defects we observed in Fer knockdown embryos were reminiscent of the defects 
observed in Shp2 knockdown embryos as well as embryos expressing NS or LS Shp2 [9,28]. To 
verify these craniofacial defects, we first used the Tg(-4.9sox10:EGFP)ba2 transgenic line, which 
expresses GFP in neural crest-derived cartilage in the head [29]. We observed heart edema 
(Figure 3Ca, Cd and Cg) an increased distance between the eyes (Figure 3Cb, Ce and Ch), an 
increased angle of the ceratohyal (Figure 3Cc, Cf and Ci, red asterisk), a less protruded Meckel’s 
cartilage (white asterisk), confirming the craniofacial defects. To verify the specificity of the Fer 
MOs again, we co-injected low doses of the two Fer-MOs that did not induce developmental defects 





























































Figure 4. Fer 
knockdown resulted in 
C&E defects but not in 
changes in cell fate.
A. Krox20/myoD in situ 
hybridization as a method 
to quantify C&E defects. 
Krox20 (red) staining 
for rhombomeres 3 and 5 
was used to measure the 
width, which correlates 
with convergence cell 
movements in the embryo. 
myoD (light blue) staining 
for the somites was used 
to measure the length, i.e. 
extension of the embryo. 
The ratio of krox20/myoD 
correlates directly with 
convergence & extension 
cell movements during 
gastrulation. B. Flatmounts 
of krox20/myoD stained 
NIC (n=70), control MO 
(n=44) and Fer MO (n=40) 
embryos. C. The ratio of the width of a krox20-positive rhombomere and the length of 8 somites was 
determined (* indicates significance, Student’s t-test p<0.005). D-X. Embryos were injected at the 1-cell 
stage with control MO or Fer e9i9 MO and subjected to ISH for various markers of cell fate determination. 
Note that the staining of the gsc, pax2, six3 and cyc probes show broader and shorter expression in Fer 




on their own (Figure 3D). Co-injection of suboptimal doses of both Fer MOs together induced a 
drastic increase in the Fer knockdown phenotype with reduced body axis extension, heart edema 
(orange) and craniofacial defects (yellow) as prominent features (see Figure 3D lower panel). This 
was further verified by alcian blue stainings on Fer knockdown embryos at 4dpf (Figure 3E). The 
angle of Meckel’s cartilage (Figure 3F) and the ratio of the distance between the eyes and the back 
of the head to the ceratohyal (Figure 3G) were used to quantify these defects. Whereas NIC 
embryos showed an angle of 85±1 degrees (n=40), injection of high levels of Fer MO e5i6 induced 
an increased angle of the ceratohyal (98±1 degrees, n=61), as did injection of high levels of Fer MO 
e9i9 (angle=179±5 degrees, n=53) which were both significant (p<0.005 Student’s t-test) (Figure 
3F). The ratio of the distance from the back of the head to Meckel’s cartilage and the width of the 
head at 4dpf showed a similar significant increase (e5i6 MO: ratio=0.82±0.01; e9i9 MO: 
ratio=0.63±0.02, compared to NIC: ratio=0.90±0.01; p<0.001, Student’s t-test) (Figure 3G). 
Embryos injected with low doses of Fer MO e5i6 alone showed an angle of the ceratohyal of 85±1 
degrees, n=57 (n.s.) and a ratio of 0.93±0.01 (p<0.001). Low dose Fer MO e9i9 injected embryos 
showed an angle of 88±1, n=50 (n.s.) and a ratio of 0.89±0.01 (n.s.). Co-injection of both MO’s at 
low doses together resulted in a drastic increase of craniofacial defects. Quantification of the 
craniofacial defects of these embryos showed an angle of 123±6, n=70 (p<0.001) and a ratio of 
0.79±0.01 (p<0.001) (Figure 3E-G). 
We tried to rescue the Fer MO-induced developmental defects by expression of mRNA encoding 
full length Fer. Unfortunately, despite many attempts, we failed to rescue the Fer MO induced 
developmental defects (Figure S2A). Expression of Fer by itself induced reduced body axis 
extension, cardiac edema and craniofacial defects (Figure S2B), which impaired assessment of the 
rescues. It is not uncommon that up- and down-regulation of signalling proteins, including Shp2 
and RhoA, induce similar developmental defects [9]. In conclusion, knockdown of Fer was specific 
and resulted in craniofacial defects, heart edema and reduced body axis extension, which is 
reminiscent of the developmental defects in Shp2 knockdown embryos as well as NS and LS Shp2 
expressing embryos.
Fer knockdown induced convergence and extension defects
Fer knockdown phenocopied Shp2 knockdown and NS and LS expression at later developmental 
stages. Loss of Shp2 and expression of NS and LS variants of Shp2 induce C&E defects in developing 
zebrafish embryos [9]. We investigated whether Fer knockdown caused developmental defects 
during gastrulation as well. To investigate C&E defects upon Fer knockdown, embryos were 
subjected to in situ hybridization (ISH) using probes for myoD, staining the somites and krox20 
staining rhombomeres 3 and 5, a verified method to quantify C&E defects in developing zebrafish 
embryos (Figure 4A) [30,31]. Indeed, Fer morphant embryos showed C&E defects compared to 
control morphants (Student’s t-test, p<0.005) (Figure 4B and 4C). In addition to C&E defects, cell 
specification may be affected by the loss of Fer function. To investigate this, we subjected 
developing embryos to ISH using panel of cell fate markers, including bmp2b, cyc, chd, ntl, six3, gsc 
and pax2 (Figure 4D-X). Expression levels of these markers were unchanged in Fer MO and control 
MO injected embryos compared to non-injected controls (NIC). However, expression of gsc, pax2, 
six3 and cyc showed broader and shorter signal in Fer knockdown embryos, compared to NIC and 
control MO injected embryos, likely resulting from C&E defects (Figure 4 J-L, P-R, S-U and V-X, 
respectively). Thus, loss of Fer leads to C&E defects similar to Shp2 knockdown in developing 
zebrafish, and does not cause alterations in early cell fate determination. 
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Fer knockdown cooperates with NS and LS, but not WT Shp2 expression.
Mass spectrometric analysis showed reduced Fer Y714 phosphopeptide. In developing zebrafish, 
we found that loss of Fer phenocopies Shp2 knockdown and expression of NS and LS Shp2, and 
leads to C&E defects. To investigate if downregulation of Fer contributes to the pathogenesis of NS 
and LS, we performed a genetic epistasis experiment, where we induced suboptimal knockdown 
of Fer in combination with injection of low amounts of NS and LS Shp2 mRNA that do not induce 
defects by themselves. Control injections only marginally affected craniofacial development. The 
ceratohyal angle in control injected embryos was 93±1 degrees, which was a slight increase 
compared to the ceratohyal angle of control injected embryos, 88±1 degrees (p<0.05). Whereas 
Fer knockdown caused developmental defects (Figure 5A, B), partial knockdown of Fer using a 
low dose of Fer MO e9i9 did not induce developmental defects (ceratohyal angle: 89±1 degrees, 
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Figure 5. Partial knockdown of Fer cooperated with suboptimal expression of NS- and LS- 
but not WT Shp2 to induce developmental defects. 
A. Embryos were injected with control MO, Fer e9i9 MO and NS, LS or WT Shp2 mRNA as indicated, and 
imaged at 4dpf. B. Alcian blue staining showing craniofacial defects scored on severity (green: wild type, 
yellow: mild phenotype, orange: moderate phenotype, red: severe phenotype). C. Embryos were scored 
based on craniofacial defect upon alcian blue staining. The number of embryos per condition is indicated. 





edema, reduced body axis extension and craniofacial defects (NS: ceratohyal angle: 110±3 
degrees, p<0.005 and LS: angle: 96±2 degrees, p<0.001). At lower doses, NS and LS Shp2 also did 
not cause major developmental defects or an increase in the angle of the ceratohyal compared to 
control injections (Low NS: 91±2 degrees, n.s and low LS: 84±2 degrees, p<0.05). When combined 
with low doses of Fer MO however, NS and LS showed heart edema and major increases in 
craniofacial defects (Low NS + low Fer MO: 103±3 degrees, p<0.001 and Low LS + low Fer MO: 
98±2 degrees, p<0.001) (Figure 5A , 5C and 5D). This indicates that a decrease in Fer cooperates 
with NS and LS to induce developmental defects seen in NS and LS. 
Discussion
Using a comparative phosphoproteomics approach focused on pTyr-containing proteins, we 
identified a phosphopeptide corresponding to Fer kinase as the main decreased phosphopeptide 
in zebrafish embryos expressing NS or LS mutant Shp2 compared to WT. Fer knockdown induced 
developmental defects in zebrafish embryos that are reminiscent of defects induced by NS and LS 
Shp2. Epistatic interaction analyses suggested a genetic interaction between Fer kinase and 
mutant Shp2. 
Previously, we used comparative phosphoproteomics in zebrafish to identify differences between 
wild type and Fyn/Yes knockdown embryos [18]. At that time, TiO2 columns were used to enrich 
for phosphopeptides, and only highly abundant phosphoserine- and phosphothreonine-containing 
phosphopeptides were identified, excluding low abundant pTyr-containing peptides [18]. 
Improved methods using immunoprecipitation of pTyr peptides allow for the identification of 
endogenous tyrosine phosphorylated peptides [27]. Stable isotope dimethyl labelling allows for 
the quantitative comparison of three different samples in an economical fashion, compared to 
other peptide labelling methods [17]. Other groups have successfully analysed the proteome of 
zebrafish under different conditions [32-34], however these experiments often focussed on the 
whole proteome in a specific organ. Given the crucial role of tyrosine phosphorylation in signalling 
during development, we hypothesized that specific analysis of the tyrosyl phosphoproteome 
would provide insights into development and disease. Particularly in case of NS and LS, two 
syndromes that are associated with expression of mutant Shp2, a protein-tyrosine phosphatase. 
Recently, a MS based approach was used to identify proteins that were affected by the altered 
binding properties of NS and leukemia associated Shp2 [35]. Although highly informative, these 
experiments were performed using the tandem SH2 of Shp2 expressed in cells. As full length NS 
and LS Shp2 exhibit different dynamic properties than WT [36,37], using the full length protein 
under physiological conditions in vivo gives more relevant insights into the etiology of the disease. 
Therefore, we performed for the first time a comparative phosphoproteomics experiment in 
zebrafish using pTyr immunoprecipitation and stable isotope dimethyl labelling. 
Using this technique, we identified several phosphopeptides that were increased or decreased in 
NS and LS Shp2 embryos. One of these peptides corresponded to the Fer autophosphorylation site 
and was the most strongly decreased phosphopeptide in the zebrafish disease model for NS and 
LS. Follow-up experiments showed that fer mRNA is maternally contributed and is expressed 
ubiquitously during gastrulation. Later, fer expression is restricted anteriorly and in the pectoral 
fins of developing zebrafish embryos (Figure 2B). Fer is conserved and fps/fes/fer homologues 
exist in sponges (Fes/FER_SR), D. melanogaster (dfps85D) and C. elegans (FRK-1) [38,39]. In chick, 
Fer expression is ubiquitous, with higher expression levels during development than at later 
stages [24]. Also in mammalian cells, Fer expression is widely distributed [23]. Fer expression is 
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vital for dorsal closure of C.elegans, yet its kinase activity seems to be redundant in development 
[39-41]. We demonstrate that in fish, a decrease in total Fer levels by MO-induced knockdown 
resulted in developmental defects that were reminiscent of Shp2 knockdown, and NS and LS 
expression in zebrafish (Figure 3A) [9]. Moreover, loss of Fer resulted in C&E defects during 
gastrulation, which were also observed in NS and LS zebrafish (Figure 4)[9,31]. Indeed, also at 
later stages craniofacial malformations and heart edema were observed in Fer knockdown 
embryos, similar to NS and LS Shp2 expressing embryos (Figure 3) [9,28,31,42]. We show a genetic 
interaction between fer and ptpn11, since loss of Fer contributes to the NS and LS phenotype 
(Figure 5). 
The mechanism underlying the role of Fer kinase in development remains to be determined 
definitively. Fer has been reported to be involved in various signaling pathways. Expression of full 
length fer is essential for Drosophila gastrulation via Src42A, a Drosophila Src homologue [40] 
However, it is unclear if kinase activity is essential for this function of Fer. In C.elegans, FRK-1 is 
essential for embryonic closure and morphogenesis but this is not dependent on FRK-1 kinase 
activity [39]. Depletion of Fer kinase activity leads to a reduction in p38 MAPK but not ERK 
activity in activated mast cells [43] Fer is able to sustain ERK activation under hypoxic conditions 
but kinase activity is not essential [44]. Interestingly, Fer kinase activity is essential for β-catenin-
cadherin complex formation. Expression of kinase dead Fer attenuates formation of this complex. 
EGF treatment rescues this defect, indicating a compensatory mechanism for the loss of Fer 
kinase activity. Interestingly, PTP1B, another member of the PTP family, associates with Cadherin 
in a Fer kinase-dependent manner, but whether PTP1B dephosphorylates Fer remains to be 
determined [45]. How NS and LS Shp2 cause a downregulation of Fer protein tyrosine 
phosphorylation remains to be determined. Since both activated NS Shp2 and catalytically 
impaired LS Shp2 have similar effects on Fer, it is unlikely that Fer is a direct substrate of Shp2. 
Disease associated Shp2 was found to bind to hyperphosphorylated substrates, both in NS and LS 
and in experimental conditions [20,46]. Fer and Shp2 share many interacting partners, including 
PDGFR, integrins, PECAM-1 and others [25,46-48]. In addition, Fer and Src (an important Shp2 
interacting protein) share many substrates, including cortactin [41,49]. Disease associated Shp2 
exhibits altered dynamics and binding properties [35-37]. Mutant Shp2 may quench binding 
proteins that are normally required for full activation of Fer kinase, resulting in reduced tyrosine 
phosphorylation of Fer upon expression of NS and LS Shp2.
Alternatively, Fer activity might be downregulated through enhanced growth factor signaling 
that occurs in NS and LS [36,45]. While many studies have shown a loss of phosphatase activity in 
LS Shp2, the ability of LS Shp2 to enhance ERK activation remains subject of debate [4,36]. In 
zebrafish, we observe enhanced ERK activation in both NS and LS [50] and hence, reduced Fer 
phosphorylation may result from a negative feedback mechanism, resulting from enhanced 
growth factor signaling. In conclusion, we identify Fer kinase as a likely downstream target of NS 







Only embryos up to 4 days post fertilization (dpf) were used for these experiments, which do not 
require approval of the animal experiments committee according to national and European law. 
Zebrafish maintenance and in situ hybridization. Wild type and Tg(-4.9sox10:EGFP)ba2 zebrafish 
were kept under standard conditions. Embryos were staged as described by Westerfield [11]. In 
situ hybridizations were done as described before [9], using probes specific for bmp2b, chd, cyc, 
gsc, krox20, myod, ntl, pax2 and six3. For the fer probe, Fer-pBSK- was digested with NotI for the 
antisense probe and with ApaI for the sense probe, respectively. T7 and T3 RNA polymerase were 
used to generate digoxigenin labeled RNA (Roche). Embryos were fixed at the indicated stages 
with 4% paraformaldehyde (PFA). Embryos were treated from 24 hpf onwards with 0.2 mM 
1-phenyl 2-thiourea (Sigma) in E3-medium to block pigmentation.
Constructs
fer was amplified from cDNA of 1 dpf WT embryos and cloned into EcoRI/XhoI sites of pCS2+ and 
pBSK- and verified by sequencing using: Fer_out_Fw: 5’-GAGAGAGACTGCGTGCCTTG-3’, Fer_out_
Rv: 5’-ATGAGATTCTGAGGGCGAAA-3’ and Fer_EcoRI_Fw:  
5’-GGCGAATTCATGGGGTTCGGCCGGGAC-3’, Fer_XhoI_Rv: 
5’-CGGCTCGAGTTAGGGATCACCTGGATG-3’. The mutation Y716F was introduced into fer by site-
directed mutagenesis using Fer_Y716F_Fw: 5’-TCCTGATGAGGAGAAGATGCCGTCGTC-3’ and Fer_
Y716F_Rv: 5’-GACGACGGCATCTTCTCCTCATCAGGA-3’. 
Morpholinos, RNAs and injections
Fer splicing morpholinos (MOs) were designed for several intron-exon boundaries and ordered 
from GeneTools (Philomath, OR, USA). The p53 MO (5’-GCGCCATTGCTTTGCAAGAATTG-3’) was 
described before and was used as recommended by the manufacturer [12]. Synthetic mRNA was 
synthesized using mMessage mMachine kit (Ambion). pCS2+ plasmid was digested with NotI and 
RNA was synthesized with SP6 RNA polymerase. The NS and LS constructs were previously 
described [9]. MOs and mRNA was injected at one cell stage and the working concentration was 
titrated for each MO and mRNA. Fer MO i5e6 (5’-GGCTTCTGGTGATCTGTTGAAATA-3’) was used 
at 1.0 ng/µl (high concentration) or 0.5 ng/µl (low concentration). Fer MO e9i9 
(5’-GGGATTACACTTACTGACGAAGAGC-3’) was used at 2.5 ng/µl (high concentration) or 1.0 ng/µl 
(low concentration). For co-injection, suboptimal concentrations of both MOs were combined. 
Alcian blue staining
Embryos were anesthetized with tricaine methane sulfonate (Sigma) and fixed in 4% PFA at 4 dpf. 
After several hours of fixing, embryos were washed for 10 min in 50% ethanol. Embryos were 
stained overnight at 4 degrees in staining solution (0.04% Alcian blue (Sigma), 70% ethanol and 
50 mM magnesiumchloride) and washed in 0.2% Triton X-100 (Sigma). Afterwards, embryos were 
bleached to remove pigmentation (8.5% hydrogen peroxide, 5% formamide, 0.5x SSC) and washed 
with 0.2% Triton X-100. Images were quantified by using ImageJ software.
RNA isolation
Total RNA of 3 dpf Nacre MO and Fer MO injected embryos was isolated. Approximately 30 
embryos were dissolved in 1.0 ml TriZol (Invitrogen). The homogenate was centrifuged (12.000g, 
4 degrees, 10 min). 0.2 ml Chloroform was added to the supernatant, vortexed for 15 sec, 
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incubated for 3 min at room temperature (RT) and afterwards centrifuged (12.000g, 4 degrees, 
15 min). 0.5 ml isopropanol was added to the upper phase, incubated for 10 min at RT and 
centrifuged (12.000g, 4 degrees, 15 min). The pellet was washed with 75% ethanol and after 
vortexing centrifuged (10.000g, 4 degrees, 5 min). The pellet was dried for 5 min and dissolved in 
100 μl deionized water. Subsequently, the solution was incubated for 10 min at 37 oC, precipitated 
in 250 μl 100% ethanol and 10 μl 3M sodium acetate and stored at -80oC.
RT-PCR
For the reverse transcription reaction (RT-PCR) with M-MLV-RT (Promega) 1 μg of total RNA was 
used. PCR of cDNA was performed using standard protocol of GoTaq (Promega) using Fer_Fw_
intron_5: 5’-TTTCTGTCCCCATTGCAAAG-3’, Fer_Rv_exon_7: 5’-GATTCTGCTGGGTTATTAGC-3’, Fer_
Fw_exon_6: 5’-GAACCTAATGTAGAATTTGATGC-3’, Fer_Fw_exon_8: 
5’-CGGAGGCCAAACTCATGGCACA-3’ and Fer_Rv_exon_10: 5’-CGCACCAGAAAGTCTCCCTG-3’. 
Gadph was used as a loading control for the RT-PCR reaction. 
Mass spectrometry
Digest Preparation. 
Embryos were injected at the 1-cell stage with 150 pg wild type Shp2, 150pg Shp2-D61G or 50pg 
Shp2-A462T RNA, respectively. Shp2 RNA injected embryos were co-injected with enhanced 
green fluorescent protein (GFP) RNA used for screening of injection efficiency. Embryos 
expressing GFP were selected, manually dechorionated and collected at 26hpf to 28hpf. Embryos 
were then deyolked and washed using deyolking buffer (1/2 Ginzburg Fish Ringer) without 
calcium (2x10µl/embryo) snap frozen and stored at -80 °C for further usage [11,13]. Embryo 
pellets corresponding to a total of approximately 2000 embryos per condition were resuspended 
and lysed in 8 M Urea, 50 mM ammoniumbicarbonate, 1 PhosSTOP tablet per 10 ml plus 1mM 
vanadate  and ethylenediaminetetraacetic acid-free protease inhibitor cocktail (Sigma). Embryo 
lysates were sonicated for 4x 30 seconds and then centrifuged at 14 500 rpm for 30 minutes at 
4°C. Lysate supernatants equivalent to 3 to 4mg total protein per condition were generated in 
principle as described previously [14,15]. Briefly, the  lysates were reduced with dithiothreitol 
(10mM) for 1 hour at 56°C and alkylated with iodoacetamide (55mM) at room temperature, in the 
dark for 45 minutes and digested for four hours with the protease Lys-C (1:100 enzyme/substrate) 
at 37°C. Samples were then diluted 4 fold with 50mM Ammoniumbicarbonate to 2M Urea and 
trypsin (1:100) was added and digestion was performed overnight at 37°C. The peptide mixtures 
were acidified to pH 3 by adding acetic acid to a final concentration of 2.5%. The individual 
peptide solutions were then desalted, dimethyl labelled on-column as described previously [16]. 
Wild type Shp2 injected embryos were labeled “light” whereas D61G (Noonan) Shp2 and A462T 
(LEOPARD) Shp2 injected embryos were labeled “intermediate” and “heavy”, respectively.
Immunoprecipitation (IP)
IP was performed as described [17]. In principle, labeled peptide solutions were mixed in equal 
concentrations, vacuum dried and resuspended in IP Buffer (50mM Tris, pH 7.4, 150 mM sodium 
cloride, 1% n-octyl-β-D-glucopyranoside and a Complete Mini protease inhibitor tablet per 10 ml 
IP buffer (Roche Diagnostics)). PY99-agarose beads (Santa Cruz Biotechnology) were washed five 
times with IP buffer prior to IP. The labeled peptide mixture was mixed with the PY99-agarose 
beads, and incubation was performed overnight at 4 °C under constant rotation. After peptide 




ultrapure water. Peptides were eluted by adding two times 50 µl of 0.15% trifluoroacetic acid for 
20 min at room temperature. Eluted peptides were then desalted and concentrated on C18 tips 
and resuspended in 10% formic acid prior to MS analysis. 
On-line Nanoflow Liquid Chromatography—As described in [17]: Nanoflow LC-MS/MS was 
performed on an Linear Trap Quadrupole-Orbitrap XL mass spectrometer (Thermo Electron, 
Bremen, Germany) coupled to an Agilent 1100 HPLC system (Agilent Technologies, Waldbronn, 
Germany). Dried peptides were trapped at 5µl/min in 100% solvent A (0.1 M acetic acid in water). 
Subsequently, peptides were transferred to an analytical column (ReproSil-Pur C18- AQ, 3 µm 
(Dr. Maisch GmbH, Ammerbuch, Germany); 40 cm * 50 µm inner diameter, packed in house) at 
~100 nl/min and eluted using a 3-h gradient from 0 to 40% solvent B (0.1 M acetic acid in 8:2 (v/v) 
acetonitrile/water). The eluent was sprayed via distal coated emitter tips (New Objective) butt-
connected to the analytical column. The LTQ Orbitrap XL was operated in data-dependent mode, 
automatically switching between MS and MS/MS. Full-scan MS spectra (from m/z 350 to 1500) 
were acquired in the Orbitrap with a resolution of 60,000 at m/z 400 after accumulation to target 
value of 500,000. The three most intense ions at a threshold above 500 were selected for collision-
induced fragmentation in the linear ion trap at a normalized collision energy of 35% after 
accumulation to a target value of 10,000. 
Data Analysis
All MS2 spectra were processed and quantified with Proteome Discoverer (version 1.3.0.399). 
Runs were searched against a concatenated forward-decoy version of the Zebrafish Uniprot 
database (version 20130916, 81920 sequences) with Mascot (version 2.3.02, Matrix Science). The 
database search was performed with the following parameters: a mass tolerance of ±50 ppm for 
precursor masses and ±0.6 Da for CID fragment ions, allowing two missed cleavages, cysteine 
carbamidomethylation as fixed modification. Light, intermediate and heavy dimethylation of 
peptide N-termini and lysine residues; methionine oxidation; phosphorylation on serine, 
threonine and tyrosine were set as variable modifications. The enzyme was specified as trypsin. 
The phosphorylation site localization of the identified phosphopeptides was performed by the 
phosphoRS algorithm 3.1 implemented in Proteome Discoverer using a 75% cut-off. For 
phosphopeptides that did not have a phosphorylation site with a pRS score above 75%, the site 
was counted as “ambiguous”. The dimethyl-based quantitation method was chosen in Proteome 
Discoverer, with mass precision requirement of 2 ppm for consecutive precursor mass 
measurements. A 0.5 min retention time tolerance was applied for isotope pattern multiplets and 
allowed spectra with maximum 1 missing channels to be quantified. Mascot results were further 
filtered with the following criteria: (i) mass deviations of ±10 ppm; (ii) Mascot ion score of at least 
20; (iii) a minimum of 6 amino-acid residues per peptide; and (iv) position rank 1, which results in 
a peptide FDR <1%. Phosphopeptides that were found to be differentially phosphorylated were 
manually validated.
Quantification
Quantified phosphopeptides were normalized against the median of all non-phosphopeptides. For 
peptides with phosphorylation sites with a pRS score above 75%, only these phosphopeptides 
were used for quantification. For peptides with only pRS scores below 75% all phosphopeptides 
were used for quantification, but the phosphorylation site was counted as “ambiguous”. Log2 
ratios of heavy/light and medium/light of more than 1 or less than -1 were accepted as significant 
changes in phosphorylation levels. 
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Annotation 
Phosphorylation sites of each peptide were compared to the total protein sequence of the 
corresponding zebrafish protein to identify the phosphorylation site. These sites were then 
compared to human protein in Phosphosite.org. For ambiguous phosphorylation sites (pRS<75) 
the sequence was compared to Phosphosite.org to identify the most commonly identified site. 





1. Gelb BD, Tartaglia M (2006) Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein 
kinase signal transduction. Hum Mol Genet 15 Spec No 2: R220-226.
2. Neel BG, Gu H, Pao L (2003) The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. 
Trends Biochem Sci 28: 284-293.
3. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG (2006) PTPN11 (Shp2) mutations in LEOPARD 
syndrome have dominant negative, not activating, effects. J Biol Chem 281: 6785-6792.
4. Oishi K, Zhang H, Gault WJ, Wang CJ, Tan CC, et al. (2009) Phosphatase-defective LEOPARD syndrome 
mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum Mol Genet 18: 
193-201.
5. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE (1998) Crystal structure of the tyrosine phosphatase SHP-2. 
Cell 92: 441-450.
6. Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, et al. (1997) Abnormal mesoderm patterning in mouse 
embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J 16: 2352-2364.
7. Saxton TM, Pawson T (1999) Morphogenetic movements at gastrulation require the SH2 tyrosine phosphatase Shp2. 
Proc Natl Acad Sci U S A 96: 3790-3795.
8. Saxton TM, Ciruna BG, Holmyard D, Kulkarni S, Harpal K, et al. (2000) The SH2 tyrosine phosphatase shp2 is 
required for mammalian limb development. Nat Genet 24: 420-423.
9. Jopling C, van Geemen D, den Hertog J (2007) Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced 
gastrulation defects. PLoS Genet 3: e225.
10. Roszko I, Sawada A, Solnica-Krezel L (2009) Regulation of convergence and extension movements during vertebrate 
gastrulation by the Wnt/PCP pathway. Semin Cell Dev Biol 20: 986-997.
11. Westerfield M (1995) The Zebrafish Book. Eugene, Oregon: University of Oregon Press.
12. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, et al. (2007) p53 activation by knockdown technologies. 
PLoS Genet 3: e78.
13. Link V, Shevchenko A, Heisenberg CP (2006) Proteomics of early zebrafish embryos. BMC Dev Biol 6: 1.
14. Ding VM, Boersema PJ, Foong LY, Preisinger C, Koh G, et al. (2011) Tyrosine phosphorylation profiling in FGF-2 
stimulated human embryonic stem cells. PLoS One 6: e17538.
15. Preisinger C, Schwarz JP, Bleijerveld OB, Corradini E, Muller PJ, et al. (2013) Imatinib-dependent tyrosine 
phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells. Leukemia 27: 743-746.
16. Boersema PJ, Raijmakers R, Lemeer S, Mohammed S, Heck AJ (2009) Multiplex peptide stable isotope dimethyl 
labeling for quantitative proteomics. Nat Protoc 4: 484-494.
17. Boersema PJ, Foong LY, Ding VM, Lemeer S, van Breukelen B, et al. (2010) In-depth qualitative and quantitative 
profiling of tyrosine phosphorylation using a combination of phosphopeptide immunoaffinity purification and 
stable isotope dimethyl labeling. Mol Cell Proteomics 9: 84-99.
18. Lemeer S, Jopling C, Gouw J, Mohammed S, Heck AJ, et al. (2008) Comparative phosphoproteomics of zebrafish 
Fyn/Yes morpholino knockdown embryos. Mol Cell Proteomics 7: 2176-2187.
19. Zhao ZJ, Zhao R (1998) Purification and cloning of PZR, a binding protein and putative physiological substrate of 
tyrosine phosphatase SHP-2. J Biol Chem 273: 29367-29372.
20. Eminaga S, Bennett AM (2008) Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR 
tyrosyl phosphorylation and promote adhesion-mediated ERK activation. J Biol Chem 283: 15328-15338.
21. Paardekooper Overman J, Yi JS, Bonetti M, Soulsby M, Preisinger C, et al. (2014) PZR coordinates Noonan and 
LEOPARD syndrome signaling in zebrafish and mice. Mol Cell Biol: (in press).
22. Greer P (2002) Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 3: 278-289.
23. Pawson T, Letwin K, Lee T, Hao QL, Heisterkamp N, et al. (1989) The FER gene is evolutionarily conserved and 
encodes a widely expressed member of the FPS/FES protein-tyrosine kinase family. Mol Cell Biol 9: 5722-5725.
24. Feldman RA, Tam JP, Hanafusa H (1986) Antipeptide antiserum identifies a widely distributed cellular tyrosine 
kinase related to but distinct from the c-fps/fes-encoded protein. Mol Cell Biol 6: 1065-1073.
25. Lee SH, Peng IF, Ng YG, Yanagisawa M, Bamji SX, et al. (2008) Synapses are regulated by the cytoplasmic tyrosine 
kinase Fer in a pathway mediated by p120catenin, Fer, SHP-2, and beta-catenin. J Cell Biol 183: 893-908.
26. Ben-Dor I, Bern O, Tennenbaum T, Nir U (1999) Cell cycle-dependent nuclear accumulation of the p94fer tyrosine 
kinase is regulated by its NH2 terminus and is affected by kinase domain integrity and ATP binding. Cell Growth 
Differ 10: 113-129.
27. Lemeer S, Jopling C, Naji F, Ruijtenbeek R, Slijper M, et al. (2007) Protein-tyrosine kinase activity profiling in 
knock down zebrafish embryos. PLoS One 2: e581.
28. Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, et al. (2010) Phosphatase-dependent and -independent 
functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell 18: 750-762.
29. Carney TJ, Dutton KA, Greenhill E, Delfino-Machin M, Dufourcq P, et al. (2006) A direct role for Sox10 in 
specification of neural crest-derived sensory neurons. Development 133: 4619-4630.
30. Li C, Inglis PN, Leitch CC, Efimenko E, Zaghloul NA, et al. (2008) An essential role for DYF-11/MIP-T3 in 
assembling functional intraflagellar transport complexes. PLoS Genet 4: e1000044.
31. Runtuwene V, van Eekelen M, Overvoorde J, Rehmann H, Yntema HG, et al. (2011) Noonan syndrome gain-of-
function mutations in NRAS cause zebrafish gastrulation defects. Dis Model Mech 4: 393-399.
91
Phosphoproteomics-mediated identification of Fer as a target of Shp2 in Noonan and LEOPARD
5
32. Singh SK, Sundaram CS, Shanbhag S, Idris MM (2010) Proteomic profile of zebrafish brain based on two-
dimensional gel electrophoresis matrix-assisted laser desorption/ionization MS/MS analysis. Zebrafish 7: 169-177.
33. Gebriel M, Prabhudesai S, Uleberg KE, Larssen E, Piston D, et al. (2014) Zebrafish brain proteomics reveals central 
proteins involved in neurodegeneration. J Neurosci Res 92: 104-115.
34. Kessels MY, Huitema LF, Boeren S, Kranenbarg S, Schulte-Merker S, et al. (2014) Proteomics analysis of the 
zebrafish skeletal extracellular matrix. PLoS One 9: e90568.
35. Muller PJ, Rigbolt KT, Paterok D, Piehler J, Vanselow J, et al. (2013) Protein tyrosine phosphatase SHP2/PTPN11 
mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia. J 
Proteomics 84: 132-147.
36. Yu ZH, Xu J, Walls CD, Chen L, Zhang S, et al. (2013) Structural and mechanistic insights into LEOPARD 
syndrome-associated SHP2 mutations. J Biol Chem 288: 10472-10482.
37. Darian E, Guvench O, Yu B, Qu CK, MacKerell AD, Jr. (2011) Structural mechanism associated with domain 
opening in gain-of-function mutations in SHP2 phosphatase. Proteins 79: 1573-1588.
38. Katzen AL, Montarras D, Jackson J, Paulson RF, Kornberg T, et al. (1991) A gene related to the proto-oncogene fps/
fes is expressed at diverse times during the life cycle of Drosophila melanogaster. Mol Cell Biol 11: 226-239.
39. Putzke AP, Hikita ST, Clegg DO, Rothman JH (2005) Essential kinase-independent role of a Fer-like non-receptor 
tyrosine kinase in Caenorhabditis elegans morphogenesis. Development 132: 3185-3195.
40. Murray MJ, Davidson CM, Hayward NM, Brand AH (2006) The Fes/Fer non-receptor tyrosine kinase cooperates 
with Src42A to regulate dorsal closure in Drosophila. Development 133: 3063-3073.
41. Craig AW, Zirngibl R, Williams K, Cole LA, Greer PA (2001) Mice devoid of fer protein-tyrosine kinase activity are 
viable and fertile but display reduced cortactin phosphorylation. Mol Cell Biol 21: 603-613.
42. Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, et al. (2013) Gain-of-function mutations in RIT1 cause 
Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet 93: 173-180.
43. Craig AW, Greer PA (2002) Fer kinase is required for sustained p38 kinase activation and maximal chemotaxis of 
activated mast cells. Mol Cell Biol 22: 6363-6374.
44. Salem Y, Shpungin S, Pasder O, Pomp O, Taler M, et al. (2005) Fer kinase sustains the activation level of ERK1/2 
and increases the production of VEGF in hypoxic cells. Cell Signal 17: 341-353.
45. Xu G, Craig AW, Greer P, Miller M, Anastasiadis PZ, et al. (2004) Continuous association of cadherin with beta-
catenin requires the non-receptor tyrosine-kinase Fer. J Cell Sci 117: 3207-3219.
46. Kogata N, Masuda M, Kamioka Y, Yamagishi A, Endo A, et al. (2003) Identification of Fer tyrosine kinase localized 
on microtubules as a platelet endothelial cell adhesion molecule-1 phosphorylating kinase in vascular endothelial 
cells. Mol Biol Cell 14: 3553-3564.
47. Kim L, Wong TW (1995) The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 
and is activated by growth factors. Mol Cell Biol 15: 4553-4561.
48. Ronnstrand L, Arvidsson AK, Kallin A, Rorsman C, Hellman U, et al. (1999) SHP-2 binds to Tyr763 and 
Tyr1009 in the PDGF beta-receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and 
chemotaxis. Oncogene 18: 3696-3702.
49. Jia D, Jing Y, Zhang Z, Liu L, Ding J, et al. (2014) Amplification of MPZL1/PZR promotes tumor cell migration 
through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res 24: 204-217.
50. Bonetti M, Paardekooper Overman J, Tessadori F, Noel E, Bakkers J, et al. (2014) Noonan and LEOPARD 
















































Q E D D G I pY S SS G L K
b1 b2 b3 b4 b5 b6 b7 b8 b9 b10 b11 b12
y1y2y3y4y5y6y7y8y9y10y11y12
Fer
Figure S1. MS2 spectrum of the identified Fer peptide. Fer peptide sequence is shown in the upper 

















































































































Figure S2. Attempted rescue of Fer MO and overexpression of Fer . Embryos were injected at the 
1-cell stage with 2.5 ng Fer MO e9i9 either alone or in combination with increasing amounts of synthetic 
Fer mRNA (5 ng, 25 ng, 37.5 ng, 50 ng, 100 ng, 150 ng, 200 ng, 250 ng). Co-injection of Fer mRNA did not 
rescue the Fer knockdown phenotype. B. embryos were injected at the 1-cell stage with Fer WT mRNA. 
Injection of Fer mRNA by itself induced craniofacial defects, shorter length and heart edema. 
Table S1. Raw MS data. Tab1 “PD_Output” shows raw, non-normalized data from Proteome 
Discoverer, which is used for normalization on all nonphosphopeptides. “numberOFphospho”: number of 
phosphoresidues present in the peptide. “numberOFlocalized”: number of localized phosphoresidue (pRS 
>75). “peptideSite”: localized site. Tab2 “Aggregation” shows data averaged per rows based on the following 
values (protein group accession, sequences, description, numberofphospho, numer of localized, peptide 
sites). “SITES” tab shows all normalized, quantified, localized, protein assigned peptides. “SITES with 
lacking protein” tab shows all normalized, quantified, localized, peptides, including non-protein assigned 
peptides. “quantified only pRS <75” shows all normalized quantified peptides for which no phosphosite 
could be assigned. “all quant phosphopepts combined” shows a combination of “SITES with lacking protein” 
and “quantified only pRS<75” with duplicate peptides for which one site is assigned and the other is not 
removed. “Table 1” shows “all quant phosphopepts combined” where non-assigned peptides are BLASTed 
against the zebrafish proteome to identify the protein, phosporylation site in zebrafish and the phosphosite 
is compared to human homologs from PhosphoSite.org to identify the site. Sites without a human homolog 
were removed from the analysis. Available on request.
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Noonan syndrome (NS) is an autosomal dominant disorder caused by activating mutations in the 
PTPN11 gene encoding for Shp2, which manifests in congenital heart disease, short stature and 
facial dysmorphia. The complexity of Shp2 signaling is exemplified by the observation that 
LEOPARD syndrome (LS) patients possess inactivating PTPN11 mutations yet exhibit similar 
symptoms to NS. Here, we identify protein zero-related (PZR), a transmembrane glycoprotein, 
which interfaces with the extracellular matrix to promote cell migration, as a major hypertyrosyl 
phosphorylated protein in mouse and zebrafish models of NS and LS. PZR hypertyrosyl 
phosphorylation is facilitated in a phosphatase-independent manner by enhanced Src recruitment 
to NS and LS Shp2. In zebrafish, PZR overexpression recapitulated NS and LS phenotypes. PZR 
was required for zebrafish gastrulation in a manner dependent upon PZR tyrosyl phosphorylation. 
Hence, we identify PZR as a NS and LS target. Enhanced PZR-mediated membrane recruitment of 
Shp2 serves as a common mechanism to direct overlapping pathophysiological characteristics of 
these PTPN11 mutations. 
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Introduction
The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase-2 (Shp2) is an 
ubiquitously expressed non-transmembrane protein tyrosine phosphatase (PTP) encoded by the 
PTPN11 gene [1]. Shp2 comprises of two SH2 domains, a PTP domain and a C-terminal tail that 
contains a proline rich region flanked by two tyrosine phosphorylation sites. The SH2 domains of 
Shp2 serve to direct protein-protein interactions with its upstream phosphotyrosyl target in a 
sequence-specific context and the SH2 domains participate in maintaining a closed conformation 
by establishing contacts with the PTP domain [2]. The phosphatase domain of Shp2 catalyzes 
substrate-specific dephosphorylation and is tightly regulated. In the basal state, the catalytic 
activity of Shp2 is suppressed by Shp2 assuming a “closed” conformation maintained through the 
NH2-terminal SH2 (N-SH2) domain forming surface contacts with the PTP domain, which 
occludes the catalytic site. SH2 domain engagement disrupts this “closed” conformation leading 
to allosteric modulation and exposure of the catalytic site in to an “open” state that is now 
substrate accessible [2]. Engagement of the SH2 domains provides an elegant molecular switch 
mechanism to activate the phosphatase that allows for targeted substrate dephosphorylation 
within a precise micro-environment. As such, the repertoire of Shp2-binding proteins plays a 
major role in dictating Shp2 signaling complexity and specificity. Consistent with this, interference 
of Shp2’s SH2 domains abrogates both physiological and pathophysiological signaling [3]. Thus, 
the integrity of the SH2 domains of Shp2 plays a critical role in its ability to signal.
A wealth of biochemical, cellular and genetic evidence in mice, Drosophila and zebrafish has 
established that Shp2 plays a positive signaling role downstream of numerous receptor tyrosine 
kinases, cytokine receptors, G protein-coupled receptor and integrins [1]. The repertoire of Shp2-
interacting proteins in combination with a wide variety of substrates [4] endows this phosphatase 
the capability of engaging a complex array of signaling molecules and pathways such as the Ras/
MAPK, PI3K/Akt, JAK/STAT, RhoA/Rac and Src family kinases (SFKs). Shp2 has been shown to 
promote a number of cellular functions including cell growth, cell survival and differentiation, 
hence affecting organismal functions such as development in mice [5,6], Drosophila [7] and 
zebrafish [8]. The highly conserved nature of Shp2 signaling in lower organisms has provided 
powerful model systems for the genetic dissection of Shp2 function in development. The 
realization that Shp2 plays an important role in human development arose through the discovery 
that germline mutations in the PTPN11 gene encoding for Shp2 cause two similar types of 
autosomal dominant disorders [9,10]. More than 50% of Noonan syndrome (NS) (NIM163950) 
cases are caused by mutations in PTPN11 that result in increased Shp2 catalysis. In contrast, as 
much as 90% of LEOPARD syndrome (LS) (NIM151100) mutations are caused by inactivating 
PTPN11 mutations that gives rise to impaired Shp2 activity. 
NS and LS are autosomal dominant disorders that manifest in short stature, ocular hypertelorism, 
cardiac defects, webbed neck and increased incidence of mental retardation [11-13]. NS and LS 
comprise part of a larger series of disorders that have thus far been characterized by mutations in 
components of the Ras/MAPK pathway and are collectively referred to as “RASopathies” [14]. As 
such, NS and LS exhibit overlapping clinical presentations such as proportionate short stature, 
facial dysmorphia, musculoskeletal anomalies and to a lesser extent congenital heart disease. 
Despite the similarities between NS and LS, these “RASopathies” are caused by opposite effects 
on Shp2 activity [9,15-18]. These observations suggest that NS and LS may utilize common 
signaling components in the pathogenesis of these developmental disorders. Interestingly, one 




propensity to adopt an “open” conformation, leading to increased affinity to upstream target 
binding through the SH2 domains and target substrates [2,8,19,20]. Hence, the “open” 
conformation of NS and LS disease mutants may underlie the molecular pathogenesis of these 
syndromes rather than altered substrate dephosphorylation by the PTP domain. Despite these 
highly plausible explanations it remains unclear how activating and inactivating mutants of Shp2 
liberate overlapping disease outcomes. Moreover, identification of the target(s) for both NS and LS 
that must presumably be shared in order for them to elicit overlapping clinical outcomes is 
unknown.
PZR is a transmembrane glycoprotein with an extracellular immunoglobulin (Ig) domain and an 
intracellular domain containing two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) 
[21-23]. The ITIMs, when tyrosyl phosphorylated, serve as Shp2 binding sites [21]. We had 
identified previously that NS-associated Shp2 mutants induce PZR hypertyrosyl phosphorylation 
and recruit increased Shp2. Moreover, in Ptpn11D61G/+ mouse embryos PZR is hypertyrosyl 
phosphorylated demonstrating that it is aberrantly regulated in NS mice during development. 
Interestingly, PZR is upregulated during blastocyst formation [24]. Moreover, in mouse embryo 
fibroblasts derived from NS mice, adhesion-dependent ERK1/2 activation is abrogated upon loss 
of PZR expression [25]. 
To gain further insight in to how NS and LS might liberate similar phenotypes we performed an 
unbiased phosphotyrosine proteomics screen in a mouse model of NS and a zebrafish model of NS 
and LS. We identified protein zero-related (PZR) as a major hypertyrosyl phosphorylated protein 
in both NS and LS in mice and zebrafish. The role of PZR in development remains unclear and the 
pathophysiological significance of PZR/Shp2 interactions in NS and LS is also unknown. NS and LS 
are linked to defects in gastrulation cell movements and Shp2 is essential for gastrulation 
movements in mouse and zebrafish [11,26]. We show that PZR/Shp2 interactions are required for 
gastrulation in zebrafish. These results define a functional role for PZR in an intact organism. 
Moreover, they suggest that PZR is a common target that contributes to altered development in 
cases of both NS and LS. 
Results
PZR is a major hypertyrosyl phosphorylated protein in NS. 
Since NS and LS exhibit overlapping clinical outcomes we set out to identify target proteins that 
are affected by both syndromes. We hypothesized that targets similarly altered in their levels of 
tyrosyl phosphorylation in both NS and LS likely represent molecules of convergence in these 
diseases. Given that NS and LS mutants exhibit opposite catalytic activities we reasoned that a 
phosphatase-independent mechanism likely represents a common pathway for these two 
syndromes. Therefore, we focused on the identification of hypertyrosyl phosphorylated proteins 
in a mouse model of NS rather than hypotyrosyl phosphorylated ones, since the latter likely 
represents phosphatase-dependent Shp2 substrates.
We performed a phosphotyrosyl proteomics screen in mice harboring a knock-in of a NS-
associated Shp2 mutant [27]. Mice containing an Asp61 to Gly61 (D61G) mutation within the 
NH2-terminal SH2 domain of Shp2 (Shp2D61G) generates a NS mutation found in humans [9]. 
Heterozygous progeny of these mice (Ptpn11D61G/+) recapitulate several NS features observed in 
humans such as cardiovascular and skeletal abnormalities [27]. Since both NS and LS exhibit 
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significant clinical defects in the heart we focused on this tissue. We performed a global survey of 
the levels of tyrosyl phosphorylated proteins in the hearts of 5 day-old wild type and Ptpn11D61G/+ 
mice using an immunoaffinity phosphoproteomics approach [28]. The relative abundance of 
tyrosyl phosphorylated proteins was assessed by quantitating the frequency of phosphopeptides 
derived from wild type and Ptpn11D61G/+ mice [28]. We identified an approximately equal 
Figure 1 Proteomic analysis of differentially tyrosyl phosphorylated proteins in hearts of 
Ptpn11D61G/+ mice. (A) Classification of hypo and hyper-tyrosyl phosphorylated proteins in the hearts of 
Ptpn11D61G/+ mice. (B) Log2-transformed values for the ratio of each phosphotyrosine-containing peptide in 
wild type and Ptpn11D61G/+ mouse hearts. (C) Heat map of differentially tyrosyl phosphorylated peptides. 
(D) Extracted ion chromatogram and peptide sequence of PZR-containing tyrosine 242 (upper panels) and 
tyrosine 264 (lower panels) by differential proteomics. (E) Amino acid sequences of PZR C-terminus in 
different vertebrates. Consensus sequences for ITIM (S/I/V/LxYxxI/V/L) are indicated in bold and tyrosine 
residues are marked red with their appropriate amino acid numbering.
Figure 2 Expression pattern of 
PZR in developing zebrafish. 
In situ hybridization for PZR was 
performed on developing zebrafish 
embryos at 8-cell, dome, bud, 
12-somite stage and at 24 hpf. The 





Figure 3 PZR is required for zebrafish development. (A) Genomic organization of zebrafish mpzl1 
gene encoding PZR. The target sites of E4I4MO (PZR-MO1) and E2I2 MO (PZR-MO2) are indicated as 
well as the positions of the oligonucleotides used for amplification of E3/E5 and E1/E3. (B) PZR mRNA 
and the positions of the oligos used for RT-PCR are depicted; the size of the PCR products is shown (bp). 
(C) Embryos were untreated (non-injected control, NIC) or injected at the one-cell stage with control MO 
(Nacre MO), PZR E2I2MO (PZR-MO2) or E4I4 MO (PZR MO1). PCR was performed for E3/E5, or E1/E3. 
(ctr-) indicates water control. (D) Embryos were injected (1-cell stage) with 2 pg control MO, 2 pg PZR MO 
or co-injected with 25 pg or 100 pg PZR mRNA. Embryos were scored at 4 dpf. (E) Zebrafish embryos 
were injected at the 1-cell stage with 2 ng Shp2 MO or 2 ng PZR MO2 or 2 ng control morpholino and 
photographed at 3 dpf. (F) Embryos were injected at the 1-cell stage with 2 pg PZR MO, 2 pg control MO or 
non-injected as a control, fixed at 4 dpf and stained with alcian blue. Meckel’s cartilage (1), the ceratohyal 
(2) and branchial arches (3-7) are indicated. The angle of the ceratohyal was measured.
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repertoire of differentially hypo and hypertyrosyl phosphorylated peptides in the hearts of 
Ptpn11D61G/+ mice (Figure 1A and B). The limited number of differentially tyrosyl phosphorylated 
peptides suggests that the NS mutant induces a discrete influence on global tyrosyl 
phosphorylation levels in the heart (Figure 1B). The highest induced hypertyrosyl phosphorylated 
peptide represented Y264, which is present in the transmembrane glycoprotein, protein zero-
related (PZR) and was induced by 6.7-fold as compared to wild type controls (Figure 1C and D). 
The sequence surrounding Y264 was identified to be part of the immunoreceptor tyrosine 
inhibitory motif (ITIMs) of PZR [23]. PZR contains two ITIMs both of which are highly conserved 
among vertebrates and when phosphorylated binds directly to the SH2 domains of Shp2 [23]. 
Notably, the other tyrosine-containing ITIM on PZR represented by Y242 was also detected to be 
hypertyrosyl phosphorylated by 2.2-fold (Figure 1C and D). For clarity, we will use the human 
amino acid numbering of PZR (Figure 1E - mouse Y242 and Y264 correspond to human Y241 and 
Y263, respectively). Previously, we found that PZR was hypertyrosyl phosphorylated during 
embryogenesis in Ptpn11D61G/+ mice [25]. These results identify Y242 and Y264 as sites of PZR 
hypertyrosyl phosphorylation in this mouse model of NS. 
Zebrafish have been shown to recapitulate both NS and LS phenotypes [11]. Therefore, 
phosphotyrosyl proteomics screens were performed in developing (26 hours post-fertilization) 
embryos to identify differentially tyrosyl phosphorylated peptides between zebrafish embryos 
expressing either NS or LS mutants as compared with controls. When injected with the Shp2D61G 
NS mutant, peptides representing the ITIMs of zebrafish PZR containing Y241 and Y263 were 
identified to be amongst the highest induced phosphotyrosyl-containing peptides (7.7 and 4.7-
fold increase for Y241 and Y263, respectively as compared with controls). In addition, LS-injected 
embryos also were found to contain PZR hypertyrosyl phosphorylated peptides at both Y241 and 
Y263 representing increases of 3.4- and 3.1-fold relative to wild type controls. These results 
identify PZR as a major hypertyrosyl phosphorylated target in zebrafish embryos expressing 
either NS or LS mutations.
PZR is expressed ubiquitously and functions in the Shp2 pathway in zebrafish. 
Our data demonstrate that PZR tyrosyl phosphorylation is aberrantly regulated in NS mouse 
embryos and post-developmentally in NS hearts ([25] and Figure 1) and during development of 
NS/LS expressing zebrafish embryos. These results suggest that altered PZR tyrosyl 
phosphorylation may play a role in NS and LS pathogenesis. To further examine the role of PZR 
during zebrafish development we determined the expression of mpzl1, the gene encoding 
zebrafish PZR. Zebrafish PZR was cloned and was used to generate an mpzl1-specific probe. In situ 
hybridization of mpzl1 expression was apparent from the 8-cell stage onwards, indicating 
maternal expression. Mpzl1 expression was ubiquitous until bud stage and at later stages mpzl1 
expression appeared to be enhanced anteriorly (Figure 2). The specificity of the antisense mpzl1 
probe was confirmed by the lack of signal of the sense control probe in parallel experiments 
(Figure 2). Thus, PZR is maternally contributed and expressed at embryonic stages during and 
after zebrafish gastrulation. 
PZR knockdown phenocopies NS and LS expression in zebrafish embryos. 
Next, PZR was knocked down in order to investigate the role of PZR in zebrafish signaling. The 
specificity of the PZR MO to block PZR splicing was confirmed (Figure 3A - C). Knockdown of PZR, 
but not a control morpholino (MO), induced a phenotype characterized by reduced body axis 
length (4.9 ± 1.1 % reduction compared with control) and heart edema and this phenotype was 
confirmed using a second non-overlapping MO (Figure 3D and E). Interestingly, similar 




dose of PZR mRNA (25 pg) rescued the PZR-MO-induced defects, whereas a higher dose of PZR 
mRNA (100 pg) failed to rescue (Figure 3D). To quantify the craniofacial defects in PZR 
knockdowns, embryos were fixed at 4 dpf and the cartilage was stained with alcian blue. The 
cartilage was greatly malformed and the angle of the ceratohyal displayed a significant increase, 
supporting the notion that PZR knockdown induced craniofacial defects, reminiscent of Shp2 
knockdown [11] (Figure 3F). 
The use of knockdown approaches by itself may lead to non-specific activation of p53 and 
subsequent apoptosis, thereby giving rise to developmental defects [30]. To rule-out this 
possibility we performed a co-knockdown of p53 and PZR, which did not attenuate the phenotype 
(Figure 4A). We subjected PZR knockdown embryos to in situ hybridization using a panel of cell 
Figure 4. PZR knockdown is specific and does not affect cell specification (A) Zebrafish 
embryos were injected at the 1-cell stage with 2ng PZR MO alone or co-injected with p53 morpholino and 
photographed at 2 dpf. (B) Zebrafish embryos were injected at the 1-cell stage with 2 ng PZR MO1 or PZR 
MO2 or 2ng control morpholino, and fixed at shield stage (bmp2b, chd, gsc, ntla), 70% epiboly (cyc), and 
bud stage (six3) and probed for cell fate markers using in situ hybridization.
Figure 5. Genetic interaction 
between Shp2 and PZR. 
Embryos were injected at the 
1-cell stage with Shp2 MO 
(0.5 pg) or PZR MO (0.5 pg), a 
combination thereof or Shp2 MO 
(1.0 pg) and PZR MO (2.0 pg). 
Embryos were imaged at 4 dpf. 
The stacked histogram in the 
left panel indicates quantitation 
of the phenotypes shown in 
representative photographs in the 
right panel.
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Figure 6. Characterization of PZR tyrosyl phosphorylation. (A) C2C12 cells were co-transfected 
with empty vector or activated GST-Shp2E76A and either empty vector (vector), wild type human PZR (WT), 
PZR mutated at tyrosine 242 (Y241F), tyrosine 264 (Y263F), or both (2YF). Cell lysates were immunoblotted 
with anti-pPZR (Y241 or Y263), PZR or Shp2 antibodies. (B) HEK 293 cells were co-transfected with empty 
vector or activated Shp2E76A and either empty vector (vector), wild type zebrafish PZR (WT), PZR mutated 
at tyrosine 236 (Y241F), tyrosine 258 (Y263F), or both (2YF). Cell lysates were immunoblotted with anti-
pPZR (Y241 or Y263), PZR or Shp2 antibodies. ERK1/2 was used as a loading control. (C) HUVEC cells 
were infected with adenoviruses expressing either GFP as a control, wild type Shp2 or Shp2E76A. Cell 
lysates were immunoblotted with anti-pPZR (Y241 or Y263), total PZR and Shp2 antibodies. (D) HEK 
293 cells were transiently transfected with empty vector, wild type Shp2 (WT) or the indicated mutants 
of Shp2 (Activated Shp2; E76A, NS mutant; N308D or LS mutants; Y279C and T468M). Cell lysates were 
immunoblotted with anti-pPZR (Y241 or Y263), PZR and Shp2 antibodies. ERK1/2 was used as a loading 
control. (E) HEK 293T cells were transfected with HA-tagged zebrafish PZR with empty vector, wild type 
Shp2, Shp2D61G or Shp2A462T. Cell lysates were immunoprecipitated with anti-HA antibodies and 
immune complexes were immunoblotted with anti-Shp2 and anti-HA antibodies. Whole cell lysates were 




fate markers at shield stage (gsc, bmp2b, chd, ntl), 70% epiboly (cyc), and bud stage (six3). All 
markers were expressed indicating that cell specification was not affected (Figure 4B). Hence, 
PZR knockdown induced similar defects to those observed in both NS and LS Shp2 expressing 
embryos.
To investigate the genetic interaction between Shp2 and PZR, we partially knocked down Shp2 
and PZR separately and together. If PZR is essential for Shp2 signaling, partial loss of both Shp2 
and PZR should induce developmental defects that are more severe than by loss of each alone [29]. 
Knocking down Shp2 and PZR at sub-optimal levels did not induce developmental defects (Figure 
5). However, partial knockdown of PZR and Shp2 together resulted in developmental defects at 4 
dpf (Figure 5). The embryos were scored in three categories: wild type, phenotype and severe and 
it was evident that co-knockdown of Shp2 and PZR greatly enhanced the percentage of embryos 
displaying a severe phenotype (Figure 5). PZR knockdown also induced wider set eyes, 
reminiscent of the phenotype that we, and others, reported in Shp2 knockdowns [11,31]. Together, 
these results are consistent with the notion that PZR and Shp2 function in a conserved signaling 
pathway in zebrafish.
NS- and LS-associated Shp2 mutants induce PZR Y241 and Y263 hypertyrosyl 
phosphorylation. 
We investigated the characteristics of PZR hypertyrosyl phosphorylation in further detail. To 
accomplish this, antibodies against tyrosyl phosphorylated PZR at Y241 (pY241-PZR) and Y263 
(pY263-PZR) were generated. When cells were co-transfected with PZR, along with an activating 
mutant of Shp2 (Shp2E76A) that induces PZR hypertyrosyl phosphorylation [25] both anti-pY241 
and anti-pY263-PZR antibodies recognized tyrosyl phosphorylated PZR (Figure 6A). When Y263 
in PZR was mutated to F263, neither anti-pY241 nor anti-pY263-PZR antibodies detected tyrosyl 
phosphorylated PZR upon co-expression of Shp2E76A (Figure 6A). Similarly, mutation of Y241 to 
F241 in PZR, also resulted in the failure of both anti-pY241 and anti-pY263-PZR antibodies to 
detect tyrosyl phosphorylated PZR (Figure 6A). The explanation for these results is that Y241 is 
required for Y263 phosphorylation, and conversely, Y263 for Y241 phosphorylation. Similar 
observations have been made by others [21,32]. Importantly, mutation of Y241 and Y263 to non-
phosphorylatable residues abolished the immunoreactivity of both phospho-specific PZR 
antibodies (Figure 6A). These antibodies also recognized Y241 and Y263 in zebrafish PZR (Figure 
6B). 
We tested whether activating Shp2 mutants induced either Y241-PZR or Y263-PZR tyrosyl 
phosphorylation in other cell types. To this end, wild type and activating Shp2E76A mutants were 
introduced into human umbilical vein endothelial cells. These results indicated that pY241-PZR 
and pY263-PZR antibodies recognized endogenous tyrosyl phosphorylated PZR at Y241 and Y263, 
respectively (Figure 6C). The LS mutant from human and zebrafish when expressed in 293 cells 
were capable of inducing PZR hypertyrosyl phosphorylation at both Y241 and Y263 (Figure 6D 
and E). As reported previously [33], increased zebrafish PZR tyrosyl phosphorylation correlated 
with enhanced PZR/Shp2 binding (Figure 6E). Hence, both NS and LS mutants in human and 
zebrafish enhance PZR tyrosyl phosphorylation.
PZR hypertyrosyl phosphorylation in NS and LS mice. 
We determined whether PZR was hypertyrosyl phosphorylated in NS mice. Hearts isolated from 8 
week-old wild type and Ptpn11D61G/+ mice showed a significant increase in pY263-PZR tyrosyl 
phosphorylation as compared with wild type controls (Figure 7A). In addition, PZR hypertyrosyl 
phosphorylation was observed in the cortex of Ptpn11D61G/+ mice (Figure 7B), as well as in the 
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kidney, liver and spleen of these mice (Figure 8A-C). Given that in cultured cells LS induces PZR 
hypertyrosyl phosphorylation (Figure 6D and E), we tested whether PZR is hypertyrosyl 
phosphorylated using Ptpn11Y279C/+ knock-in mutant mice, which represented a human LS mutant 
[34]. Hearts from Ptpn11Y279C/+ mice were isolated and, although to a much lesser extent to 
Ptpn11D61G/+ mice, PZR was hypertyrosyl phosphorylated on Y263 (Figure 7C). In addition, PZR 
was robustly hypertyrosyl phosphorylated in the cortex of Ptpn11Y279C/+ mice (Figure 7D). In 
agreement with these data, we also observed that when zebrafish embryos were injected to 
express either the NS or LS mutants, PZR was also hyper tyrosyl phosphorylated at Y241 and 
Y263 (Figure 7E). No apparent differences were observed in the basal levels of Shp2, phosho-
ERK1/2 or phospho-Akt between either NS or LS mice (Figure 9A-D). Collectively, these results 
show that both NS and LS mutants induce PZR hypertyrosyl phosphorylation within the ITIM 
Shp2 binding motif of PZR in mice and zebrafish.
NS and LS mutants induce PZR hypertyrosyl phosphorylation by enhancing Src/
Shp2/PZR complex. 
In order to investigate the mechanisms underlying how both NS and LS mutants induce PZR 
hypertyrosyl phosphorylation, we examined the dependency of NS and LS mutants to induce PZR 
hypertyrosyl phosphorylation through the SFKs. ITIMs serve as potent Src family kinase (SFK) 
substrates and SFKs phosphorylate ITIMs within PZR [35]. Pharmacological inhibition of the SFKs 
by SU6656 impaired both NS- and LS-induced PZR hypertyrosyl phosphorylation at pY241 and 
pY263 (Figure 10A). Similar results were also observed with the activated E76A mutant (Figure 
10B). 
Next, we determined the ability of the activating Shp2 mutant to induce PZR hypertyrosyl 
phosphorylation in fibroblasts lacking the expression of Src, Fyn and Yes (SYF cells). Here, we 
found that an activating Shp2 mutant failed to induce PZR hypertyrosyl phosphorylation at Y241 
and Y263 (Figure 11A). Consistent with this, a kinase-dead mutant of c-Src blocked the ability of 
the activated Shp2 mutant to induce PZR hypertyrosyl phosphorylation at these sites (Figure 
11B). Both human and zebrafish PZR served as c-Src substrates in vitro (Figure 11C and D) and 
co-expression of a constitutively activated mutant of c-Src promoted tyrosyl phosphorylation of 
zebrafish PZR in cells (Figure 11E). Hence, c-Src phosphorylates human and zebrafish PZR at the 
Shp2 binding sites demonstrating that the SFKs likely mediates PZR hypertyrosyl phosphorylation. 
It has been previously suggested that the “open” conformations of both NS and LS mutants exhibit 
properties that increase their propensity to interact with other signaling proteins. Based upon 
our observations that SFKs may play a role we tested whether the SFKs are NS and/or LS binding 
targets. To test this, c-Src was immunoprecipitated from cells expressing either wild type Shp2, 
NS or LS mutants and these immune complexes were immunoblotted to detect for the presence of 
Shp2. We found that in both NS and LS expressing cells that the amount of NS/LS-Shp2 present in 
c-Src complexes was significantly greater as compared with wild type Shp2 expressing cells 
(Figure 12A). 
To determine whether Src is present in PZR complexes and whether this is enhanced by the “open” 
conformation of mutated Shp2 we immunoprecipitated Src and assessed the extent of PZR 
interactions. We found that when Src was immunoprecipitated, PZR and Shp2 were present in the 
complex (Figure 12B). However, Src failed to co-immunoprecipitate with the form of PZR that was 
mutated in both the ITIMs but still exhibited enhanced Shp2 binding to the “open” conformation 
Shp2 mutants (Figure 12B). Wild type PZR, as expected was found to exist in a complex with Shp2 




Figure 7. PZR tyrosyl phosphorylation in Ptpn11D61G/+ and Ptpn11Y279C/+mice and zebrafish 
expressing D61G or A462T Shp2. The heart (A and C) and the cortex (B and D) were isolated from 
5-week-old WT and Ptpn11D61G/+ mice (A and B) or 8-week-old WT and Ptpn11Y279C/+ mice (C and D). Tissue 
lysates were immunoblotted with pPZR (Y263) and total PZR antibodies. Phosphorylation of tyrosine 
264 in PZR represents n=5 per genotype. All data are mean ± S.E.M. *; P < 0.05, **; P < 0.01, ***; P < 
0.001. (E) Lysates prepared from zebrafish embryos expressing either wild type, D61G or A462T Shp2 were 
immunoblotted with anti-PZR (pY241) and PZR pY263 antibodies. Relative quantitation shown below and 
ERK1/2 expression was used as a loading control.
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expressed (Figure 12B). In contrast, double ITIM-containing mutant PZR, failed to form a complex 
(Figure 12B). These results suggest that the “open” conformation of Shp2 mutants exhibit an 
increased propensity to bind c-Src and that the likely explanation for PZR induced hypertyrosyl 
phosphorylation is causally related to the ability of Src to increase its proximity to PZR through 
Shp2 binding.
Convergence and extension defects induced by NS and LS are recapitulated by PZR 
in a phosphotyrosyl-dependent manner. 
The similarities between the Shp2 [29] and PZR morphant phenotypes (Figure 3 and 5) indicate 
common defects during development. Previous results have shown that Shp2 knockdown and NS 
and LS PTPN11 mutant overexpression lead to convergence and extension (C/E) cell movement 
defects during gastrulation resulting in shorter embryos with craniofacial defects and cardiac 
edema [11]. To test whether PZR knockdown also induces C/E defects, embryos were injected 
with PZR-, Shp2- or control morpholino, or LS mRNA as a positive control. Embryos were fixed at 
the 8- to 10-somite stage and subjected to in situ hybridization and stained for krox20 and myoD, 
markers for rhombomeres three and five, and the somites, respectively. Loss of PZR led to shorter 
and wider embryos compared with controls at the same stage, and these phenotypes were similar 
Figure 8 PZR tyrosyl phosphorylation in Ptpn11D61G/+ mice. (A) liver, (B) kidney and (C) spleen 
were isolated from 5-week-old wild type and Ptpn11D61G/+ mice. Tissue lysates were immunoblotted with 
anti-pPZR (Y263) and total PZR antibodies. Densitometric analysis of the phosphorylation levels of 
tyrosine 263 in PZR was determined and the results represent the mean ± S.E.M. from 5 mice per genotype. 




to Shp2 knockdown and LS-Shp2 injected embryos (Figure 13A). These results indicated that PZR 
is essential for C/E cell movements, analogous to that of both NS and LS mutants during zebrafish 
gastrulation. 
To assess whether PZR tyrosyl phosphorylation sites were important for C/E phenotypes we 
overexpressed wild type PZR and PZR tyrosyl phosphorylation site-deficient mutants and 
performed in situ hybridization at the 8- to 10-somite stage using markers for krox20 and myoD. 
Overexpression of wild type PZR resulted in shorter and wider embryos (Figure 13B). When 
mRNA encoding double ITIM tyrosine to phenylalanine mutants (Y241F and Y263F; 2YF) and as a 
control mRNA encoding GFP were injected into zebrafish embryos the C/E phenotype was 
inhibited (Figure 13B). As expected, PZR tyrosyl phosphorylation and Shp2 binding to zebrafish 
PZR is inhibited in the double ITIM Y241F/Y263F mutant (Figure 13C). These data indicate that 
both tyrosyl phosphorylation sites within each of the ITIMs are required for PZR signaling for the 
promotion of the C/E phenotype during early development in zebrafish. 
Figure 9. ERK and Akt phosphorylation in Ptpn11D61G/+ and Ptpn11Y279C/+  mice. The heart (A 
and C) and the cortex (B and D) were isolated from 5-week-old wild type and Ptpn11D61G/+ mice (A and B) 
or 8-week-old wild type and Ptpn11Y279C/+ mice (C and D). Tissue lysates were subjected to immunoblotting 
with anti-Shp2, pERK1/2, total ERK1/2, pAkt and Akt antibodies. Results represent densitometric analyses 
of the mean ± S.E.M. for pERK1/2 and pAkt from 5 mice per genotype.
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Discussion
Here, we identified using non-biased proteomic approaches PZR as a major hypertyrosyl 
phosphorylated protein in both NS and LS models of mice and zebrafish. Remarkably, disruption 
of PZR function resulted in similar phenotypes to that observed in NS or LS mutant expressing 
zebrafish. Mechanistically, NS and LS mutants induce PZR tyrosyl phosphorylation in a Src-
dependent manner and these mutants acquire an enhanced Src interaction as compared with wild 
type Shp2. PZR is required for zebrafish gastrulation and tyrosyl phosphorylation is necessary to 
promote convergence and extension movements. Thus, NS and LS mutants function in a 
phosphatase-independent manner to promiscuously promote PZR hypertyrosyl phosphorylation 
leading to dysfunctional gastrulation. Collectively, these results suggest that PZR is a novel 
evolutionarily conserved target for NS and LS-associated Shp2 mutants. 
The extracellular matrix serves to integrate dynamically processes that govern cell fate, tissue 
maintenance and homeostasis to outcomes that dictate organ architecture [36]. Growth factor 
receptors, chemokines and G-protein coupled receptors are either directly or indirectly influenced 
by the ECM to control cell proliferation, differentiation and cell survival. The “RASopathies” 
represent mutated components of the SOS/Ras/Raf/Erk and there has been much focus on the 
role this cascade plays in NS and LS as it relates to cell proliferation and cell survival [10]. PZR has 
been shown to function in the control of cell adhesion and migration [24,25,32,35,37]. Therefore, 
our findings imply that aberrant cell migration and adhesion likely play important roles in the 
pathogenesis of both NS and LS. The development of PZR mutant mice will be necessary to test 
these conclusions more comprehensively.
Figure 10. Effect of Src family kinases on PZR Y241 and Y263 phosphorylation. (A) HEK 293 
cells were transiently transfected with the indicated Shp2 mutants and treated with either DMSO as a 
control or 5 mM SU6656. (B) NIH-3T3 cells were infected with the adenoviruses expressing either GFP as 
a control or a constitutively active Shp2E76A, in the presence of DMSO, PP2 or SU6656 at the indicated 
concentration. Cell lysates were immunoblotted with anti-Shp2, pSrc (Y416), Src, pPZR (Y241 or Y263) and 




Figure 11. Src family kinases mediate NS/LS-induced PZR hypertyrosyl phosphorylation 
and increase NS/LS Src binding. (A) SYF (Src-/-/Fyn-/-/Yes-/- MEFs) and Src+/+ (SYF-expressing 
wild type Src) cells were infected with adenoviruses expressing either GFP or Shp2 E76A. (B) SYF cells 
were transiently transfected with wild type c-Src or kinase-dead c-SrcK295R/Y527F (KR/YF) and infected with 
adenoviruses expressing either GFP, wild type Shp2 or Shp2E76A. Cell lysates were immunoblotted with 
anti-Shp2, pSrc (Y416), pPZR (Y241 or Y263), PZR and Src antibodies. ERK1/2 was used as a loading 
control. (C and D) HEK-293 cells were transfected with Flag-tagged human PZR (C) or HA-tagged zebrafish 
PZR (D). The cell lysates were immunoprecipitated with indicated antibody. The immunoprecipitates 
were subjected to in vitro Src kinase assay with Src recombinant protein. The reaction products were 
immunoblotted with anti-pPZR (Y241 or Y263) antibodies. (E) HEK-293 cells were co-transfected with 
constitutively active Src mutant and either HA-tagged wild type zebrafish PZR (WT), PZR mutated at 
tyrosine 236 (Y241F), tyrosine 258 (Y263F), or both (2YF). Cell lysates were immunoblotted with anti-
pPZR (Y241 or Y263) or HA antibodies.
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phosphatase activity leads to developmental defects in zebrafish, mice and humans. Our findings 
that PZR is a target for Ptpn11 mutations that exhibit either increased or decreased catalytic 
activity argue for a central role for PZR in ECM-mediated signaling for both NS and LS mutations. 
Using a zebrafish model system, we found that PZR is required for development. PZR RNA was 
apparent at early stages in zebrafish embryos, suggesting a maternal contribution and either 
knockdown or overexpression of PZR in zebrafish resulted in a gastrulation defect. PZR knock 
down in zebrafish resulted in similar defects to Shp2 and NS and LS-like phenotypes. In addition, 
partial knockdown of both PZR and Shp2 resulted in developmental defects. Together, this 
genetically links PZR to a pathway in which both NS and LS mutations participate. Importantly, 
we found that the loss of PZR in zebrafish led to convergence and extension defects, which is 
consistent with deterioration in the fidelity of cell migration. Intriguingly, overexpression of PZR 
induced gastrulation defects similar to that of both overexpression and reduced expression of 
Shp2, reported previously [11]. These results suggest a tight balance and interplay exist between 
PZR and Shp2 signaling, consistent with the biochemical evidence demonstrating that Shp2 binds 
directly to PZR within its ITIMs [11]. Collectively, these observations argue that PZR-mediated 








(A) HEK 293 cells 
were transiently 
transfected either 
with Shp2 WT 
and the indicated 
Shp2 mutants. 
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a Dunnet’s test 
comparing Shp2 mutants with WT. *, P < 0.05; **, P < 0.01. (B) HEK 293 cells were co-transfected with 
Shp2 WT, E76A or Y279C and either empty vector (vector), wild type human PZR WT or PZR 2YF mutant. 
Cell lysates were immunoblotted with anti-pPZR (Y241 or Y263) or Shp2 antibodies. ERK1/2 was used as a 




What are the consequences of increased PZR 
tyrosyl phosphorylation? PZR acts as an adhesion-
responsive glycoprotein where upon engagement 
to the extracellular matrix it becomes rapidly 
tyrosyl phosphorylated within its ITIMs. Upon 
tyrosyl phosphorylation Shp2 is recruited to PZR 
and it has been shown that this event is responsible 
for promoting the pro-migratory and cell adhesive 
effects in a variety of cell types [24,25,32,35,37]. 
Given the importance of cell migration and cell 
adhesion in developmental processes such as 
gastrulation it is conceivable that aberrant PZR 
tyrosyl phosphorylation induced by both NS and 
LS mutants disrupts this process. In mice, PZR is 
expressed during early development and we have 
demonstrated that PZR is hypertyrosyl 
phosphorylated in the developing embryo of 
Ptpn11D61G/+ mice [25]. These observations support 
the notion that altered PZR tyrosyl 
phosphorylation and hence downstream signaling 
are associated with developmental defects. The 
significance of PZR tyrosyl phosphorylation was 
demonstrated in experiments in which 
overexpression of the ITIM mutants of PZR failed 
to induce gastrulation defects. These results 
define PZR tyrosyl phosphorylation as critical for 
development.
Figure 13. PZR tyrosyl phosphorylation is 
necessary for zebrafish convergence and 
extension phenotype. (A) Embryos were injected 
with Shp2 MO, PZR MO or LS mRNA at the 1-cell stage 
and fixed at the 8-10 somite stage. In situ hybridization 
was performed using krox20 and myoD staining for 
rhombomeres 3 and 5, and somites, respectively. 
Quantification of the width of the rhombomeres 
(red) and the length of the first 8 somites (light blue) 
is shown schematically. Krox20/myoD ratios are 
plotted compared to non-injected controls (NIC). 
Data represent the mean ± S.E.M. **; P < 0.01, ***; P 
< 0.001. (B) Embryos were injected at the 1-cell stage 
with mRNA encoding GFP, wild type (WT) PZR or 
PZR with the indicated mutations. Ratios of krox20/
myoD were calculated and compared to NIC. All data 
represent the mean ± S.E.M. ***; P < 0.001. (C) HEK-
293 cells were co-transfected with either HA-tagged 
zebrafish PZR WT or 2YF mutant and constituvely 
active Src. Cell lysates were immunoprecipitated with 
HA antibody and blotted with anti-pY, Shp2 and HA 
antibodies.
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A provocative finding from our study is 
that these results implicate the actions 
of a tyrosine kinase that promotes PZR 
tyrosyl phosphorylation by both NS and 
LS mutants. The observation that PZR 
is hypertyrosyl phosphorylated in both 
NS and LS indicates that the ability of 
the kinase to phosphorylate PZR occurs 
in an Shp2 catalytically-independent 
manner. We had shown previously that 
enhanced PZR tyrosyl phosphorylation 
caused by NS mutants does not occur as 
a result of SH2 domain protection [25]. 
Rather, the data here supports a Src 
family kinase as responsible for NS and 
LS-induced PZR hypertyrosyl phosphorylation. Previous work had initially suggested a lack of 
SFK involvement in NS-mediated PZR hypertyrosyl phosphorylation [25]. In the Eminaga et al. 
study we immunoprecipitated Shp2 and analyzed total tyrosyl phosphorylation of Shp2-
associated proteins. The Shp2-associated tyrosyl phosphorylated complex that migrated with a 
molecular weight of ~40kDa was found to contain at least PZR. It is likely that in this p40 complex 
that “site-specific” PZR tyrosyl phosphorylation was obscured by other co-migrating tyrosyl 
phosphorylated proteins. Whereas, in the experiments presented here, PZR tyrosyl 
phosphorylation is assessed directly using site-specific phospho-antibodies. 
We found that both NS and LS mutants contain increased levels of c-Src complexes as compared 
with wild type Shp2. In addition, we showed increased PZR in Src complexes from activating and 
LS-associated Shp2 mutants and this was abolished in cells expressing the PZR tyrosyl 
phosphorylation-deficient mutant. The nature of this increased association with c-Src correlates 
with the common underlying property that both NS and LS mutants exhibit an “open” conformation 
[19,38]. Other groups have suggested that the “open” conformation of NS and LS may represent an 
important molecular mechanism for the pathogenesis of these mutant forms of Shp2 [19,20,31,38]. 
The open conformation of NS and LS mutants exposes the PTP and SH2 domains, presumably this 
presents binding surfaces for Src that are otherwise inaccessible. Indeed, it has been shown 
previously that Shp2 binds to Src through its SH3 domains [39,40]. Our findings support this 
observation, and extend it by providing a mechanism that reconciles the behavior of both NS and 
LS in their capacity to promote similar phenotypic outcomes. 
The results from our proteomic screen are consistent with activation of a SFK-mediated pathway 
as we identified the Src substrate, focal adhesion kinase (FAK) and PECAM as hypertyrosyl 
phosphorylated in the hearts of NS mice. JNK was increased in its level of tyrosyl phosphorylation 
at one of its activating phosphorylation sites in NS hearts. Interestingly, Marin et al. showed that 
JNK and FAK were hypertyrosyl phosphorylated in LS mice suggesting a catalytic-independent 
mechanism for the activation of these molecules through the effects of enhanced Src function 
[34]. Whether or not PZR/Shp2/Src pathway accounts for the entirety of either NS or LS-like 
phenotypes will need to be determined. However, Jopling et al. have shown that Shp2 lies 
upstream of the SFKs in zebrafish development and the Shp2/SFK pathway is required for 
convergence and extension cell movements [11]. An integrated interpretation of our results 
support a model in which we invoke the actions of enhanced Src-mediated PZR tyrosyl 
Figure 14. Model for the effects of NS and LS mutants 




phosphorylation that results in altered development. An important aspect of Shp2-mediated 
signaling is that it is required to be appropriately localized to its upstream target. Disruption of 
the SH2 domains of Shp2 results in the abrogation of its ability to signal [1]. Therefore, enhanced 
PZR tyrosyl phosphorylation results in increased recruitment of Shp2 to PZR to promote further 
PZR tyrosyl phosphorylation and presumably other Src substrates that are in close proximity 
(Figure 14). It should also be noted that Src couples to Ras, and in some cases does so through 
Shp2 [41]. It is formally possible that both NS and LS engage Ras via this mechanism. However, the 
contribution of Ras signaling specifically for the manifestation of NS- or LS-related pathologies 
has yet to be determined. Collectively, these observations go some way towards providing an 
explanation as to how both the NS and LS mutants, which have enhanced and inactive PTP 
activities, respectively result in overlapping phenotypes.
In summary, we have identified PZR as a proximal target of both NS and LS mutants. PZR functions 
to regulate cell adhesion and cell migration. Therefore, in NS and LS the augmentation of PZR’s 
interaction with Shp2 when it is hypertyrosyl phosphorylated presumably disrupts key 
developmental events that rely on the appropriate delivery of migratory ques. This mechanism 
occurs through enhanced binding of NS and LS mutants to Src. The implications of our findings 
clinically are that they suggest that the magnitude of PZR tyrosyl phosphorylation may reflect the 
“openness” of Ptpn11 mutants and hence the severity of NS and LS-related diseases. As such, it 
would be instructive to assess the clinical genotype-phenotype relationship in context of PZR 
tyrosyl phosphorylation in NS and LS patients.
Materials and Methods
DNA constructs and cloning 
Ptpn11 was cloned previously [11]. Mpzl1 was cloned by nested PCR from zebrafish embryos (bud 
to 48hpf) cDNA with Phusion DNA polymerase (Finnzymes, Vantaa, Finland) using fwPZRout: 
5’-GGGCGTTATTCATGAAATCTAAA-3’, rvPZRout: 5’- CTCAGGTTGGCAGAGATGT-3’, fwPZRstart: 
5’- GCGGATCCATGGAAATAAGGCTT -3’ and rvPZRstop: 5’-GCCGAATTCTCAGTTCTTGCGGATG-3’. 
PCR product was cloned into pCS2+ using BamHI and EcoRI. PZR ITIM mutants Y236F, Y258F and 
Y236F/Y258F were made using site-directed mutagenesis with the following primers: 
Fw_Y>F236_PZR:5’-GGACCGGTGATTTTCGCTCAGCTCGAT-3’
Rv_Y>F236_PZR: 5’ATCGAGCTGAGCGAAAATCACCGGTCC-3’ 
RvstopY258F: 5’- CCGAATTCTCAGTTCTTGCGGATGTCTGCGAACACCACCGGCTC-3’ PZR was then 
sub-cloned using BamHI and XhoI restriction enzymes into pSG5 vector encoding an RPTPa signal 
sequence and HA tag [42] using the following primers: 
FwBamHI AGVSDPZR: 5’-GCCGGATCCGCCGGGGTCTCAGAT-3’ 
RvXhoI stopPZR:  5’-GCCCTCGAGTCAGTTCTTGCGGAT-3’. 
Antibodies, chemicals, cell lines and expression reagents 
Rabbit monoclonal phospho-PZR(Y241) and rabbit monoclonal phospho-PZR(Y263) antibodies 
were generated in collaboration with Cell Signaling. Mouse monoclonal Src antibody, rabbit 
polyclonal Src antibody, rabbit polyclonal phospho-ERK1/2(T202/Y204), mouse monoclonal 
ERK1/2 antibody, rabbit polyclonal phospho-Akt(S473) Ab and mouse monoclonal Akt antibodies 
were purchased from Cell Signaling. Rabbit polyclonal Shp2 antibodies and rabbit polyclonal 
ERK1/2 antibody were purchased from Santacruz Biotechnology. Mouse monoclonal Shp2 
antibody was purchased from BD bioscience. Rabbit polyclonal PZR (105-6) was generously 
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provided by Dr. Z. J. Zhao. Src family kinase inhibitors, PP2 and SU6656, were purchased from 
Calbiochem. HEK-293, NIH-3T3, SYF (Src-/-/Yes-/-/Fyn-/- MEFs) and Src++ (Src overexpressing SYF) 
cells were purchased from ATCC and grown in growth medium (Dulbecco’s modified Eagle’s 
medium supplemented with 1% penicillin/streptomycin and 10% feral bovine serum) in a 5% 
CO2 incubator at 37°C. Replication-deficient adenoviral constructs harboring Shp2 WT (Ad-Shp2 
WT), gain-of-function Shp2 mutant (Ad-Shp2 E76A) and GFP (Ad-GFP) were prepared as 
previously described [25,43]. NIH-3T3 and SYF cells were infected with by adenovirus at a dosage 
of 50 MOI. The pJ3 vectors containing Src WT and dominant negative Src mutant (Src K295R/
Y527F) have been described in previously [44]. The pIRES-GFP plasmids encoding Shp2 WT, gain-
of-function/Noonan syndrome mutants of Shp2 (Shp2 E76A and Shp2 N308D) and LEOPARD 
syndrome mutants of Shp2 (Shp2 Y279C and Shp2 T468M) have been described in previously 
[15,25]. DNA transfection into HEK-293 and SYF cells was performed using Lipofectamine 2000 
according to the manufacturer’s protocol. Mouse anti-phosphotyrosine antibody 4G10 (#05-321) 
from Merck Millipore, rabbit anti GFP (TP401) from Acris and mouse anti HA.11 clone 16B12 was 
from Covance. 
Animal handling
Ptpn11D61G/+ mice were provided from Dr. Benjamin Neel (University of Toronto, Toronto) and 
were genotyped as described previously [27]. Briefly, Ptpn11D61G/+ male mice were crossed with 
WT C75BL/6 X SV129 female mice and their offspring were genotyped by PCR and digestion with 
AgeI for D61G allele. Animal handling was approved by The Yale University Institutional Animal 
Care and Use Committee. Tissues from Ptpn11Y279C/+ mice were provided by Dr. Maria Kontaridis 
(Harvard University, MA).
In situ hybridization
Zebrafish were kept and embryos were staged as described (Westerfield 1995). In situ 
hybridizations were performed as described in Thisse et al., 1993. Bmp2b, chd, gsc, ntla, dlx3, hgg, 
krox20 and myod probes were as described [11,45]. Antisense and sense Mpzl1 probe was 
synthesized by T7 and SP6 mRNA polymerase (Promega), from pCS2+PZR, respectively. 
Morpholino’s RNA and injections – Zebrafish were kept and embryos were injected at the 1-cell 
stage. PZR morpholino 5’-CAGAGACCCTTACTGTGGTGGGACGC-3’, Shp2 morpholino 5’- 
GGTGGAACCACCTTCGGGATGTCAT-3’, nacre morpholino 5’-CATGTTCAACTATGTGTTAGCTTCA-3’ 
and standard P53 morpholino were from Genetools (Philomath, OR). 5’- capped sense synthetic 
mRNA was synthesized with SP6 or T7 mRNA polymerase using mMessage mMachine kit from 
Ambion . The amount of RNA that was injected at the 1-cell stage was optimized for each synthetic 
RNA. Morpholino’s were titrated down to give a specific phenotype without inducing increased 
apoptosis as co-injection of 1nmol p53 morpholino did not attenuate the phenotype. Likewise, 
mRNA was titrated down to either induce a phenotype or to rescue a morpholino induced 
phenotype. 
Immunoprecipitation and immunoblotting 
Cells were lysed on ice in lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 
1% Nonidet P-40, 1 mM Na3VO4, 10 mM NaF, 1 mM benzamidine, 1 mM PMSF, 1 mg/ml pepstatin 
A, 5 mg/ml aprotinin, and 5 mg/ml leupeptin. Tissues from Noonan (NS) and LEOPARD (LS) mice 
were lysed by homogenizing with lysis buffer. Cell or tissue lysates were incubated at 4 °C for 30 
min and clarified by centrifugation at 14,000 rpm at 4 °C for 10 min. Protein concentration was 




immunoprecipitations, 500 mg of lysate was incubated with 1 mg of indicated antibodies at 4 °C for 
overnight. Immune complexes were collected on either protein A- or protein G-Sepharose beads 
for 4 hr at 4 °C, washed three times with same lysis buffer and then heated to 95 °C in sample 
buffer for 5 min. Total cell or tissue lysates and immune complexes were subjected to SDS-PAGE 
and immunoblotting. The sites of antibody binding were visualized using enhanced 
chemiluminescence detection or Odyssey Imaging System. 
Transfected cells were lysed in RIPA buffer (150 mM NaCl, 20 mM Tris pH 8.0, 10 mM Na2HPO4, 5 
mM EDTA, 1 mM Na-orthovanadate, 10% glycerol, 1% NP-40, 1% Sodium deoxycholate, 0,1% SDS, 
sodium fluoride 2.5 mM, b-glycerolphosphate 5 mM, aproptinin 1 mg/ml, leupeptin 1 mg/ml) for 15 
minutes on ice with 1 ml per 10 cm dish. Samples were centrifuged for 30 min at 14,000 rpm 4°C. 
Then samples were pre-cleared using protein A agarose beads for 1 hr, an aliquot of whole cell 
lysate was immunoprecipitated with 1 mg antibody against HA for approximately 1hr on ice. 
Samples were precipitated using 25 ml protein A agarose slurry for approximately 1 hr at 4°C. 
Samples were boiled in 2x laemmli buffer and SDS-PAGE was performed.
For zebrafish, bud stage embryos were snap frozen in liquid nitrogen and stored in -80°C. 
Subsequently embryos were ground in cell lysis buffer containing 50 mM Tris, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 1% Nonidet P-40, 0.1% sodium deoxycholate , 
sodium fluoride 2.5 mM, b-glycerolphosphate 5mM, aproptinin 1mg/ml, leupeptin 1mg/ml . 
Samples were then boiled in Laemmli sample buffer containing 4% SDS and β-mercaptoethanol. 
Proteins equivalent to 4 embryos per lane were subjected to SDS-PAGE and blotted onto a PVDF 
membrane. After blotting, membranes were stained using coomassie blue to verify equal loading. 
293T cells were maintained in DMEM/F12 medium containing penicillin streptomycin and 10% 
and 7.5% FCS, resspetively. For serum starvation experiments non-essential amino acids were 
added. 293T and COS7 cells were passed twice a week at 1:20 and 1:7 before transfection. 
Transfection of zebrafish PZR was performed using polyethyleneimide (PEI) from Sigma with 20 
mg DNA. After transfection overnight, medium was replaced with serum and harvested 40 hr 
after transfection.  
Mass Spectrometric Analysis 
The PhosphoScan method was performed as previously described [28,46-48].  Wild type and 
Shp2 mutant (Noonan Syndrome) mouse hearts were homogenized, sonicated, and centrifuged to 
remove cellular debris.  Total protein for each tissue was normalized using the ProteinPlus 
Coomassie Reagent (Pierce), and proteins were reduced, alkylated, and digested overnight using 
trypsin (Worthington). Resulting peptides were separated from non-peptide material by solid-
phase extraction with Sep-Pak Classic C18 cartridges (Waters). Lyophilized peptides were re-
dissolved, and phosphopeptides were enriched by immunoaffinity purification using pY-100 
phosphotyrosine antibody (#9411, Cell Signaling Technology). Peptides were eluted with 0.15% 
TFA and concentrated with C18 spin tips immediately prior to LC-MS analysis.
Duplicate injections of each sample were run to generate analytical replicates and increase the 
number of MS/MS identifications from each sample. Peptides were loaded directly onto a 10 cm x 
75 μm PicoFrit capillary column packed with Magic C18 AQ reversed-phase resin. The column was 
developed with a 45-minute linear gradient of acetonitrile in 0.125% formic acid delivered at 280 
nL/min. Tandem mass spectra were collected with an LTQ-Orbitrap XL mass spectrometer 
running XCalibur using a top 10 method, a dynamic exclusion repeat count of 1 and a repeat 
duration of 30 seconds. MS spectra were collected in the Orbitrap component of the mass 
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spectrometer, and MS/MS spectra were collected in the LTQ.
MS/MS spectra were processed using SEQUEST and the Core platform (Gygi Lab, Harvard 
University) [49-52]. Searches were performed against the mouse NCBI database with reverse 
decoy databases included for all searches to estimate false positive rates.  Peptide assignments 
were obtained using a .98 precision cut-off in the linear discriminant analysis module of Core. 
Cysteine carboxamidomethylation was specified as a static modification, and methionine 
oxidation and serine, threonine, and tyrosine phosphorylation was allowed.  Results were further 
narrowed using mass accuracy (–/+ 5ppm) filters and the presence of a phosphotyrosine in the 
peptide.  Label-free quantitation was performed using Progenesis v4.1 (Nonlinear Dynamics). 
Peptide abundance data was manually reviewed in Progenesis for all peptides with at least a 2.0-
fold change to ensure accuracy of results.
Global phosphotyrosine differential proteomic analysis in the heart 
Heart tissue was lysed in urea buffer (20 mM Hepes, pH 8.0, 9 M Urea, 1 mM sodium vanadate, 2.5 
mM sodium pyrophosphate, 1 mM b-glycerophosphate). The lysate was sonicated and clarified by 
centrifugation. Tissue lysate was reduced by DTT and alkylated with iodoacetamide. Samples 
were then diluted 4 times with 20 mM Hepes to reduce Urea concentration to 2M, and digested by 
trypsin overnight at room temperature with gentle shaking. Phosphotyrosine-containing 
peptides were isolated using immobilized phospho-tyrosine specific antibody PY100 
(PhosphoScan Kit; Cell Signaling Technology). Following immuno-purification, phosphotyrosine-
containing peptides were analyzed by LC-MS/MS as described previously [48].
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Germline mutations in PTPN11, encoding Shp2, cause Noonan syndrome (NS) and LEOPARD 
syndrome (LS), two developmental disorders that are characterized by multiple overlapping 
symptoms. Interestingly, Shp2 catalytic activity is enhanced by NS mutations and reduced by LS 
mutations. Defective cardiac development is a prominent symptom of both NS and LS, but how the 
Shp2 variants affect cardiac development is unclear. Here, we expressed the most common NS and 
LS Shp2-variants in zebrafish embryos to investigate their role in cardiac development in vivo. 
Heart function was impaired in embryos expressing NS and LS variants of Shp2. The cardiac 
anomalies first occurred during elongation of the heart tube and consisted of reduced 
cardiomyocyte migration, coupled with impaired leftward heart displacement. Expression of 
specific laterality markers was randomized in embryos expressing NS and LS variants of Shp2. 
Ciliogenesis and cilia function in Kupffer’s vesicle was impaired, likely accounting for the left/
right asymmetry defects. Mitogen activated protein kinase (MAPK) signaling was activated to a 
similar extent in embryos expressing NS and LS Shp2-variants. Interestingly, inhibition of MAPK 
signaling prior to gastrulation rescued cilia length and heart laterality defects. These results 
suggest that NS and LS Shp2-variant mediated hyperactivation of MAPK signaling leads to 
impaired cilia function in Kupffer’s vesicle, causing left-right asymmetry defects and defective 
early cardiac development. 
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Introduction
PTPN11 encodes Shp2, a ubiquitously expressed non-receptor protein-tyrosine phosphatase 
(PTP) with two Src homology 2 (SH2) domains [1-3], that is involved in a variety of signal 
transduction processes, such as the Ras-Raf-MAP kinase [4], Jak-Stat [2,5], and 
Phosphatidylinositol-3 kinase (PI-3K) pathways [6]. Shp2 plays a critical role in the transduction 
of the signal from Receptor Tyrosine Kinases (RTKs), including the receptors of platelet-derived 
growth factor (PDGFR) [7], fibroblast growth factor (FGFR) [8] and the epidermal growth factor 
(EGFR) [9,10] as well as from cytokine receptors and Integrins [8,9].
Missense germline mutations in PTPN11 are associated with Noonan syndrome (NS) (OMIM: 
163950) and LEOPARD syndrome (LS) (OMIM: 151100), two autosomal dominant disorders. NS is 
a relatively common disorder that affects 1 in 1,000-2,000 live births. NS patients are 
characterized by congenital heart defects, including atrial and ventricular septal defects, 
pulmonary stenosis and hypertrophic cardiomyopathy (HCM) [11,12]. In addition, NS patients 
display short stature and facial abnormalities. LS is a more rare disorder (1:3,500 live births) that 
shows a substantial overlap with the various symptoms of NS patients with two more clinical 
manifestations that are specific for LS patients: deafness and “café-au-lait” spots on the skin 
[13,14]. The congenital heart defects among patients with PTPN11 mutations differ between NS 
and LS patients, in that pulmonary stenosis is most common in NS, while HCM prevails in LS 
patients [15,16].
Interestingly, the biochemical properties of NS-Shp2 and LS-Shp2 are distinct, in that NS 
mutations enhance catalytic activity and LS mutations strongly reduce PTP activity [17,18]. The 
crystal structure of Shp2 shows that in the absence of a binding partner, the N-SH2 domain 
interacts with the PTP domain and blocks the catalytic site [19]. NS mutations predominantly 
reside in the interface between the N-SH2 domain and the PTP domain, resulting in the disruption 
of the closed conformation and enhanced catalytic activity of NS-Shp2 [17,20]. In contrast, most 
LS mutations reside close to the active site and result in strongly reduced, yet detectable catalytic 
activity [17,21,22]. How two mutations with opposite effects on catalytic activity result in 
syndromes with similar clinical symptoms is a conundrum that still needs to be resolved. 
NS-Shp2 causes up-regulation of the MAPK pathway [6]. Whereas several studies show that LS 
mutations down-regulate the level of phosphorylated ERK [18,23], the role of LS-Shp2 mutation 
on the MAPK pathway is still controversial [24-26]. Increased RAS/MAPK signaling is implicated 
in the gain-of-function phenotypes that are caused by expression of the LS Drosophila orthologue 
of PTPN11, corkscrew (csw) [26], suggesting a mechanism by which NS and LS variants may result 
in similar phenotypes. However, NS- and LS-signaling is distinct, because it is well established 
that LS-mutations, but not NS mutations [27], enhance PI3K/AKT signaling in hearts of LS/+ 
knock-in mice [18] as well as in fibroblasts isolated from LS patients [24]. The similarities in RAS/
MAPK signaling of NS and LS variants may underlie the overlapping symptoms in NS and LS, 
whereas the differences in PI3K/Akt signaling may cause the differences in NS- and LS-induced 
developmental defects.
Shp2 knock-out, knock-down and gain-of function studies in a variety of organisms have begun to 
reveal the roles of Shp2 in embryonic development. Shp2 null mouse embryos die pre-implantation 
due to defective Erk activation and trophoblast stem cell death [28]. Dominant-negative Shp2 




the two most prevalent NS and LS mutations, 
Ptpn11D61G/+ and Ptpn11Y279C/+, respectively. These 
mice exhibit developmental defects, including 
reduced length, cranio-facial abnormalities and 
congenital heart defects, reminiscent of the 
clinical characteristics of the human disorders 
[30,31]. In particular pulmonary stenosis and HCM 
are evident in the NS and LS mice, respectively. 
Shp2 is conserved in zebrafish and we previously 
generated the most common human NS and LS 
mutations in a cDNA encoding full length zebrafish 
Shp2. Micro-injection of mRNA encoding mutant 
Shp2 variants into zebrafish embryos at the one-
cell stage induces gastrulation cell movement 
defects as well as craniofacial and cardiac defects 
[32]. Furthermore, Stewart et al. used zebrafish 
embryos to show that the function of Shp2 in 
neural crest cells underlies LS pathogenesis [23]. 
The role of NS and LS Shp2 variants in the 
development of cardiac defects is still unclear. 
Zebrafish has become a powerful model to study 
cardiac development in recent years [33,34]. We 
set out to study early heart development in 
zebrafish embryos expressing NS and LS variants 
of Shp2, taking advantage of the transparency of 
zebrafish embryos, which facilitates time-lapse 
analysis of the onset and nature of the cardiac 
defects in vivo. Our analyses revealed impaired 
heart function and morphogenesis, which were 
highly similar in NS- and LS-Shp2 expressing 
embryos. Furthermore, the heart defects were 
accompanied by randomization of left-right 
asymmetry, which was likely due to impaired 
ciliogenesis and defective cilia function in 
Kupffer’s vesicle that we observed in early 
embryos. Treatment with a MEK-inhibitor, CI-
1040, prior to gastrulation rescued defective 
leftward heart displacement and the laterality 
defects in NS- and LS-Shp2 expressing embryos. 
Taken together, our results provide insight into 
the mechanism by which NS and LS Shp2-variants 
induced laterality defects through hyperactivation 
of MAPK signaling, resulting in cardiac defects 
during early development.
Figure 1. Impaired cardiac function in 
embryos expressing Shp2-D61G and Shp2-
A462T. (A-B) The hearts of WT-Shp2 (Shp2) and 
Shp2-D61G expressing zebrafish embryos were 
imaged by high speed video recording microscopy 
at 2 dpf. White dotted lines through the atrium 
(a) and the ventricle (v) are indicated. (C-F) 
Ventricular (C,D) and atrial (E,F) kymographs 
from 2 dpf embryonic hearts. Note the longer 
period of the Shp2-D61G expressing heart, 
compared to the WT-Shp2 expressing heart 
(double arrow and white dotted vertical lines). (G) 
Quantitative analysis of the heart period in the 
ventricle or atrium of WT-Shp2, Shp2-D61G and 
Shp2-A462T expressing embryos. Whisker plots 
are depicted.
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Results 
Expression of NS and LS Shp2-variants caused defects in cardiac function
To investigate the role of Shp2 variants in cardiac function, Shp2-D61G and Shp2-A462T mRNAs 
were injected at the 1-cell stage. In order to monitor expression of mutant Shp2, we fused a green 
fluorescent protein (GFP)-peptide 2A sequence to the NH2-terminus of Shp2, which is cleaved off 
autoproteolytically [35] (Supplemental Figure 1). Following expression of (mutant) Shp2, the 
developing heart was analyzed at 55 hpf by high-speed video recording. Kymographs of the 
atrium and ventricle were generated, allowing quantification of heart function as described 
before [36]. Representative examples of kymographs of embryos expressing WT-Shp2 and Shp2-
D61G are depicted (Figure 1A-F). Quantification of the kymographs of WT-Shp2, Shp2-D61G and 
Shp2-A462T injected embryos revealed significantly longer cardiac cycles in the Shp2-variant 
expressing embryos, reflecting a reduced but regular heart rate (Figure 1G). Other functional 
defects, such as an atrio-ventricular block or uncoupling of the two chambers were not detected 
in Shp2-D61G and Shp2-A462T expressing embryos. These results illustrate functional cardiac 
defects, particularly a reduced heart rate, in embryos expressing NS and LS variants of Shp2.
Impaired heart asymmetry in embryos expressing NS and LS Shp2-variants
To further characterize the cardiac phenotype in response to expressing of NS and LS variants of 
Shp2, we first examined the overall morphology and regionalization of the heart at 55 hpf by in 
situ hybridization (ISH), using a panel of cardiac markers. At this stage, the heart chambers are 
completely formed in wild type embryos and the heart undergoes looping morphogenesis. 
Analysis of heart shape using a myl7-specific probe (formerly known as cmlc2) revealed that the 
hearts of Shp2-D61G and Shp2-A462T expressing embryos exhibited either inverted looping (14% 
Figure 2. Heart defects in 
embryos expressing Shp2-
D61G and Shp2-A462T. Non-
injected control embryos (NIC) and 
embryos injected at the one-cell 
stage with mRNA encoding WT-
Shp2 (Shp2), Shp2-D61G, or Shp2-
A462T were fixed at 48 hpf and in 
situ hybridization was performed 
using probes for the myosin genes 
myl7 (A-D, cardiomyocytes), vmhc 
(E-H, ventricle), amhc (I-L, atrium), 
and for has2 (M-P, endocardial 
cushions). Representative pictures 
are shown and the number of 
embryos showing this pattern as 
well as the total number of embryos 
that were analyzed is indicated 
in the bottom right corner of each 
panel. The outline of the heart is 





and 11%, respectively) or non-looped heart (39% and 25%, respectively) in contrast to non-
injected control and WT-Shp2 injected embryos, (Figure 2A-D). Myocardial chamber specification 
was not affected in NS-Shp2 and LS-Shp2 injected embryos as determined by expression of 
ventricular myosin heavy chain (vmhc) (Figure 2E-H) and atrium myosin heavy chain (amhc) 
(Figure 2I-L). Next, the formation of the endocardial cushions, from which the atrioventriclar 
valves will develop, was assessed by has2 expression. In Shp2-D61G and Shp2-A462T expressing 
embryos, has2 expression was not affected, compared to non-injected control and WT-Shp2 
expressing embryos (Figure 2M-P). Expression of this panel of markers was also assessed in 
embryos expressing Shp2-T73I (NS) and Shp2-G465A (LS) with similar results (Supplemental 
Figure 2), indicating that all NS and LS variants induced similar defects. Taken together, these 
data indicate that expression of NS- and LS-variants of Shp2 led to a failure to undergo heart 
looping in a large proportion of the embryos without inducing defects in cardiac chamber 
specification or endocardial cushion formation. In addition, the NS- and LS-variants of Shp2 
induced cardiac defects to a similar extent during early development.
To investigate at which stage the cardiac defects arise in embryos expressing NS and LS variants 
of Shp2, myl7 expression was analyzed at different time points of heart development, particularly 
during cardiac fusion and heart tube elongation. Zebrafish heart formation is initiated by fusion 
Figure 3. Randomized heart displacement in response to expression of Shp2-D61G and 
Shp2-A462T. Embryos were injected at the one-cell stage with mRNA encoding WT-Shp2, Shp2-D61G 
or Shp2-A462T and fixed at the 16-somite stage, the 22-somite stage or at 28 hpf. In situ hybridization 
was done using a myl7-specific probe to mark cardiomyocytes. (A-H) The ratio of the number of embryos 
displaying the depicted pattern and the total number of embryos that were analyzed for each condition 
is indicated in the bottom right of each panel. (I-K) Representative pictures are shown displaying heart 
displacement to the left (I), middle (J) and right (K). (L) Percentages of left, middle and right cardiac 
displacement are depicted. 
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Figure 4. Impaired cardiomyocyte migration in embryos expressing Shp2-D61G and Shp2-
A462T. Embryos from the tg(myl7:GFP) line were injected with mRNA encoding WT-Shp2, Shp2-D61G or 
Shp2-A462T lacking eGFP-peptide 2A sequences to allow imaging of GFP-positive cardiomyocytes from the 
22-somite stage onwards. (A-F) Representative individual GFP-positive cells were color-coded according 
to their location within the cardiac field at the 22-somite stage and tracked over a 200 min period. The 
resulting cell tracks are indicated. Dorsal view with the anterior to the top. Schematic representations 
of the embryos on the left indicate the position and shape of the heart in green. (A-C) WT-Shp2; (D-F) 
Shp2-A462T (G) Quantification of the total speed of posterior (P) and anterior (A) cardiac progenitor 
cells. Following imaging, heart displacement was assessed in the embryos. WT-Shp2 expressing embryos 
displayed normal leftward heart displacement; embryos expressing Shp2-D61G and Shp2-A462T that did 
not display normal heart displacement were selected for further analysis. (H) Clockwise cardiomyocyte 
rotation was determined of the same embryos as in (G). Rotation was quantified as depicted in (I). In (G) 
and (H), averages are indicated and error bars indicate standard error of the mean. Statistical significance 




of two bilateral pools of cardiomyocytes at the 16-somite stage (16 hpf) into a cardiac disc at the 
midline of the embryo at 22 somites (20 hpf) [33,37]. No obvious defects were detected in myl7 
expression or cardiac fusion between non-injected control, WT-Shp2, Shp2-D61G and Shp2-A462T 
expressing embryos up to 22 somites (Fig 3A-H). At 28 hpf, the heart in WT-Shp2 expressing 
embryos formed a tube that extended from the midline to the area under the left eye (Figure 3I), 
which resembled normal heart displacement. In contrast, in Shp2-D61G and Shp2-A462T 
expressing embryos the displacement of the heart is randomized: 23% of Shp2-D61G expressing 
embryos and 28% of Shp2-A462T expressing embryos showed the heart on the right, while 34% 
of Shp2-D61G expressing embryos and 24% of Shp2-A462T expressing embryos displayed 
positioning of the heart tube at the midline (Figure 3J-L). Taken together, these results indicate 
that the first signs of cardiac abnormality in embryos expressing Shp2 variants are observed 
during asymmetric displacement of the heart tube.
Decreased cardiomyocyte migration speed and rotation in embryos expressing NS 
and LS Shp2-variants
Randomization of heart displacement may be caused by compromized cardiomyocyte migration 
[38]. Tg(myl7:GFP) embryos express eGFP in cardiomyocytes and were used for high-resolution 
confocal time-lapse imaging to assess cardiomyocyte migration. Since WT-Shp2 expressing 
embryos were indistinguishable from non-injected control embryos in in situ hybridization 
experiments (Figure 2, 3), we used WT-Shp2 expressing embryos as a control for the embryos 
expressing NS and LS variants of Shp2 from here on after. Single cells were tracked in WT-Shp2, 
Shp2-D61G and Shp2-A462T expressing embryos from cardiac disc stage (21 somites, 19.5 hpf) 
for 4 hours and their velocities and directions were determined. Consistent with observations of 
heart morphogenesis in wild type embryos [39,40], cardiac cells moved towards the left and 
anterior part of the embryo in WT-Shp2 expressing embryos (n=4). Cardiomyocytes in the 
posterior part of the cardiac disc moved faster than anterior cells (Figure 4A-C). The Shp2-D61G 
and Shp2-A462T expressing embryos were imaged at 19.5 hpf, like the WT-Shp2 expressing 
embryos and subsequently, heart displacement was assessed at 24 hpf, allowing correlation 
between early migration defects and heart displacement. Embryos that displayed impaired heart 
displacement were selected for further analysis. It is noteworthy that none of the selected 
embryos displayed heart displacement to the right (Shp2-D61G, n=8; Shp2-A462T, n=8), which 
may be due to low penetrance of rightward heart displacement. Although cardiomyocytes in the 
selected embryos formed a cardiac tube, they showed reduced migration to the left. Representative 
images of an embryo expressing Shp2-A462T are depicted in Figure 4D-F. Quantification of the 
speed of cardiomyocytes confirmed slower migration of cells in embryos expressing Shp2-D61G 
and Shp2-A462T, compared to WT-Shp2 (Figure 4G). Cardiomyocytes in selected embryos 
expressing Shp2-D61G and Shp2-A462T did not cross the midline, but instead migrated anteriorly, 
which is consistent with defective heart displacement to the left. Rotation of the heart tube was 
quantified as described before and the observed 30° clockwise rotation of the cardiac cone in WT-
Shp2 expressing embryos was consistent with the previously reported clockwise rotation in 
control embryos [39]. Clockwise rotation was significantly decreased in embryos expressing 
Shp2-D61G and Shp2-A462T with impaired leftward heart displacement, compared to control 
WT-Shp2 (Figure 4H). Our results indicate that directional cardiomyocyte migration and heart 
tube rotation is reduced in embryos expressing NS and LS Shp2-variants, which is consistent with 
the observed defects in heart tube displacement.
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NS and LS Shp2-variants disrupt left/right asymmetry
To determine if the loss of asymmetry in the hearts of embryos expressing NS and LS Shp2-
variants is associated with disruption of overall L/R asymmetry, we analyzed the expression of a 
number of laterality markers. Southpaw (spaw) is one of the earliest markers displaying 
asymmetric expression in development [41]. Spaw was predominantly expressed in the left lateral 
plate mesoderm (LPM) in WT-Shp2 expressing embryos (Figure 5A). Spaw expression was 
affected in embryos expressing Shp2-D61G and Shp2-A462T, compared to WT-Shp2, in that 23% 
of Shp2-D61G and 17% of Shp2-A462T expressing embryos displayed bilateral spaw expression 
and 26% of Shp2-D61G and 28% of Shp2-A462T expressing embryos expressed spaw exclusively 
in the right LPM (Figure 5B-D). Next, expression of Lefty2 (lft2), a downstream target of spaw, was 
investigated at the 22 somite stage (20 hpf). In WT-Shp2 expressing embryos, lft2 was detected in 
the left cardiac field in all cases (Figure 5E). In contrast, expression of lft2 in Shp2-D61G and Shp2-
A462T expressing embryos was randomized. 30% of the Shp2-D61G expressing embryos 
expressed lft2 on the right side (Figure 5E-G). Similarly, in Shp2-A462T expressing embryos, lft2 
expression was detected at the right side in 42% of the embryos. Southpaw is required for visceral 
organ L/R asymmetry [41], suggesting that defects in L/R asymmetry may not be limited to the 
heart in embryos expressing Shp2 variants. To investigate this, the position of the liver was 
Figure 5. Expression of Shp2-D61G and Shp2-A462T induced L/R asymmetry defects. 
Embryos were injected at the one-cell stage with mRNA encoding WT-Shp2 (Shp2), Shp2-D61G or Shp2-
A462T and fixed at the stage indicated in the panel. In situ hybridization was done using probes specific 
for spaw (A-D, southpaw), lft2 (E-G, lefty2), and fabp (H-K, fatty acid binding protein, marking the liver). 
Representative pictures are shown of Shp2-D61G expressing embryos. Note that lft2 expression was only 
observed on the left side or on the right side. Organ asymmetry as assessed using the different markers 
was scored for embryos injected with WT-Shp2, Shp2-D61G and Shp2-A462T. Percentages of left, middle/




assessed by analysis of the expression of fabp. Fabp expression was randomized at 48 hpf in 
embryos expressing Shp2-D61G and Shp2-A462T, in that the liver developed on the opposite side 
in 20% of the Shp2-D61G expressing embryos and 24% of the Shp2-A462T expressing embryos, or 
on both sides in 18% of the Shp2-D61G and 9% of the Shp2-A462T expressing embryos (Figure 
5H-K). In control WT-Shp2 expressing embryos, the liver always developed on the left side of the 
embryos. Analysis of the embryonic midline using the sonic hedgehog marker [42] indicated that 
expression of Shp2-D61G and Shp2-A462T altered left-right patterning without disrupting the 
Figure 6. Impaired ciliogenesis and cilia function in Kupffer’s vesicle in embryos expressing 
Shp2-D61G and Shp2-A462T. (A-C) Immunohistochemistry was done using anti-acetylated tubulin 
on WT-Shp2, Shp2-D61G or Shp2-A462T expressing embryos that were fixed at the 10-somite stage. 
Representative confocal images are depicted here. Scale bar indicates 50 µm. (D-F) Quantification of the 
cilia number, cilia length and KV area in WT-Shp2, Shp2-D61G and Shp2-A462T expressing embryos that 
were treated with 0.5% DMSO (control) or 0.25 µM CI-1040 at 4.5 hpf for 1 h and fixed at the 10-somite 
stage (n=10 for each condition). Averages are depicted with error bars indicating standard error of the 
mean. Statistical significance was determined using Student’s t-test: ***, p<0.001; **, p<0.01. (G-L) Tracks 
of fluorescent beads injected in KV. (G–L) Maximum projections of fluorescent bead movements injected 
in the KV of WT-Shp2, Shp2-D61G or Shp2-A462T expressing embryo, respectively that were treated with 
0.5% DMSO or 0.25 µM CI-1040 at 4.5 hpf for 1 h and fixed at the 10-somite stage. (M) Average flow velocity 
of beads in KV of embryos expressing WT-Shp2, Shp2-D61G and Shp2-A462T for the DMSO treatment and 
for the CI-1040 treatment. Averages are depicted with error bars indicating standard error of the mean. 
Statistical significance was determined using Student’s t-test:  ***, p<0.001.  
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midline that provides a barrier between the left and the right side (Supplemental Figure 4). These 
results show that L/R patterning in the LPM is impaired in embryos expressing NS and LS Shp2-
variants, which may lead to randomization of heart and gut laterality. 
Ciliogenesis and cilia function in Kupffer’s vesicle are impaired in embryos 
expressing NS and LS Shp2-variants
It is well established that Kupffer’s vesicle (KV), a fluid-filled ciliated organ, is involved in the 
establishment of L/R asymmetry in zebrafish [43,44]. Through the oriented rotation of the cilia 
inside the KV, asymmetric expression of genes such as spaw and lft2 is established. 
Immunohistochemistry was done using an acetylated tubulin antibody to detect cilia in the KV of 
10 somite-stage embryos (14 hpf) (Figure 6A-C). The mean number of cilia was 51.4 ± 0.5 in WT-
Shp2 expressing embryos, whereas in embryos expressing Shp2-D61G and Shp2-A462T, the 
number of cilia was significantly reduced to 30.4 ± 0.7 and 28.5 ± 0.4, respectively (n=10 embryos 
each) (Figure 6D). Also, the cilia length was significantly reduced in embryos expressing NS and 
LS Shp2-variants (both 3.2 µm ± 0.1, n cilia=241 for Shp2-D61G and n cilia=172 for Shp2-A462T, 
respectively) compared to control (4.2 ± 0.1 µm, n cilia=379 for WT-Shp2) (Figure 6E). 
Measurements of the area of KV indicated significant differences in lumen size among wild-type 
(4517 ± 355 μm², n=10), Shp2-D61G (2243 ± 190 μm², n=10) and Shp2-A462T (1914 ± 256 μm², 
n=10) embryos (Figure 6F). These results suggest that disruption of L/R asymmetry in embryos 
expressing NS and LS variants of Shp2 was a consequence of defective KV function, resulting from 
impaired ciliogenesis in the KV. To determine the KV functionality directly, we analyzed the fluid 
flow in embryos expressing NS and LS variants of Shp2. Tracking of fluorescent beads injected 
into the KV lumen of wild-type Shp2 expressing embryos showed counterclockwise rotation of 
the beads (Fig 6G). By contrast, tracking of the beads in Shp2-D61G and Shp2-A462T expressing 
embryos showed that the beads moved about randomly (Fig6 H-I), indicating a loss of coordinated 
flow. In addition, beads tracked in Shp2-D61G and Shp2-A462T expressing embryos showed a 
strongly reduced average flow velocity relative to wild-type Shp2 expressing embryos (Figure 
6M). These results indicate that ciliogenesis and cilia function is impaired in the KV of embryos 
expressing NS and LS variants of Shp2, resulting in defective KV function.
Early treatment with the MEK-inhibitor, CI-1040, rescued L/R asymmetry, heart 
asymmetry and KV function in embryos expressing NS and LS Shp2-variants
Shp2 variants enhance RAS/MAPK signaling [6]. Previously, we and others showed that inhibition 
of MEK rescued developmental defects in zebrafish embryos that were caused by expression of 
activators of the RAS/MAPK pathway [45,46]. We investigated whether inhibition of MEK would 
also rescue the cardiac defects in embryos expressing NS and LS Shp2-variants. First, the efficacy 
of the MEK inhibitor, CI-1040, to rescue early developmental defects was assessed. Expression of 
Shp2-D61G or Shp2-A462T in zebrafish embryos induced cell movement defects, resulting in 
elongated embryos at bud stage (10 hpf) (Figure 7A-C). Treatment with 0.25 µM CI-1040 at 4.5 hpf 
for 1 h rescued development at 10.5 hpf of embryos expressing Shp2-D61G and Shp2-A462T 
(Figure 7D-F). Quantification of the epiboly defects confirmed the rescue of the embryos 
expressing NS and LS Shp2-variants (Figure 7G). In addition, we confirmed that elevated pERK 
levels in embryos expressing Shp2-D61G and Shp2-A462T were reduced by CI-1040-mediated 
inhibition of MEK at 10 hpf (Figure 7H). 
Next, the effect of CI-1040 treatment was assessed on asymmetry of the heart in embryos 




Figure 7. Early treatment with the MEK-inhibitor CI-1040 rescued leftward heart 
displacement and cilia length in embryos expressing NS and LS Shp2-variants. Embryos were 
injected with mRNA encoding WT-Shp2 (Shp2), Shp2-D61G and Shp2-A462T at the one cell stage. (A-F) 
Representative images of bud stage embryos are depicted. The shape of the NS- and LS-Shp2 expressing 
embryos is restored by treatment with 0.25 µM CI-1040 at 4.5 hpf for 1h. (G) The ratio between the length 
of the major and minor axis was determined as quantitative measure of the epiboly defects in NS- and LS-
Shp2 expressing embryos. Averages are depicted with error bars indicating standard error of the mean. 
Statistical significance was determined using Student’s t-test (**, p<0.01; ***, p<0.001). (H) Embryos were 
treated with MEK inhibitor CI-1040 (0.25 µM) for 1 h at 4.5 hpf or mock-treated with DMSO and lysed 
at 10 hpf. Immunoblots of the zebrafish lysates were stained using antibodies specific for pErk and Erk. 
The experiment was repeated three times and representative blots are depicted here. (I-K) Embryos were 
mock-treated with DMSO (I) or with CI-1040 for 1h at 4.5 hpf (J) or at 10 hpf (K). Heart displacement 
was determined in embryos following in situ hybridization with a myl7-specific probe as in Figure 4. 
Histograms represent the percentage of embryos with heart displacement to the left, middle or right. 
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leftward displacement of the heart at 24 hpf of Shp2-D61G and Shp2-A462T expressing embryos 
(Figure 7I,J). However, treatment of these embryos for 1 h with CI-1040 at the 10-somites stage 
(14 hpf) did not restore normal heart displacement in embryos expressing NS and LS Shp2-
variants (Figure 7K). Treatment with 0.25 µM CI-1040 at 4.5 hpf for 1 h largely rescued 
randomization of the left-right asymmetry markers and of the liver (Supplemental Figure 5). 
These results indicate that inhibition of MEK at early stages rescues L/R asymmetry in embryos 
expressing NS and LS Shp2-variants. 
Finally, the effect of CI-1040 treatment on ciliogenesis and cilia function in KV was assessed. The 
cilia number was not rescued upon treatment with 0.25 µM CI-1040 at 4.5 hpf for 1 h. In fact, the 
cilia number in CI-1040-treated WT-Shp2 expressing embryos was significantly reduced to 
similar levels as in CI-1040 treated embryos expressing NS or LS variants of Shp2 (Figure 6D). Yet, 
CI-1040 treatment rescued cilia length in embryos expressing Shp2 variants (3.6 ± 0.1 µm in 
Shp2-D61G and 3.8 ± 0.1 µm in Shp2-A462T expressing embryos, compared to 3.2 ± 0.1 µm in 
untreated embryos) (cf. Figure 6E). Cilia length in WT-Shp2 expressing embryos was reduced 
somewhat in response to CI-1040 treatment (from 4.2 ± 0.1 µm to 3.7 ± 0.1 µm; cf. Figure 6E,) and 
hence, CI-1040 treatment abolished the difference in cilia length between embryos expressing 
WT-Shp2 and Shp2 variants. Moreover, CI-1040 treatment rescued KV area (3736 ± 373 μm² in 
Shp2-D61G and 3055 ± 294 μm² in Shp2-A462T expressing embryos, compared to 3986 ± 398 μm² 
in WT-Shp2 expressing embryos; cf. Figure 6F). Importantly, treatment with 0.25 µM CI-1040 at 
4.5 hpf rescued the counterclockwise rotation of the fluorescent beads in Shp2-D61G and Shp2-
A462T expressing embryos to levels that were comparable to WT-Shp2 expressing embryos 
(Figure 6 J-M). Taken together, these results suggest that the cardiac defects in zebrafish embryos 
expressing NS and LS Shp2-variants are due to hyperactivate MAPK-induced laterality defects 
originating from impaired cilia function in KV.
Discussion
In this paper, we used zebrafish to investigate defects in cardiac development in response to 
expression of NS and LS variants of Shp2. We found that NS- and LS-Shp2 expressing embryos 
showed impaired leftward heart displacement. Our results are consistent with a report that 
Noonan-associated mutations induce a cardiac looping defect in Xenopus [47]. Here, we provide 
insight into the underlying mechanism. The cardiac defects that we observed in zebrafish 
embryos are associated with L/R laterality defects and with defects in ciliogenesis. Expression of 
NS and LS variants of Shp2 in zebrafish embryos enhanced MAPK activation. The laterality defects 
were rescued by early treatment with CI-1040, a MEK inhibitor, indicating that the defects in 
heart asymmetry were caused by enhanced MAPK signaling before gastrulation.
Here, we focused on the cardiac defects in embryos expressing NS and LS Shp2-variants. The 
heart defects only became evident during cardiac tube formation, the first asymmetric process 
that occurs in the zebrafish heart [33]. Normally, the cardiac tube is displaced to the left, but in 
embryos expressing NS and LS Shp2 variants, heart displacement was randomized (Figure 3). Cell 
movement analyses revealed a delay in cell movements, coupled with reduced cardiac tube 
rotation, resulting in morphologically abnormal hearts at 28 hpf (Figure 4). Cell tracking studies 
showed that loss of Nodal or BMP signaling leads to similar defects [39,40]. Nodal mutant embryos 
show reduced speed and directional movement of the cardiomyocytes, resulting in disruption of 
the leftward morphogenesis and cardiac cone rotation. Asymmetric spaw expression in the LPM 




findings, we found that expression of spaw was randomized in embryos expressing NS and LS 
Shp2-variants, concomitantly with its downstream gene target lft2. As a consequence, left/right 
asymmetry was lost and leftward displacement of the heart in embryos expressing Shp2-D61G 
and Shp2-A462T was compromised. In addition, randomized fabp expression suggested that not 
only asymmetry of the heart, but also of the liver was impaired. 
Left-right asymmetry is conserved across species and defects in left-right asymmetry are 
collectively called laterality disease [48]. The phenotype we observed in zebrafish embryos 
expressing NS and LS Shp2-variants was characterized by randomization of left/right asymmetry. 
It is noteworthy that laterality disease is frequently associated with congenital heart defects 
(CHD) [38]. Impaired left-right patterning can affect cardiac morphogenesis, resulting in defective 
septation and/or double outlet right ventricle (DORV) [38]. Cardiac defects associated with 
laterality diseases are also reported in Shp2-D61G knock-in mice. A proportion of the heterozygous 
Shp2-D61G mice displays septal defects and DORV [30]. However, laterality defects are not the 
only cause of septation defects or DORV. Other laterality defects were not reported in NS or LS 
Shp2 knock-in mice and laterality defects have not been commonly reported in human individuals 
with NS and LS. Hence, it remains to be determined whether laterality defects have a role in 
human NS and LS. 
In zebrafish expressing NS and LS variants of Shp2, we found that the underlying mechanism for 
randomization of L/R asymmetry is likely impaired cilia function in the KV. Particularly cilia 
length and KV area were associated with Shp2 variant induced impaired fluid flow in KV and 
subsequent loss of asymmetry (Figure 6). It is well established that L/R asymmetry is mediated 
by cilia that generate fluid flow within the KV, resulting in expression of spaw in the left side of the 
LPM [49,50]. Laser-mediated ablation of KV randomises expression of spaw and lft2 [50]. 
Moreover, shorter cilia result in perturbed intravesicular fluid flow, leading to loss of asymmetry 
in the heart, brain and viscera [51]. KV formation is completed by the 6-somites stage (12 hpf) 
[52,53] and the generation of the KV depends on the dorsal forerunner cells (DFCs) that are 
induced during the blastula period [54]. Defects in the specification, clustering or organisation of 
DFCs induce defective KV organogenesis and/or ciliogenesis [50,53]. Therefore, it will be 
interesting to investigate the role of the NS and LS Shp2 variants in DFC biology. 
Shp2 is a well-known downstream factor in FGFR signaling [8]. It has been reported that FGFR1 
signaling regulates cilia length in zebrafish. Morpholino (MO)-mediated knockdown of FGFR1 in 
zebrafish reduces cilia length in KV and perturbs directional fluid flow, thus impairing L/R 
patterning of the embryo [43]. That knockdown of FGFR1, a positive regulator of MAPK signaling, 
has similar effects as mutant Shp2-induced hyperactivation of MAPK appears to be contradictive. 
However, it is not uncommon that attenuation and activation of a signaling pathway have the 
same effect on developmental processes. Apparently, FGFR1 knockdown on the one hand and 
Shp2 variant mediated enhanced MAPK activation on the other have similar effects on cilia 
function in KV and both impair L/R asymmetry. Our results predict that ectopic activation of 
MAPK signaling for instance by overexpression of (activated) MAPK around gastrulation would 
induce laterality defects as well. 
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Defective ciliogenesis was observed in the KV of NS and LS-Shp2 expressing embryos. It remains 
to be determined whether ciliogenesis in other organs is affected in these embryos as well. It is 
noteworthy that deafness is associated with LS in human patients. Deafness is typically associated 
with defective cilia in the inner ear and future work should focus on ciliogenesis in organs other 
than KV in NS and LS Shp2-variant expressing zebrafish embryos.
The cardiac defects that were induced by expression of NS and LS Shp2-variants in zebrafish 
embryos were indistinguishable. MAPK activation was elevated at bud stage in response to 
expression of both Shp2-D61G (NS) as well as Shp2-A462T (LS) (Figure 7H), which might explain 
why we observed similar developmental defects at early stages. It is well established that NS-
Shp2 mutations enhance MAPK activation, but LS-Shp2 often does not activate MAPK signaling. 
Nevertheless, it is not unprecedented that LS mutations induce defects that are associated with 
activation of MAPK signaling. Expression of LS-Shp2 mutants in Drosophila results in ectopic wing 
veins and a rough eye phenotype, characteristics of increased Erk activation. This gain-of-
function phenotype is similar to that of NS-Shp2 transgenic flies [25,26]. Moreover, a recent study 
shows that induced pluripotent stem cells (iPSCs) from LS patient-derived fibroblasts display 
higher basal pERK levels compared to those of control iPSCs [55]. How the NS and LS variants of 
Shp2 would both activate MAPK signaling remains to be determined. Whereas catalytic activity 
of Shp2 is enhanced by the NS mutations, it is reduced by the LS mutations, indicating that MAPK 
activation is not directly affected by alterations in Shp2 catalytic activity. Rather, the NS and LS 
Shp2-variant induced defects may result from a phosphatase-independent function of Shp2. 
Alternatively, as suggested in a recent report, the LS-variants of SHP2 retain some catalytic 
activity and mediate GOF phenotypes, because they have an increased propensity for the open 
conformation. Thus, the LS variants bind upstream activators preferentially and stay in complex 
with their scaffolding adapters longer, thus prolonging specific substrate turnover [22], which in 
turn may lead to MAPK activation.
Whereas MAPK activation may be elevated by both NS and LS variants of Shp2, elevated PI3K/
AKT signaling is exclusively associated with LS. Hyperactivation of AKT signaling in response to 
LS-Shp2 is responsible for HCM in mouse hearts [31,56,57]. We also observed elevated pAkt levels 
in response to LS-Shp2 in zebrafish embryos (Supplemental Figure 3), but we did not observe 
HCM in these embryos. The cardiac defects in embryos expressing NS and LS Shp2-variants were 
indistinguishable. Moreover, these heart defects were rescued by early treatment with the MEK 
inhibitor to a similar extent, indicating a causal role for elevated MAPK activation in the observed 
cardiac defects, independently of Akt signaling. 
In summary, our data provide new insights into the role of pathogenic Shp2 variants in cardiac 
development. Expression of NS and LS Shp2-variants led to similar cardiac defects in zebrafish 
that were associated with impaired L/R asymmetry, resulting from impaired cilia function in KV. 
Treatment with a MEK inhibitor prior to gastrulation rescued cilia function, L/R asymmetry and 
heart displacement, suggesting a causal relation with enhanced MAPK signaling. No studies to 
date have examined the effect of NS and LS Shp2-variants on L/R asymmetry. Our paper opens a 
new prospective to understand how pathogenic SHP2 and downstream MAPK activation relates 






Zebrafish were maintained and the embryos were staged as previously described [58]. The 
tg(myl7:GFP) line was previously described [59]. All procedures involving experimental animals 
were approved by the local animal experiments committee and performed in compliance with 
local animal welfare laws, guidelines and policies, according to national and European law.
Constructs, RNA and injections.
The eGFP-peptide 2A-Shp2 construct was derived by PCR. 5′ capped sense mRNAs were 
synthesized using the mMessage mMachine kit (Ambion) and linearized plasmid DNA. mRNA 
injections were performed at the one-cell stage as described [60] using optimized amounts of 
mRNA (D61G=150pg, A465T=50pg, T73I=80pg G465A=100pg, WT-Shp2=150pg). 
Immunoblotting
Zebrafish embryos (10hpf) were lysed in buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1 
mM EDTA, 1 mM sodium orthovanadate, 1% Nonidet P-40, 0.1% sodium deoxycholate, protease 
inhibitor mixture (Complete Mini, Roche Diagnostics) and vanadate. Samples were run on SDS-
PAGE gel (10%), transferred to PVDF membrane and stained with Coomassie Blue to verify equal 
loading. The blots were probed with antibodies specific for SHP2, Actin, pERK, ERK, pAKT, AKT 
(all Cell Signaling) and GFP (Torrey Pines). Detection was done using enhanced chemiluminescence 
(Thermo Scientific kit).
In situ Hybridization and Immunofluorescence Microscopy
In situ hybridizations were done essentially as described [61] using probes specific for, myl7 [37], 
vmhc [62], amhc [63], has2 [64], lefty-2 [65], southpaw [41], fabp, shh [42]. 
For zebrafish immunohistochemistry, embryos were fixed in 4% DENT’S solution at 4°C, and 
subsequently blocked for 1 hour in PBS containing 5% lamb serum, 1% BSA, 1% DMSO, and 0.1% 
Triton-X. Embryos were incubated in mouse anti-acetylated Tubulin (1:500, Sigma) for 3 hours at 
RT. After extensive washing, embryos were incubated in goat anti-mouse Alexa Fluor 488. 
Embryos were flat-mounted in glycerol. Images were acquired using an SPE laser scanning 
confocal microscope. Confocal z-series images were assembled to present the sum of the focal 
planes; cilia length, cilia number and KV lumen area were manually measured using Image J 
software (http://rsb.info.nih.gov/ij/). 
Pharmacological inhibition of MAPK signaling
To test the prevention of the NS/LS Shp2 mRNA phenotype, embryos injected with NS/LS Shp2 
mRNA were incubated with 0,25 µM CI-1040 at 4.5 hpf or 10 hpf for 1 hour at 28.5°C in the dark. 
Time-Lapse Imaging and Analysis
Embryos at the 22-somite stage were dechorionated and mounted in glass-bottom 6-well plates 
using 0.25% agarose in E3 embryo medium containing 16 mg/ml 3-amino benzoic acid ethylester 
to block contractile movements. Confocal imaging was performed using a spinning disc confocal 
laser scanning microscope with 20x magnification, acquiring stacks every 5 min. Embryos were 
kept at 28.5°C during recordings. ImageJ software (http://rsb.info.nih.gov/ij/) was used to 
generate time-lapse movies and for cell counting. Cell tracking was done using Volocity software 
(Improvision) followed by manual inspection of individual tracks generating quantification of 
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total speed (track length/time). Rotation was calculated by measuring the angle with the LR axis 
of four imaginary lines connecting four individual cells at the start and the end of the time-lapse 
(200 min). All statistical analyses were performed in Excel (Microsoft) using the two-tailed 
student’s T-test.
KV fluid flow and cilia motility
Fluorescent beads (Polysciences) were injected into KV to visualize flow as described [50]. Bead 
flow was imaged at the 8- to 10-somite stage (SS) on a Leica AF7000 microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) using a 63× water dipping objective and an Hamamatsu 
C9300-221 high speed CCD camera (Hamamatsu Photonics, Hamamatsu City, Japan) at 80 fps to 
record a 10 sec movie. Movies were generated using ImageJ software. Bead tracking was done 
using Volocity software (Improvision). For each embryo, four to five beads were tracked for a 
minimum of 50 frames of the movie and the average bead velocity was calculated. 
High-speed imaging and analysis
2 dpf embryos were mounted in 0.25% agarose prepared in E3 medium embryonic medium with 
16 mg/ml 3-amino benzoic acid ethylester. Embryonic hearts were imaged with a Hamamatsu 
C9300-221 high speed CCD camera (Hamamatsu Photonics, Hamamatsu City, Japan) at 150 fps 
mounted on a Leica AF7000 microscope (Leica Microsystems GmbH, Wetzlar, Germany) in a 
controlled temperature chamber (28.5°C) using Hokawo 2.1 imaging software (Hamamatsu 
Photonics GmbH, Herrsching am Ammersee, Germany). Image analysis was carried out with 
ImageJ (http://rsbweb.nih.gov/ij/). Statistical analysis and drawing of the box-whisker plot were 
carried out in Excel 2007 (Microsoft, Redmond, WA, USA).
Statistics
Cilia measurements were analyzed using the two-tailed student’s t-test. Averages for controls and 
experimental were compared within each clutch of embryos. Results were considered significant 
when p<0.05 and results are expressed as mean ± standard error of the mean (p values * p<0.05, 
** p<0.01, *** p<0.001).
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Supplemental data
eGFP- peptide 2A- Shp2 fusions allow monitoring of expression of (mutant) Shp2.
In order to monitor injection efficiency, we fused an eGFP-peptide 2A sequence to the NH2-
terminus of Shp2. The peptide 2A sequence in the fusion protein is cleaved autoproteolytically 
[35], producing eGFP and (mutant) Shp2 (Figure S1A), which was confirmed by immunoblotting 
(Figure S1B). Moreover, eGFP was readily visualized in the injected embryos at 48 hpf (Figure 
S1C,D). Injection of wild type Shp2 was used as a control and throughout this study Shp2-D61G 
was used as prototypical NS-variant and Shp2-A462T as LS-variant. Some of the experiments 
were done with additional variants with similar results. Morphological analysis of the embryos at 
48 hpf indicated that injections of the GFP-peptide 2A-Shp2 fusions phenocopied the previously 
published phenotypes of NS-Shp2 and LS-Shp2, including short stature, craniofacial defects and 
cardiac defects [32]. (Figure S1C-D). Therefore, we used the GFP-peptide 2A-Shp2 fusions, 
monitored GFP expression and selected efficiently injected embryos for further analysis unless 
indicated otherwise.
Supplemental Figure S1. EGFP-Peptide 2A-Shp2 fusions induced defects in zebrafish 
embryos. (A) Schematic representation of eGFP-Peptide 2A-Shp2 with D61G, T73I (NS) and A462T, 
G465A (LS) mutations indicated. The full length fusion protein is produced and is then cleaved 
autoproteolytically, resulting in eGFP and (mutant) Shp2. (B) One- or two-cell stage embryos were injected 
with in vitro transcribed mRNAs encoding the indicated proteins. Immunoblotting analysis reveals 
that autoproteolytic cleavage of the fusion proteins is highly efficient in zebrafish embryos. The injected 
embryos were lyzed at 10 hpf, proteins were separated on SDS-polyacrylamide gels, blotted and probed 
with antibodies specific for Shp2, GFP and β-actin as a loading control. (C-D) Two representative injected 
embryos (D61G and A462T) show craniofacial defects (red asterisks), a decrease in body length and cardiac 
edema (blue asterisks). These defects are absent in WT-Shp2 injected control embryos. Injection efficiency 




Supplemental Figure S2. Heart looping defects in embryos expressing Shp2-T73I (NS) and 
Shp2-G465A (LS). Non-injected control embryos (NIC) and embryos injected at the one-cell stage 
with mRNA encoding WT-Shp2, Shp2-T73I (NS) or Shp2-G465A (LS) were fixed at 48 hpf and in situ 
hybridization was performed using probes for the myosin genes myl7 (A-D, cardiomyocytes), vmhc (E-
H, ventricle), amhc (I-L, atrium), and for has2 (M-P, endocardial cushions). Representative pictures are 
shown and the number of embryos showing this pattern as well as the total number of embryos that were 
analyzed is indicated in the bottom right corner of each panel. The outline of the heart is indicated with a 
dashed line in panels M-P.
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Supplemental Figure S4. Midline structures are intact in NS and LS Shp2-variants. Bright-
field images of WT-Shp2 control (A) D61G (B) and A462T (C) embryos, showing normal notochord 
formation. (D-I) In situ hybridization analysis showed contiguous shh expression in the floorplate. The 
total number of embryos analyzed is: WT-Shp2, n=20/20; Shp2-D61G, n=30/30; Shp2-A462T, n=30/30. 
Supplemental Figure S3. Enhanced Akt signaling in 
Shp2-A462T (LS), but not Shp2-D61G (NS) expressing 
embryos. Zebrafish embryos were injected with WT-Shp2, Shp2-
D61G (NS) or Shp2-A462T (LS) at the one-cell stage. Embryos 
were lysed at 10 hpf. Immunoblots of the zebrafish lysates were 




Supplemental Figure S5. Early treatment with the MEK-inhibitor, CI-1040, rescued L/R 
asymmetry in embryos expressing NS and LS Shp2-variants. Embryos were injected at the one-
cell stage with mRNA encoding WT-Shp2 (Shp2), Shp2-D61G (NS) or Shp2-A462T (LS). Embryos were 
treated with MEK inhibitor CI-1040 (0.25 µM) for 1 h at 4.5 hpf or mock-treated with DMSO and fixed at the 
stage indicated in the panel. In situ hybridization was done using probes specific for spaw (A-B, southpaw), 
lft2 (C-D, lefty2), and fabp (E-F, fatty acid binding protein, marking the liver). Markers asymmetry was 
scored for embryos injected with WT-Shp2, Shp2-D61G and Shp2-A462T. Percentages of left, middle/
bilateral and right expression of the markers are depicted. The total number of embryos analyzed is: spaw 
(WT-Shp2 n=40, Shp2-D61G n=50, Shp2-A462T n=35); lft2 (WT-Shp2 n=50, Shp2-D61G n=42, Shp2-
A462T n=34) and fabp (WT-Shp2 n=26, Shp2-D61G n=28, Shp2-A462T n=35).
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Noonan syndrome (NS) is a developmental disorder characterized by short stature, facial 
dysmorphisms and congenital heart defects. To date, all mutations known to cause NS are 
dominant, activating mutations in signal transducers of the RAS/MAPK pathway. In 25% of cases, 
however, the genetic cause of NS remains elusive, suggesting that factors other than those 
involved in the canonical RAS/MAPK pathway may also play a role. Here, we used family-based 
whole exome sequencing of a case-parent trio and identified a de novo mutation, p.(Arg802His), in 
A2ML1 which encodes the secreted protease inhibitor Alpha-2-Macroglobulin-Like-1. Subsequent 
resequencing of A2ML1 in 155 cases with a clinical diagnosis of NS led to the identification of 
additional mutations in two families, p.(Arg802Leu) and p.(Arg592Leu). Functional 
characterization of these human A2ML1 mutations in zebrafish showed NS-like developmental 
defects, including a broad head, blunted face and cardiac malformations. Using the crystal 
structure of A2M, which is highly homologous to A2ML1, we identified the intramolecular 
interaction partner of p.Arg802. Mutation of this residue, p.Glu906, induced similar developmental 
defects in zebrafish, strengthening our conclusion that mutations in A2ML1 cause a disorder 
clinically related to NS. This is the first report of the involvement of an extracellular factor in a 
disorder clinically related to RASopathies, providing potential new leads for better understanding 
of the molecular basis of this family of developmental diseases. 
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Introduction
Noonan syndrome (NS) is an autosomal dominant, clinically variable condition, with an estimated 
prevalence of 1 in 1,000-2,500.[1] NS patients are characterized by facial dysmorphism, a wide 
spectrum of cardiac disease, reduced postnatal growth, variable cognitive deficits, ectodermal 
and skeletal defects.[2-4] Congenital heart defects are observed in a large proportion of NS 
patients, in particular pulmonary stenosis (66%), and hypertrophic cardiomyopathy (14%).[5] 
Other relatively frequent clinical features of NS patients include webbed neck, cryptorchidism, 
bleeding tendency, and hydrops fetalis. NS is genetically heterogeneous and mutations in PTPN11, 
SOS1, KRAS, NRAS, RAF1, BRAF, SHOC2, CBL and RIT1 account for approximately 75% of affected 
individuals.[4,6] To date, all mutations causing NS result in enhanced activation of signal 
transducers belonging to the RAS-mitogen activated protein kinase (MAPK) pathway.[7] 
To identify new genetic causes of NS, we used a family-based whole-exome-sequencing approach 
in a patient-parent trio with sporadic disease to detect de novo changes in the proband. Genetic 
testing had previously excluded mutations in known NS genes. We identified a de novo mutation in 
A2ML1, which encodes the secreted protease inhibitor Alpha-2-Macroglobulin-Like-1 (A2ML1). 
A2ML1 was re-sequenced in a cohort of cases with a clinical diagnosis of NS. Moreover, to provide 
more evidence for the involvement of the gene in this disorder resembling NS, protein modeling 
was performed and A2ML1 mutants were functionally characterized in zebrafish.  
Results
Exome sequencing in a NS case-parent trio
Exome sequencing in case 1 (Figure 1A) and her parents revealed four potential de novo mutations, 
two of which were validated by Sanger sequencing and confirmed to be of de novo origin 
(Supplementary Table 1). The first mutation is predicted to lead to p.(Arg129Pro) in OR12D3 
(NM_030959.2:c.386G>C), encoding an olfactory receptor. Based on the function of the gene 
product (odor perception) combined with the low evolutionary conservation at base pair level 
(PhyloP 0.55), we do not consider this variant to be relevant for the phenotype of the patient, but 
assume that this de novo mutation reflects the human per-generation background mutation rate.
[16] The second de novo mutation was detected in A2ML1 (NM_144670.3:c.2405G>A) and is 
predicted to lead to p.(Arg802His). This de novo mutation occurred at a highly conserved 
nucleotide (PhyloP 3.41) and affects a residue within the alpha-2-macroglobulin domain (Figure 
2A). It is noteworthy that the c.2405G>A variant in A2ML1 is also reported in 4/12,194 alleles in 
the NHLBI Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS/). Further 
analysis of the ESP database indicated that several frequently reported causal mutations in 
known NS genes, including PTPN11, are described in this database at similar frequency (Table 2). 
Mutation analysis of the A2ML1 gene in a NS cohort
Next, 155 individuals with a clinical diagnosis of NS were analyzed for mutations in A2ML1 by 
direct Sanger sequencing and Ion PGM system. This screen led to the identification of two 
additional likely causal missense mutations in two unrelated individuals (Figure 1B-C, Table 2). 
The mutation identified in case 2, c.2405G>T, affects the same residue as identified in family 1 but 
is predicted to result in a different substitution, p.(Arg802Leu). Segregation analysis showed that 
the mutation is transmitted to his son (case 3), who is also diagnosed with the same disorder 






























Figure 1. Photographs and pedigrees of families diagnosed with Noonan(-like) syndrome 
with likely pathogenic mutations in A2ML1.  (A) Family 1 – case 1. De novo mutation p.(Arg802His); 
(B) Family 2 – cases 2, 3 and 4. Familial p.(Arg802Leu). The sister of case 2 is reported upon 
heteroanamnesis to have the same clinical phenotype. However, DNA nor detailed clinical information 
were available for this study. (C) Family 3 – cases 5, 6, 7 and 8. Familial p.(Arg592Leu). Clinical details of 
all cases are presented in Table 3. Note, the absence of genotypes for (un)affected family members indicates 
that DNA samples of these individuals were not available for testing. Black solid squares/circles represent 
clinically affected individuals, whereas as open squares/circles represent healthy individuals. 
151
Mutations in A2ML1 are associated  with a disorder clinically related to Noonan syndrome 
8
mutation (Figure 1B). In the proband of family 3 (case 5), a c.1775G>T mutation (p.(Arg592Leu)) 
was detected. Familial segregation studies revealed the same mutation in her daughter (case 6) 
and her father (case 7), who were both clinically diagnosed with a disorder resembling NS (Figure 
1C). Strikingly, the patient’s first pregnancy resulted in intra-uterine fetal death at 29 weeks of 
gestation because of hydrops foetalis (case 8, Figure 1C). Pathological examination of the fetus 
showed facial features suggestive for NS. Molecular analysis of fetal DNA indicates maternal 
inheritance of the A2ML1 mutation p.(Arg592Leu). The clinical features of all individuals with an 
A2ML1 mutation are summarized in Table 3. A full description of the clinical data is provided in 
the supplement. Screening of selected exons of A2ML1 in an additional cohort of 140 individuals 
with a clinical phenotype fitting or suggestive for NS did not reveal any pathogenic mutations. All 
variants detected are shown in Supplementary Table 2. 
Figure 2. A2ML1 domain structure and modeling of the intramolecular interactions 
involving p.Arg802. (A) Schematic representation of A2ML1 protein domain structure and mutations 
in individuals with Noonan syndrome-like disorder. Numbers correspond to amino acid positions of 
A2ML1. MG: macroglobulin-like domain; BRD: bait region domain; CUB: complement C1r/C1s, Uegf, 
Bmp1 domain; TED: trioester domain; RBD: receptor binding domain. (B) Crystal structure of A2M (pdb 
code 4ACQ). Overall structure with p.Arg598 and p.Arg804 highlighted, corresponding to p.Arg592 and 
p.Arg802 in A2ML1, respectively. (C) Close-up of A2M-R804, corresponding to A2ML1-R802 (in green), 
which interacts with A2M-E908 (A2ML1-E906) (in blue) through hydrogen bonds (yellow dashed lines) 
and electrostatic interactions. A2M-E941 and A2M-E942 (in blue) may also interact with A2M-R802, but 




Protein modeling of mutations detected in A2ML1
All three A2ML1 mutations, p.(Arg592Leu), p.(Arg802His) and p.(Arg802Leu), affect highly 
conserved residues among orthologs (Supplementary Figure 2). For protein modeling of the 
mutation locations and their predicted effect, the crystal structure of alpha-2-macroglobulin 
(A2M; pdb 4ACQ) was used (Figure 2, Table 1). A2ML1 is highly homologous to A2M and it is 
highly likely that protein folding of the two related proteins is similar (Supplementary Figure 1). 
Arginine 592, corresponding to A2M p.Arg598, is located at the edge of the Bait Region Domain 
and is buried in a large cavity on the back face of the A2ML1 monomer[17] whereas Arginine 802, 
corresponding to A2M p.Arg804, is located within macroglobulin-like domain 7 and is positioned 
more at the surface of the protein (Figure 2B). Mutations of either residue likely lead to 
conformational changes in A2ML1 by loss of hydrogen bonds or charge interactions. In more 
detail, within the intramolecular binding network, disease-associated mutations of p.Arg802 
were predicted to disrupts the interaction with p.Glu906 (Figure 2C).
Functional consequences of A2ML1 mutations
A2ml1 is relative highly conserved in zebrafish (38% identity) and we investigated the functional 
consequences of expression of mutant A2ml1 on zebrafish development. A2ml1 is predominantly 
expressed in the liver during embryonic development and morpholino-mediated knockdown of 
A2ml1 has previously been shown to induce defective liver development.[18] We introduced 
human A2ML1 mutations (p.R802H, p.R802L and p.S592L, human numbering for clarity, see Table 
1) in zebrafish A2ml1, C-terminally fused with GFP, allowing to monitor (mutant) A2ml1 
expression in tissue culture cells and during development (Supplementary Figure 3, 4). 
Expression of most mutant NS-associated genes in tissue culture cells augments activation of the 
RAS/MAPK pathway, measurable by excessive ERK/MAPK phosphorylation in cycling cells. To 
investigate the effect of mutant A2ml1 on the RAS/MAPK pathway, we expressed mutant A2ml1-
gfp fusion proteins in HEK-293T and COS7 cells to determine the levels of ERK/MAPK 
phosphorylation. Expression of A2ml1 mutants in normally growing HEK-293T cells or in serum-
stimulated COS7 cells did not significantly enhance ERK/MAPK phosphorylation (Supplementary 
Figure 3). These results suggest either that (mutant) A2ml1 does not modulate ERK/MAPK 
signaling, or that HEK-293T cells and COS7 cells are not responsive to (mutant) A2ml1. The effect 
of (mutant) A2ml1 on embryonic development was investigated by microinjection of CMV-
promoter-driven expression vectors for wildtype or mutant A2ml1 in zebrafish embryos at the 
one-cell stage. Exogenous A2ml1-GFP was detected throughout the zebrafish embryo, despite 
mosaicism of the transgene, which is consistent with A2ml1-GFP being a secreted factor 
(Supplementary Figure 4). 
Expression of mutant A2ml1 resulted in developmental defects in zebrafish embryos that involved 
the heart and craniofacial structures, whereas expression of GFP alone or wildtype A2ml1 did not 
affect zebrafish development (Figure 3). The morphological defects elicited by mutant A2ml1 
resembled those induced by NS-associated Shp2-D61G and N-Ras-I24N.[12,19] Of note, A2ml1-
mutation-induced morphological defects appeared later in development (apparent from 3dpf 
onwards) and were less severe than those observed for Shp2-D61G-induced defects (from 6hpf 
onwards). Alcian blue staining of cartilaginous structures in 4dpf zebrafish embryos revealed 
craniofacial defects that are characteristic of NS. Morphometric analysis showed statistically 
significant broadening of the head and blunting of the faces in embryos expressing mutant A2ml1 
(Figure 3B). Also, in situ hybridization using the heart-specific probe myl7 (formerly known as 
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cmlc2) indicated that cardiac looping was impaired in mutant a2ml1-injected embryos in a similar 
manner as in Shp2-D61G expressing embryos (Figure 3C). Protein modeling suggested that the 
p.(Arg802His) and p.(Arg802Leu) mutations would lead to a loss of the interaction between p.
Arg802 and p.Glu906. Therefore, p.Glu906 was mutated to leucine and this mutant was expressed 
in zebrafish embryos to study the functional defect. Expression of mutant A2ml1-E906L induced 
developmental defects to a similar extent as NS-associated A2ml1-R802L mutants (Figure 3B), 
further supporting a causal role of A2ml1 mutations involving substitution of p.Arg802. 
Discussion
Analysis of a case-parent trio with a clinical suspicion of NS revealed a de novo mutation in A2ML1 
(c.2405G>A; p.(Arg802His)). A2ML1 encodes the protease inhibitor A2ML1, which is a member of 
the alpha-macroglobulin superfamily of proteins that contains both complement components and 
protease inhibitors. These proteins display a unique trap mechanism of inhibition, by which the 
alpha-2-macroglobulin inhibitor undergoes a major conformational change upon its cleavage by a 
protease, thereby trapping the protease and blocking it from subsequent substrate binding.[20] 
Figure 3. Mutant A2ml1 causes a developmental disorder resembling NS. (A) Expression of 
mutant A2ml1 results in developmental defects in zebrafish embryos at 4dpf. The craniofacial defects were 
highlighted by cartilage staining using alcian blue. The heads are broader and the faces blunted. ‘n’ refers 
to the number of embryos examined for x/y ratio. (B) To quantify the craniofacial defects, the ratio of the 
width of the ceratohyal and the distance to Meckel’s cartilage (x and y, respectively in bottom left panel 
of A) was determined. The averages are plotted, error bars indicate standard error of the mean. Student 
t-test to compare ratios with non-injected control (NIC) indicate that wild type A2ml1 is not significantly 
different, but mutant A2ml1 and mutant Shp2 are significantly enhanced compared to NIC as indicated. 
Note that human numbering of residues was used for A2ml1 mutants. (C) In situ hybridization of 55hpf 
embryos using a heart-specific probe (myl7) which stains cardiomyocytes. Cardiac looping was assessed 
as normal looping (loop) or impaired looping (no loop) as indicated schematically. The number of no loop 
hearts in embryos expressing mutant A2ml1 or mutant Shp2 / total number of embryos is indicated in the 




Moreover, A2ML1 binds to the lipoprotein receptor-related protein 1 (LRP1) receptor[21], an 
upstream activator of the MAPK/Extracellular signal-regulated kinase (ERK) cascade.[22] 
Additionally, LRP1 directly interacts with CBL.[23] Together, these reports suggest that A2ML1 
may act upstream of signaling pathways known to be involved in NS.
Two additional missense mutations in families with a disorder clinically resembling NS were 
identified by Sanger sequencing of the entire coding region of the gene (c.2405G>T; p.(Arg802Leu), 
and c.1775G>T; (p.(Arg592Leu)). The frequency of A2ML1 mutations in the cohort tested in this 
study is therefore approximately 1%. However, since mutations in the major NS genes had already 
been excluded, the contribution of A2ML1 mutations to the total population clinically diagnosed 
with NS is expected to be less than 0.5%. The fact that two of the three A2ML1 mutations have 
been reported in the EVS database with a frequency comparable to that in the NS patients, could 
either mean that the A2ML1 mutations are not pathogenic, or that the phenotypic features of 
people with an A2ML1 mutation is milder and they are unrecognized in the general population 
(making A2ML1 a relatively high frequency gene in mild NS). The fact that case 4 does not show 
phenotypic features of NS would fit both of these theories, since cases with non-penetrance, which 
albeit very rare, have previously been described in NS.[24] Evidence for the pathogenicity of the 
A2ML1 mutations therefore had to be provided by functional studies.
Whereas most NS-associated mutations have an effect on RAS/MAPK signaling, we did not detect 
RAS/MAPK activation in response to expression of A2ml1 mutations in HEK293T cells or COS7 
cells. Cell type specific MAPK activation by NS-associated genes is not unprecedented; NS-
associated mutant SHOC2 enhances stimulus-induced MAPK activation in Neuro2A cells, but not 
in Cos-1 or 293T cells.[25] Hence, our results do not exclude involvement of A2ML1 in NS, but 
either suggest that A2ML1 does not modulate ERK/MAPK signaling, or that COS7 and HEK-293T 
cells are irresponsive to A2ML1. Future studies of A2ML1 variants in cell systems expressing 
LRP1 receptor might shed more light on the role of A2ML1 in ERK/MAPK signaling. 
Expression of mutant A2ml1 in zebrafish embryos resulted in developmental defects that were 
characterized by craniofacial and cardiac defects, resembling those induced by expression of 
mutant Shp2. The A2ml1-mutation-induced morphological defects appear however later in 
development (apparent from 3dpf onwards) and are less severe than those observed for Shp2-
D61G-induced defects (from 6hpf onwards). In line with this notion, the affected individuals in 
families 2 and 3, who transmitted the A2ML1 mutation to their offspring, do not fulfill all classical 
van der Burgt criteria for NS[3], but present with a less severe phenotype suggestive of the 
disorder. Of note, phenotypic variability is well known for NS, and more explicitly, not all patients 
with NS have a cardiac malformation.[5,26] Also, the affected individuals in the two families with 
an A2ML1 mutation do not have a heart defect, while the same mutations in zebrafish cause 
cardiac malformation. Zebrafish mutants of the most recently described NS gene, RIT1, show 
incomplete looping of the heart and hypoplastic heart chambers, while the heart phenotype was 
variable or even absent in patients with RIT1 mutations.[6]
Finally, we hypothesized that a conformational change in A2ML1 is the underlying mechanism 
leading to the developmental defects resembling NS. This conformational change may lead to 
destabilization of A2ML1, or it may interfere with its trap mechanism of inhibition. Since both 
intragenic deletions of A2ML1 (reported in the Database of Genomic Variants[27]), as well as 
frameshift mutations are detected in healthy controls (Supplementary Table 2), haploinsufficiency 
is highly unlikely as a the underlying disease mechanism. Given that the A2M family of proteins 
acts in multimeric complexes, it is expected that conformational changes might have a dominant 
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negative effect or lead to gain of function of the complex. Since mutation of p.Arg802 likely 
disrupts the interaction with p.Glu906, we reasoned that mutation of p.Glu906 should have the 
same effect on A2ML1 function as mutation of p.Arg802. Indeed, expression of mutant A2ml1-
E906L induced developmental defects to a similar extent as NS-associated A2ml1-R802L mutants, 
providing additional support that A2ML1 is involved in NS.
In summary, our results provide evidence that mutations in A2ML1 are a cause of Noonan-like 
syndrome, with a variable phenotype ranging from severe (resulting in intra-uterine fetal death) 
to very mild (or even non-penetrance). Although mutations in this gene did not lead to detectable 
enhanced activation of the RAS/MAPK pathway in HEK293T cells or COS7 cells, expression of 
A2ml1 mutants in zebrafish embryos induced developmental defects that are comparable to 
mutations of other NS genes. Thus, we identified a causal role of an extracellular factor in NS for 
the first time and our results pave the way for further exploration of the function of A2ML1, its 
binding partners/receptors, and other relevant extracellular cascades in the pathogenicity of NS.
Materials and Methods
Patients
The individual (case 1) selected for exome sequencing had a clinical diagnosis of NS based on the 
criteria defined by Van der Burgt et al. (2007)[3]. For Sanger sequencing of the A2ML1 gene we 
obtained a total of 295 DNA samples from unrelated individuals with NS or a clinically related 
phenotype. All patients, including patient 1, had been tested negative for mutations in previously 
identified disease genes (PTPN11, KRAS, SOS1, NRAS, SHOC2, CBL, RAF1, BRAF, MAP2K1, MAP2K2, 
HRAS, and RIT1). These samples were collected from three genetic centers (35 patients selected 
by IPATIMUP, Porto, Portugal, 120 patients from the Department of Human Genetics, RUNMC, 
Nijmegen, the Netherlands and 140 patients from the Department of Pediatrics, Università 
Cattolica del Sacro Cuore (UCSC), and Department of Hematology, Oncology and Molecular 
Medicine, Istituto Superiore di Sanità (ISS), Rome, Italy). The clinical diagnosis for NS or 
suggestive of a related trait was made on the basis of standardized clinical criteria assessed by 
experienced clinical geneticists. 
Genomic DNA from whole blood was extracted using standard protocols. This study was approved 
by the Review Boards of all participating institutions. Informed consent to participate in the 
study was obtained for all individuals as well as permission to publish photographs of individuals 
shown in Figure 1.
Exome sequencing for de novo variants
Exome sequencing was performed as described before.[8] In brief, exome enrichment was 
performed using a SOLiD optimized SureSelect Human Exome Kit (v1, 37Mb; Agilent), 
subsequently followed by SOLiDv3 PLUS sequencing. Read mapping and variant calling for the 
patient-parent trio was performed as described before.[8] All candidate de novo mutations 
present in the individual with NS were independently validated using Sanger sequencing. 
Mutation analysis
For 120 individuals with NS from the department of Human Genetics, Nijmegen, the Netherlands 
and 35 individuals with NS from IPATIMUP, Porto, Portugal, all coding exons and flanking intronic 




system, respectively, using standardized protocols. All variants and protein codons are referred 
to according to NM_144670.3 using HGVS nomenclature. Mutations identified were checked for de 
novo occurrence whenever parental DNAs were available. For the 140 individuals with NS or a 
clinically related phenotype selected from the ISS and UCSC, Rome, Italy, exons 15, 16, 19, 24, 25, 
26, 29, 31 and 32 and flanking intronic sequences were considered, based on the identification of 
possible pathogenic mutations in the first cohort. For all variants detected, an in-silico-based 
method was used to assess the effect of the mutation (Alamut software, version 2.1; http://www.
interactive-biosoftware.com/) in addition to an assessment of variant pathogenicity according to 
guidelines by the CMGS and VKGL, for the British and Dutch Molecular Genetic Societies 
respectively.[9] 
Protein modeling of mutations identified in A2ML1
Pathogenic mutations were modeled for their effect on protein function. Because the three-
dimensional structure of A2ML1 (Uniprot entry A8K2U0) is unknown, protein modeling was 
performed using PDB entry 4ACQ which represents the crystal structure of A2M. Overall, A2M 
and A2ML1 share 40% sequence identity. Mutations used for modeling occur within a sequence 
stretch that is highly conserved (Supplementary Figure 1). Graphical representations for 
mutations modeled on 4ACQ were generated and analyzed through project HOPE and YASARA.
[10,11] Residue numbers in the paper are based on residues in A2ML1 (not 4ACQ). The residues in 
A2ML1 and their counterparts in 4ACQ and zebrafish (see section below) are listed in Table 1.
Cell culture, transfection and immunoblotting
COS7 cells and 293T cells were maintained using standard protocols and transfected using 
polyethyleneimine (PEI) (Sigma). Cells were lysed directly in 2x SDS sample buffer (125mM Tris-
HCl pH 6.8, 20% glycerol, 4% SDS, 2% β-mercatoethanol and 0.04% bromophenol blue) and boiled. 
Lysates were separated on a 10% SDS-polyacrylamide gel and blotted using mouse anti-pERK, 
rabbit anti-ERK (Cell Signalling Technologies) and rabbit anti-GFP (Torrey Pines Biolabs). 
Enhanced chemiluminescence was used to detect signal from HRP conjugated secondary 
antibodies (BD Bioscience). 
Zebrafish injections and in situ hybridization 
Zebrafish were kept and embryos were raised under standard conditions. Zebrafish a2ml1 
(GenBank: BC125959.1) was cloned into pCS2+. Mutants were derived by PCR and verified by 
sequencing. The gene encoding eGFP was fused in frame to the 3’end of (mutant) a2ml1 which 
allows monitoring of expression of (mutant) A2ml1 protein in zebrafish embryos. Cytomegalovirus 
(CMV)-driven expression vectors for (mutant) A2ml1, CMV:a2ml1-egfp, were injected into 
zebrafish embryos at the one-cell stage. Synthetic RNA encoding mutant Shp2-D61G was injected 
at the one cell stage as a control.[12] Morphological phenotypes were assessed at 4 days post 
fertilization (dpf). Embryos were anesthesized at 4 dpf with MS-222 (Sigma), fixed in 4% PFA and 
the cartilage was stained with alcian blue. The width of the ceratohyal and the distance to the tip 
of Meckel’s cartilage were determined using Image J software[13] and the ratio was determined 
as a direct measure for craniofacial defects. Averages were determined and a student t-test was 
done to determine whether the differences between the different conditions were statistically 
significant. To investigate cardiac defects, embryos were fixed at 55 hpf and in situ hybridizations 
were done essentially as described[14] using probes specific for myl7.[15]
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Deposition of genetic data
The data obtained in this study are submitted to LOVD, an online gene-centered collection and 
display of DNA variations (http://databases.lovd.nl/shared/genes). 
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Supplementary Information
Supplementary Clinical Descriptions of families with  A2ML1 mutations 
Family	1:	c.2405G>A,	p.(Arg802His),	de novo
Case 1  This individual was referred because of hypotonia and facial dysmorphisms noticed 
directly after birth. Her parents were non-consanguineous, apparently healthy, and had no 
features suggestive for Noonan syndrome (NS). During pregnancy hygroma colli and 
polyhydramnion were noticed. Birth weight was 4005 gr. (+2 SD), length 49 cm (-0.5 SD).  Clinical 
examination after birth showed short stature, developmental delay, typical Noonan syndrome 
facial features: a broad and high forehead, hypertelorism, low-set posteriorely rotated ears and 
webbed neck (Figure 1A). She had a broad thorax with widely spaced nipples (10,5 cm at 6 months 
of age) and pectus excavatum. Cardiologic evaluation revealed no structural heart defect. At 2 
years the clinical diagnosis of NS was made. Her OFC at 12 years was 55 cm (+0,5 SD), at 15yrs and 
9 months puberty stage : MIII,PIII-IV,A0.  At16 years of age her height is 156 cm (-2 SD).
Of note, in this individual another de novo mutation was identified using exome sequencing being 
a missense change in OR12D3 (NM_030959.2:c.386G>C). Evaluation of its pathogenicity in the 
context of the patients phenotype, however, excluded this variant as a likely cause. 
Family	2:	c.2405G>T,	p.(Arg802Leu)
Case 2  The patient was referred together with his son. Clinical examination at the age of 48 
years revealed general mild central hypotonia, height 181 cm (0 SD), weight 69,2 kg (0 SD), head 
circumference 58.1 cm (0SD). He had Noonan-like facial features with a high forehead, prominent 
eyes, slightly hypertelorism (intercanthal distance 3,6 cm at adult age , and thick hooded eyelids 
(Figure. 1B). Multiple pigmented nevi were noticed. The inter-nipple distance was 22cm at adult 
age. No heart abnormalities were seen. The patient was born prematurely at 34 weeks of gestation 
and stayed in an incubator for three months. He was part of a twin; His twin brother died at birth 
unexplained. He has social fears, performance anxiety and poor concentration. 
Case 3  This individual is the son of case 2. He was born with a pulmonary valve stenosis. 
Physical examination at 11 years 9 months showed facial hypotonia with Noonan-like features 
(Figure 1B). His height was 155 cm (+0.5 SD), head circumference 54.5 cm (0SD), and intercanthal 
distance (2,9 cm) and genitalia were normal. The inter-nipple distance was 15,7 cm. Puberty was 
at Tannerstage 1-2 with  no axillary hair. He walked clumsy with pes planus. His psychomotor 
development was mildly delayed. At the age of 6 years he was diagnosed with autistic-like 
behavior with attention deficit. 
Case 4  This individual is the mother of case 2. She was healthy and had normal basic education. 
Examination at 73 years of age showed normal height and no facial dysmorphisms (Figure 1B). 
Cardiac evaluation revealed no abnormalities. No typical Noonan-like features were recognized.
Family 3: c.1775G>T, p.(Arg592Leu)
Case 5 This individual was referred in her second pregnancy. She has short stature with adult 
height of 157 cm (<-2 SD), facial features suggestive for Noonan syndrome and easy bruising 
(Figure 1C). The intercanthal distance was 3,4 cm at adult age. She had severe neonatal feeding 





Case 6 This individual is the second child of case 5, and was born after 37 weeks of gestation 
with a birth weight of 3,195 gram and length of 50 cm. The intercanthal distance was 3,0 at 9 
months (>+2SD). She had facial features suggestive for Noonan syndrome and bilateral hearing 
loss (30/40 dB) (Figure 1C). Cardiac evaluation revealed no abnormalities.  
Case 7 This individual is the father of case 5. He has an adult height of 172 cm (-1,5 SD), relatively 
large head (OFC  59,5 cm (+ 1 SD)), hypertelorism (intercanthal distance 3,5 cm at adult age), a 
short broad neck. The inter-nipple distance was 25 cm at adult age. Cardiac evaluation revealed 
no abnormalities.
Case 8  This individual is the first child of case 5. The first pregnancy of case 5 ended at 29 weeks 
of gestation in an intra-uterine fetal death because of severe hydrops. There was polyhydramnios. 
The presence of MPS or a viral infection during pregnancy was excluded. Karyotyping and SNP 
array analysis on amniotic cells revealed no abnormalities. After birth, no pathologic examination 
has been done. The child had facial features compatible with Noonan syndrome. Analysis of fetal 
DNA material showed the same mutation as identified in his mother. There was insufficient 
amount of DNA  left to exclude mutations in the other NS associated genes. 
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For protein modeling pdb file 4ACQ (representing A2M) was used, which shares 40% identity with A2ML1, 
and has positive scores for 57% and gaps for only 3% of sequence. Local protein alignments indicate that 
both affected amino acids are conserved in A2M (A,B, with the mutated residues highlighted in red boxes). 
A2ML1 proteins form a homotetrameric complex (C, with each monomer indicated by a different colour and 
dashed lines indicating planes of symmetry). The secondary structure of each of its monomers contains 
β-barrels (in red), that twist and coil to form a closed structure in which the beta-strands are arranged in 




Supplementary Figure 2: Regional conservation of residues affected by mutations A2ML1 
amino acid conservation across various species (listed on the left) for the residues affected by mutations. 
(A) Region surrounding p.Arg592 (highlighted in red box); note that p.Arg592 is not conserved in zebrafish 
A2ml1. (B) Region surrounding p.Arg802 (highlighted in red box), with full conservation in zebrafish. 
(C) Region surrounding p.Glu906, which is predicted to interact with p.Arg802 in wildtype A2ML1. This 
residue is conserved in Zebrafish. Asterisk in (A) represents cysteine involved in disulfide bridge formation. 
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Supplementary Figure 3. Expression of mutant A2ml1 does not induce MAPK activation 
(A) Human embryonic kidney HEK-293T cells were transfected with CMV-promoter-driven expression 
vectors for (mutant) A2ml1 or (mutant) N-Ras (known to induce MAPK activation). Cells were cultured in 
the presence of 10% fetal calf serum, lysed and the whole cell lysates were processed for immunoblotting 
using pERK1/2 specific antibodies and ERK1/2 specific antibodies to monitor protein levels. Expression 
of wild type (WT) and mutant A2ml1 (p.R802H or p.R802L) did not induce phosphorylation of ERK1/2, 
whereas NS-associated N-Ras-I24N induced mild activation and oncogenic N-Ras-G12V induced strong 
activation of ERK1/2. (B) Serum stimulation of COS7 cells expressing mutant A2ml1 did not affect ERK1/2 
phosphorylation. COS7 cells were transfected with expression vectors encoding (mutant) A2ml1 or Shp2-
D61G. Serum-starved cells were treated with 20% FCS for the indicated periods of time and subsequently, 
the cells were lysed and processed for immunoblotting using pERK1/2- and ERK1/2-specific antibodies. 
Expression of (mutant) A2ml1-GFP and (mutant) Shp2 was monitored using antibodies specific for GFP 
and Shp2, respectively. The ERK phosphorylation levels of wildtype (WT) and mutant A2ml1 expressing 
cells were indistinguishable, whereas ERK phosphorylation was enhanced in Shp2-D61G expressing cells. 
These results suggest either that A2ml1 does not modulate ERK/MAPK signaling, or that HEK-293T cells 




Supplementary Figure 4: A2ml1-GFP expression in zebrafish Expression of A2ml1-GFP was 
monitored in the transgenic reporter line Tg(kdrl:mcherry-CAAX) with expression of mCherry in all 
endothelial cells, thus highlighting vasculature. Zebrafish embryos were injected with plasmid DNA 
encoding a CMV-promoter-driven expression vector for A2ml1-GFP at the one-cell stage and imaged at 
2 dpf. Lateral view of the trunk (A-C) and the head (D-F) are depicted. The dorsal aorta (DA), the Dorsal 
Longitudinal Anastomotic Vessel (DLAV) and intersegmental vessels (ISV) are indicated. 
The expression patterns of A2ml1-GFP and mCherry were largely overlapping. A2ml1 is a secreted 
factor and these results confirm A2ml1-GFP localization throughout the vasculature system, even 
though not all cells express A2ml1-GFP due to mosaicism of the injected plasmid DNA. 
Confocal imaging
Embryos at 48 hpf were dechorionated and mounted in glass-bottom 6-well plates using 0.25% 
agarose in E3 embryo medium containing 16 mg/ml 3-amino benzoic acid ethylester to block 
movements. Confocal imaging was performed using a SPE live confocal laser scanning microscope 
with 20x magnification for the head and 40x magnification for the trunk.
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Raw sequencing statistics Case 1 Father Mother
Total number of mapped reads (Million) 56.02 79.73 59.88
Total number of bases mapped (Gb) 2.63 3.87 2.83
Total bases mapping to targets (Gb) 1.87 3.02 2.12
% mapping to target 71.10 78.04 74.91
% targets with 10x coverage 85.96 93.55 88.42
Mean target coverage 32.20 52.83 35.33
Median target coverage 39.14 66.87 45.28
Variant prioritization Case 1
Total variants 23,021
QC* 19,771
Located in coding sequence/canonical splice site 10,887
Leading to nonsynonymous change 5,063
Excluding variants in controls** 124
Excluding variants inherited from healthy parent (possible de novo variants) 4
* ≥ 5 variant reads, ≥ 20% variantion reads
** dbSNPv130; in-house exome database




Exon Variant                
(mRNA level)
Predicted     
protein effect
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A. Presumable non-pathogenic variants*
11 c.1123C>T p.(=) - - -
11 c.1215A>G p.(=) - - -
16 c.1918G>A p.(Asp640Asn) - - -
27 c.3287C>T p.(Ser1096Phe) - - -
B. Non-pathogenic variants
2 c.105C>A p.(=) rs201185025 T=9/C=11923 0.08
2 c.186C>T p.(=) rs17792974 T=550/C=11532 4.55
3 c.289C>G p.(Arg97Gly) rs199701571 G=10/C=11922 0.08
5 c.463-9C>G p.(?) rs11047493 G=317/ C=11591 2.66
6 c.619G>C p.(Gly207Arg) rs11047499 C=329/G=12037 2.66
9 c.861C>A p.(Asp287Glu) rs61921916 A=124/C=12108 1.01
11 c.1101T>C p.(=) rs61744222 C=313/T=11763 2.59
11 c.1109T>C p.(Phe370Ser) rs61744220 C=310/T=11762 2.57
12 c.1275A>G p.(=) rs7308106 G=932/A=11214 7.67
12 c.1476+9G>A p.(?) rs7136813 A=3383/G=6475 34.32
15 c.1686T>G p.(=) rs12296765 G=102/T=9772 1.01
15 c.1777del** p.(Ala593fs) - - -
16 c.2026C>T p.(Arg676Trp ) rs200503836 T=1/C=12065 0.09
18 c.2197T>C p.(Phe733Leu) rs117213221 C=3/T=11915 0.03
19 c.2367G>A p.(=) rs1860927 A=9912/G=2358 80.78
20 c.2550A>C p.(Glu850Asp) rs1860926 A=9644/C=372 96.29
22 c.2749T>C p.(=) rs200462659 C=7/T=12181 0.06
24 c.2868C>T p.(=) rs56179521 T=438/C=11740 27.24
24 c.2909G>A p.(Cys970Tyr) rs1558526 A=2356/G=10066 18.97
26 c.3237G>A p.(=) rs11612600 A=3769/G=8527 30.65
26 c.3252C>T p.(=) rs61745125 T=41/C=12247 0.33
27 c.3269G>A p.(Gly1090Asp) rs200964353 A=16/G=12812 0.12
27 c.3272T>C p.(Val1091Ala) rs61736726 C=172/T=12648 1.34
28 c.3364C>T p.(Arg1122Trp) rs1860967 T=3694/C=8552 30.16
29 c.3569C>T p.(Ala1190Val) rs73040625 T=742/C=11430 6.10
29 c.3676_3677del p.(Ala1226fs) rs144686314 - 2.1***
30 c.3686G>T p.(Arg1229Leu) rs10219561 G=11720/A=386 96.81
30 c.3769A>C/G p.(Met1257Leu) rs7308811 G=9457/A=2707 77.75
30 c.3843T>C p.(=) rs61749073 C=1326/T=10942 10.81
31 c.3878A>G p.(Asn1293Ser) rs201478459 G=10/A=12246 0.08
31 c.4020A>G p.(=) rs1476910 G=9125/A=3099 74.65
31 c.4061+1G>A**** p.(?) rs202067416 A=6/G=10106 0.01
Supplementary Table 2: Presumable non-pathogenic variants detected by A2ML1 
sequencing (NM_144670.3)
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*Parental DNAs not available for further segregation analysis. Guidelines for variant classification (see 
section Mutation interpretation) however predicts these variants to be non-pathogenic. As no rs-identifier 
is known for this variant, nor has been observed in 1000 genomes and/or ESP we cannot formally show its 
non-pathogenicity. 
**Variant also detected in non-affected family members. 
*** Minor Allele frequency from 1000 genomes project. 
****For this variant segregation analysis was not possible. Since both c.1777del and c.3676_3677del are 
predicted to result in loss of function of the A2ML1 protein and are considered not pathogenic (see also 
under**), we hypothesize also the c.4061+1G>A is a rare non-pathogenic loss-of-function variant. 
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Over the past years, several studies described the function of SHP2 in Noonan syndrome (NS) and 
LEOPARD syndrome (LS) and its crucial role during development. The work described in this 
thesis contributes to the understanding of the developmental and molecular mechanisms by 
which Shp2 variants that are associated with NS and LS result in two genetic disorders with 
similar features. Below, we discuss the major findings of this thesis and in Figure 1 we provide an 
integrated view of this thesis, with a schematic representation of the main findings of each 
chapter. 
Role of the ptpn11 gene in zebrafish development.
Zebrafish has developed into a very powerful model for genetic studies as its genome is fully 
sequenced and it is annotated as part of the Ensembl project [1]. Moreover, the zebrafish model 
allows to study gene function in vivo and to analyze vertebrate embryogenesis as development 
occurs externally and the embryos are transparent [2]. We took advantage of the zebrafish model 
to characterize the phenotype of knock-out zebrafish embryos with impaired ptpn11 gene 
function. Our analysis aimed to understand the function of Shp2 in zebrafish development and the 
mechanism underlying how NS- and LS-variants of Shp2 induce similar defects. In our study, 
ptpn11a-/- and double mutant embryos died during early embryogenesis, indicating that Shp2a 
was essential during zebrafish embryonic development. Notably the double mutant phenotype 
was more severe than the ptpn11a-/- phenotype, indicating that ptpn11b contributes to zebrafish 
development. Rescue experiments show that ptpn11a and ptpn11b are partially redundant with 
ptpn11a having a dominant role. At 5 dpf, the ptpn11a homozygous single mutant and the double 
homozygous mutant zebrafish embryos showed craniofacial defects, reduced length and absence 
of swim bladder (Chapter 4). The phenotype of ptpn11a-/- and double mutant embryos resemble 
the clinical characteristics of NS/LS patients. In fact, the embryos show reduced body length 
reminiscent of the growth defects in NS/LS patients [3] [4]. Moreover NS/LS patients present 
visible craniofacial defects, including high forehead, hypertelorism, downslanting palpebral 
fissures, epicantal folds, ptosis, low-set and/or posteriorly rotated ears [5, 6]. Similarly, ptpn11a-/- 
and double mutant embryos display craniofacial defects. Similar to the double mutant phenotype, 
also expression of NS/LS Shp2 led to reduced body length and craniofacial defects in zebrafish at 
4 dpf [7, 8]. Shp2 acts upstream in the Erk/MAPK signaling pathway [9]. We investigated Erk/
MAPK signaling in the double and single ptpn11 mutant embryos and we found that pErk levels 
are downregulated only in double mutant embryos. However, we cannot exclude the possibility 
that the observed developmental defects are independent of Erk/MAPK signaling, since in the 
ptpn11a-/- embryos pERK levels are similar as in the wildtype. 
In our study, we also investigated the Erk/MAPK pathway upon NS/LS Shp2 expression. We found 
hyperactivation of Erk after injections of either NS Shp2 or LS Shp2 at bud stage, which is 
consistent with a role of Erk in gastrulation cell movements. Importantly, we were able to rescue 
the elongated shape of the embryos by early treatment with CI-1040, a MEK inhibitor, indicating 
that the gastrulation defects are caused by enhanced MAPK signaling before gastrulation 
(Chapter 7). It has already been established in several models that NS associated mutations are 
gain-of-function (GOF) mutations and they promote sustained activation of ERK [10]. LS mutations 
reside in the PTP domain and they affect Shp2 catalytic properties. Although biochemical studies 
show that LS variants of Shp2 are catalytically impaired in vitro [11], suggesting these are loss-of-
function mutations, genetic models argue against this [12]. Moreover, it has been shown that LS 
associated-mutations still retain significant phosphatase activity compared to the catalytically 
dead C460S Shp2 mutant [13]. A more recent study demonstrates that LS mutations weaken the 




constitutive open conformation of the protein [14]. As a consequence, LS Shp2 is more prone to 
bind upstream effectors, compensating for the diminished phosphatase activity. In addition, 
previous studies in Drosophila report that LS-associated mutations induce developmental defects 
and hence act as GOF mutations. In our case it is feasible to hypothesize that although LS mutations 
are catalytically impaired, they affect the conformation of Shp2, leading to an open conformation 
that is more prone to bind to upstream activators than wildtype Shp2 or the C460S mutant. This 
is in concordance with our results with PZR (Chapter 6). Expression of catalytically inactive 
C460S Shp2 in parallel to the NS and LS shp2 variants may provide insight into the role of the 
catalytic activity of Shp2 in the developmental defects that we observed in NS and LS. Moreover, 
rescue experiments by expression of catalytically inactive Shp2 in double mutant embryos will 
provide insight into whether or not catalytic activity is important for Shp2 function and hence 
whether Shp2 acts as a phosphatase or as an adaptor in embryonic development. 
Role of SHP2 in Noonan and LEOPARD heart defects
Congenital heart defects (CHDs) are the most common type of birth defect (~1/100 live births) 
and the major cause of birth-related deaths [15]. NS is the second most common syndromic cause 
of CHD, exceeded only by Down-syndrome [16]. A role of SHP2 in human developmental heart 
defects was established after the finding that missense mutations in the PTPN11 gene are 
associated with NS and LS. The heart defects appear to be distinct between NS and LS patients, in 
that NS patients usually develop valve defects, such as pulmonary stenosis and hypertrophic 
cardiomyopathy (HCM) is observed more in LS patients. HCM has also been reported in NS 
patients without PTPN11 mutations [6] and most cases of LS patients present HCM associated 
with valve anomalies [17]. However, the exact mechanism that leads to two different heart defects 
in syndromes with overlapping symptoms, still needs to be addressed. In our study, we used 
zebrafish as a model to investigate the cardiac development in NS and LS. We showed that NS/LS 
Shp2 mRNA injections lead to phenotypes similar to the clinical features in human patients, 
characterized by cranio-facial defects, short body length and cardiac anomalies. Concerning the 
heart defects, we found that injected embryos show a pericardial edema varying in penetrance 
from mild to severe. In situ hybridization for the heart specific probe myl7, reveals that around 
50% of NS and LS embryos show a left/right randomization of the heart displacement and an 
impairment of the cardiac chambers asymmetry at 48 hpf. Consistent with our findings, Langdon 
et al. [18] showed that Noonan-associated mutations lead to failure of the complete looping in 
Xenopus. Notably, even though the cardiac phenotype in humans is quite distinct, we did not 
detect any difference between NS and LS cardiac defects in zebrafish embryos. Moreover, the first 
defect that appears in NS/LS injected embryos, consists of an elongation of the embryo at the end 
of gastrulation, resulting in oval-shaped embryos, rather than the almost perfect sphere of 
wildtype embryos (Chapter 7). Immunoblotting of NS/LS embryos at bud stage showed hyper-
activation of the MAPK pathway both in NS and LS Shp2-associated mutants, which may explain 
why the early developmental defects were indistinguishable. Furthermore, the development of 
the endocardial cushions in zebrafish is relatively late (36 hpf) and at that stage, the stability of 
the NS/LS Shp2 could already be compromised. The formation of the cardiac tube is the first 
manifestation of L/R asymmetry in the vertebrate heart [19]. Usually, failure in cardiac jogging is 
a consequence of aberrant expression of southpaw (spaw) and lefty-2, two genes that are usually 
expressed on the left side. In NS/LS Shp2 injected embryos, the expression pattern of spaw is 
randomized which also affects the correct expression of the more downstream gene lefty-2. Our 
studies link NS/LS Shp2 with the disruption of L/R asymmetry in zebrafish embryos. The 
misplacement of spaw gene expression  is caused by the impairment of the ciliated organ Kupffer’s 




rotate in counter-clockwise direction, generating a fluid flow that induces leftward expression of 
spaw in the LPM. Laser ablation of the KV leads to randomized expression of spaw and lefty-2. We 
demonstrated that ciliogenesis of the KV is impaired in NS and LS embryos. The KV in NS and LS 
embryos showed reduced cilia length and cilia number; moreover the KV’s lumen in NS and LS 
embryos is smaller compared to the WT-Shp2 injected embryos and cilia function is impaired. 
This leads to a reduction or absence of fluid-flow in the KV and consequent disruption of laterality 
in the LPM. Our investigations show that the increased level of pERK was associated with 
perturbation of KV in NS and LS embryos, in that we were able to rescue the laterality defects and 
the ciliogenesis impairment by early treatment with CI-1040, a MEK inhibitor. Hence, the defects 
in heart asymmetry were caused by enhanced MAPK signaling before gastrulation. In summary, 
our data open a new prospective to understand how Shp2 relates to cardiac development and 
disease in NS and LS.
A2ML1: an extracellular protein causing Noonan-like syndrome
The genetic cause of some 25% of all Noonan cases still remains to be determined. We identified 
mutations in A2ML1 in patients that were diagnosed with NS. Mutations were found in the same 
codon in two separate families with Noonan-like symptoms, which strengthens the hypothesis 
that these mutations in A2ML1 are indeed causative for Noonan syndrome. Alpha-2-macroglobulin 
like 1 (A2ML1) is a 170 kDa extracellular broad range protease inhibitor of the A2M family, that is 
present in the epidermis and circulates the bloodstream [20, 21]. Hence, A2ml1 is the first 
extracellular protein to be associated with NS-like features. Overexpression of mutated A2ml1 
caused enhanced Noonan-like phenotypes in developing zebrafish embryos, compared to WT 
A2ml1. A2ml1 is a ligand for the transmembrane receptor LRP1 [23]. Activation of LRP1 may 
potentiate growth factor signaling by RTKs like EGFR, FGFR and VEGFR [24, 25]. Concurrent 
activation of LRP1 by LDL and lactoferrin with RTK activation causes a sustained activation of the 
MAPK pathway by downregulation of the MAPK targeting phosphatases DUSP-5 and DUSP-6 [24]. 
Upon activation of PDGFR, the receptor is internalized in LRP1 containing endosomes, where it 
forms a signaling complex [25]. Shp2 is able to bind both PDGFR and LRP1 directly, and LRP1 
competes with PDGFR for Shp2 in endosomes [26]. A MAPK-potentiating LRP1-dependent 
mechanism may drive A2ml1-induced signaling in NS. Importantly, both NS and LS Shp2 cause 
sustained MAPK activation upon GF stimulation in cells [14]. As we were not able to show 
sustained MAPK activation in response to A2ml1, further investigations are essential to elucidate 
the mechanism by which A2ML1 mutations cause NS. We cannot exclude the possibility that 
variation in the genetic landscape between patients affect the response to (mutant) A2ML1. 
Distinct genetic backgrounds that mildly influence the MAPK activation pathway may contribute 
differently to (mutant) A2ML1 signaling. Previously, a single Shp2 variant was observed in a 
family with both NS patients and healthy siblings, underlining the importance of enhancers and 
suppressors of the phenotype [27]. Other Noonan causing mutations in MYST4, KRAS and SOS1 are 
also known to show heart defects with variable penetrance [27-30]. The patients with mutations 
in A2ML1 did not display all symptoms of classical NS and expression of mutant A2ml1 in cells or 
zebrafish did not induce sustained MAPK activation. For these reasons, we conclude that the 
mutations we identified in A2ML1 are associated with Noonan-like syndrome, rather than NS 
proper. 
Downregulation of Fer tyrosine kinase in Noonan and LEOPARD syndrome
Noonan and LEOPARD syndromes are complex congenital disorders, and the elucidation of 
affected pathways may provide key elements for targeted therapies [31, 32]. High throughput 




based phosphoproteomic experiments showed an increase in phosphorylation of several proteins 
including MEK, caveolin, EGFR and FAK, while other proteins like vinculin and LCK were less 
phosphorylated [33]. Whereas these data from in vitro studies are useful, they may not reflect the 
phosphorylation status and thus the activity of these proteins in vivo and during development. 
Mass spectrometry based proteomics have been proven feasible in developing zebrafish embryos 
[34-36]. We combined multiple methods previously pioneered by Lemeer et al. and sought out to 
identify a common mechanism on how activating and inactivating mutations of Shp2 may drive 
the development of similar phenotypes. We identified the auto-phosphorylation loop of Fer kinase 
as a major downregulated tyrosyl phosphorylation site. In contrast to 1 dpf zebrafish, 5 day old 
Shp2D61G/+ mouse hearts showed an increase in Fer phosphorylation (Chapter 6). The discrepancy 
may be explained by differences in developmental time points or tissue-specific activation of Fer 
in NS. Tissue specific expression of NS genes is not unknown [28]. MYST4, a Noonan gene 
discovered in a patient not showing any cardiac defects, showed tissue specific expression. Cell 
type and growth factor specific roles for Shp2 have also been described [10, 37]. It is therefore not 
unlikely that tissue-specific activation or inactivation may contribute to clinical signs of NS and 
LS [28]. Loss of Fer expression leads to convergence and extension (C/E) defects, indicating an 
essential role in gastrulation. Using epistasis experiments, we showed a genetic interaction 
between Fer and disease associated Shp2. Partial loss of Fer expression concurrent with either NS 
or LS Shp2 expression, but not WT Shp2 expression, leads to developmental defects, phenocopying 
those seen in NS/LS expressing embryos. Epistasis experiments are a powerful tool to show 
genetic interactions that may cause disease [38]. Fer and Shp2 interact in many ways [39, 40], and 
the altered binding properties of NS/LS Shp2 may affect the function of interacting proteins like 
Fer. Indeed, in Chapter 6 we show enhanced complex formation of Shp2, PZR and Src. It is not 
difficult to imagine signalling pathways other than the canonical MAPK pathway to be affected by 
the altered properties of NS and LS Shp2. As both Fer and Shp2 share common binding partners 
[26, 40, 41], it may be that Fer is “quenched off” from its binding partners by the enhanced binding 
properties of NS/LS Shp2. Further studies are necessary to uncover the mechanism how Fer down 
regulation may contribute to NS/LS. 
Enhanced Src-Shp2-PZR complex formation in Noonan and LEOPARD syndromes
Like Fer, we identified PZR in a mass spectrometric approach to identify novel factors that drive 
NS and LS. PZR was found hyperphosphorylated in both mouse hearts and zebrafish in NS and LS, 
compared to WT Shp2. PZR was previously identified as a Shp2 binding protein [42, 43]. PZR is a 
transmembrane protein with two immunoreceptor tyrosine inhibitory motifs (ITIMs). These 
ITIMs serve as Shp2 binding sites and Shp2 is able to dephosphorylate these ITIMs, thus acting in 
a negative feedback loop under normal conditions [42, 43]. In addition to enhanced PZR 
phosphorylation, we observed enhanced binding of NS/LS Shp2 to Src, compared to WT Shp2, 
causing a change in the flux of Shp2/Src signaling. We hypothesize a model in which NS/LS Shp2 
binds Src, which leads to sustained PZR phosphorylation and binding. This may mediate hyper-
activation of cortactin and abnormal cell migration [44]. Previous reports showed that PZR 
affects cell migration in vitro and that PZR is expressed during early mouse embryogenesis, 
consistent with our results [45]. PZR forms lacking the ITIM sites do not show this effect on cell 
migration or induce developmental defects [45]. These results indicate that altered signaling of 
the PZR/Shp2/Src complex, either too little or too much results in disease. This hypothesis is 
strengthened by the finding that recently, copy number variations of PZR were found to cause cell 
migration in tumor cells [44]. This was mediated by activation of cortactin. Moreover, duplication 
of PTPN11 was identified recently in a NS patient, indicating that not only GOF mutations but also 




remains to be investigated. Taken together, our finding that NS/LS mutations leads to an altered 
flux of signaling, that PZR duplication leads to disease [44] and that Shp2 duplication may cause 
NS [22], a protein interaction-based view on the etiology of NS an LS would be the next step into 
identifying novel mutations (or CNVs) that, together may be causative of unexplained NS/LS. The 
discovery of PZR as a hyperphosphorylated protein in LS, in addition to NS [46], provides insights 
into the aetiology of both syndromes. Clearly, a common mechanism is shared between activating 
(NS) and inactivating (LS) forms of Shp2, which leads to PZR phoshorylation. Src binding may be 
causative for some of the clinical features that are observed in NS and LS . Additionally, this may 
provide an explanation into how Fer may be downregulated in NS/LS, given the high probability 
that these proteins may act in a complex. Hyperactivation of cortactin by Shp2 mediated Src 
activation may possibly lead to a negative feedback signal to Fer [47]. Therapeutically, PZR 
phosphopeptide might inhibit hyperactivation of Shp2, possibly in both NS and LS [48]. 
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Figure 1. Schematic overview of the highlights of this thesis and proposed mechanisms. 
Enhanced binding of mutant A2ml1 (green) to LRP1 in combination with RTKs (red) may result in 
enhanced MAPK activation. Due to the open state of Shp2, it is more prone to bind other proteins like 
Src (orange) and RTKs. Enhanced binding of NS/LS Shp2 leads to Src recruitment to PZR (blue) and PZR 
phosphorylation, which in turn results in gastrulation defects and changes in MAPK activation flux. On the 
other hand, potential “quenching” of Fer from RTKs by Shp2 may lead to inactivation of Fer (red). MAPK 
activation gives rise to altered gene expression including Spw and lefty-2. This in turn results in changes in 




activation due to quenching of Shp2 from its physiological substrates [48]. Alternatively, PZR 
phosphorylation might be used in the clinic to assess the effect of Shp2 mutations in patients. 
Conclusion
Overall, we demonstrate that Shp2 plays a crucial role in zebrafish development. Genetic 
duplication of ptpn11 allowed us to study gene dosage effects and the role of Shp2a and Shp2b at 
various stages of development (Chapter 4). Moreover, we show that both NS and LS Shp2 cause 
hypo- and hyperphosphorylation of Fer and PZR, respectively compared to WT. Genetic 
interaction studies indicated a role for reduced signaling by Fer in the etiology of NS and LS 
(Chapter 5). Functional studies showed indications for enhanced signaling complex formation of 
NS and LS Shp2 with PZR and Src (Chapter 6). Changes in protein-protein interactions are an 
important contributor to NS and LS. Both NS and LS Shp2 can lead to GOF phenotypes, showing 
enhanced Erk phosphorylation at the end of gastrulation in zebrafish. Both NS and LS lead to early 
heart defects in a similar way as well (Chapter 7). In addition, we identified mutations in an 
extracellular protein, A2ml1, to be associated with Noonan-like phenotypes (Chapter 8). Taken 
together, our findings show that NS and LS Shp2 share many mechanistic and developmental 
features, and that these disease associated proteins should not only be viewed as “activating” or 
“inactivating”. Using a versatile in vivo model, we show that these proteins should rather be 
viewed in a network of interacting proteins that gives rise to similar developmental defects. 
Overall, we used zebrafish embryos as a model to study the etiology of NS and LS at the genetic, 
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This thesis describes the use of zebrafish to study Noonan- (NS) and LEOPARD  syndromes (LS). 
In the first three chapters, we provide a background for the following six chapters. In Chapter 1, 
we briefly discuss zebrafish gastrulation and the associated signaling mechanisms. The use of 
zebrafish to study protein tyrosine phosphatases (PTP) is discussed in Chapter 2. A brief 
overview of previous studies on PTPs using zebrafish is given and genetic tools available in 
zebrafish are discussed. As our lab is interested in gastrulation, we further outline the tools we 
use to study zebrafish gastrulation. Moreover, phosphoproteomics is discussed as a method to 
study PTPs in vivo. Chapter 3 describes the role of PTPN11 (protein-tyrosine phosphatase, non-
receptor type 11), the gene encoding SHP2, a cytoplasmic PTP that is essential for vertebrate 
development. Mutations in PTPN11 are associated with NS and LS, two autosomal dominant 
disorders with overlapping symptoms. Intriguingly, while NS mutations result in a more ‘active’ 
state of Shp2, LS mutations give rise to a PTP defective protein. NS and LS patients display various 
symptoms, including short stature, craniofacial defects and heart abnormalities. Interestingly, 
the cardiac phenotype of NS and LS patients is quite distinct; in this sense NS patients present 
pulmonary stenosis (PS) while hypertrophic cardiomyopathy (HCM) is the most common cardiac 
defect present in LS. 
In Chapter 4 we have used the zebrafish as a model to investigate the role of Shp2 in embryonic 
development. We characterized in details the role of the two ptpn11 zebrafish isoforms (ptpn11a 
and ptpn11b). We show that ptpn11a is expressed constitutively and ptpn11b expression is 
strongly upregulated during development. In addition, the products of both ptpn11 genes, Shp2a 
and Shp2b, are functional. Target-selected inactivation of ptpn11a and ptpn11b revealed that 
double homozygous mutants are embryonic lethal at 5-6 days post fertilization (dpf). Ptpn11a-/-
ptpn11b-/- embryos showed pleiotropic defects from 4 dpf onwards, including reduced body axis 
extension and craniofacial defects, which was accompanied by low levels of phosphorylated Erk at 
5 dpf. Interestingly, defects in homozygous ptpn11a-/- mutants overlapped with defects in the 
double mutants albeit they were milder, whereas ptpn11b-/- single mutants did not show detectable 
developmental defects and were viable and fertile. Ptpn11a-/-ptpn11b-/- mutants were rescued by 
expression of exogenous ptpn11a and ptpn11b alike, indicating functional redundancy of Shp2a 
and Shp2b.
Using phoshoproteomics, in Chapter 5 we describe the identification of Fer kinase as a potential 
downstream protein in the etiology of both NS and LS. Phosphotyrosine immunoprecipitation of 
lysates from zebrafish injected with wild type, NS or LS Shp2 followed by mass spectrometry 
showed a decrease in a phosphopeptide corresponding to the tyrosine kinase Fer in both NS and 
LS. We showed that fer is expressed in early embryos and that loss of Fer results in developmental 
defects, including convergence and extension defects. Partial loss of Fer cooperated with low 
expression of NS and LS variants of Shp2 but not with wild type Shp2 expression. Thus, the loss of 
Fer contributed to NS and LS phenotypes in zebrafish.
In Chapter 6 a similar approach is used in NS mouse hearts to identify Protein zero related (Pzr) 
as the most hyper phosphorylated protein in NS. Loss of Pzr leads to gastrulation defects in 
zebrafish and phenotypes reminiscent of loss of Shp2, NS and LS. Pzr is hyper phosphorylated at 
its immunoreceptor tyrosine inhibitory motifs (ITIMs) in multiple tissues and is shown to be 
dependent on Src activation. Co-immunoprecipitation studies show that NS and LS Shp2 exhibit 
enhanced binding to Src and PZR, consisting of a complex. Moreover, the ITIMs, binding sites for 
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Shp2 are essential for induction of the zebrafish convergence and extension phenotype. Thus, NS 
and LS Shp2 form a complex with Src and Pzr to induce developmental defects in zebrafish. 
In Chapter 7 we investigated the role of the most common NS and LS Shp2 mutations in zebrafish 
in cardiac development. Defective heart development is a prominent symptom of both NS and LS, 
but how the Shp2 variants affect cardiac development is unclear. We showed that the heart 
function was impaired in embryos expressing NS and LS variants of Shp2. The cardiac anomalies 
consisted of reduced cardiomyocyte migration, coupled with impaired leftward heart 
displacement. Expression of specific laterality markers was randomized in embryos expressing 
NS and LS variants of Shp2. Ciliogenesis and cilia function in Kupffer’s vesicle was impaired, likely 
accounting for the left/right asymmetry defects. Mitogen activated protein kinase (Mapk) 
signaling was activated in embryos expressing NS and LS Shp2-variants. Interestingly, inhibition 
of Mapk signaling prior to gastrulation rescued cilia length and heart laterality defects suggesting 
that NS and LS Shp2-variant mediated hyperactivation of Mapk signaling leads to impaired cilia 
function in Kupffer’s vesicle, causing the heart impairment at later stages.
Finally we investigated the role of Alpha-2-Macroglobulin-Like-1 (A2ML1) in NS in Chapter 8. To 
date, all mutations known to cause NS are dominant and they enhance the RAS/MAPK signaling 
pathway. However in 25% of cases, the genetic cause of NS remains unknown, suggesting that 
factors other than those involved in the canonical RAS/MAPK pathway may also play a role. In our 
study, we used family-based whole exome sequencing of a case-parent trio and identified a de 
novo mutation, p.(Arg802His), in A2ML1 which encodes the secreted protease inhibitor Alpha-2-
Macroglobulin-Like-1. Subsequent resequencing of A2ML1 in 155 cases with a clinical diagnosis of 
NS led to the identification of additional mutations in two families, p.(Arg802Leu) and p.
(Arg592Leu). Functional characterization of these human A2ML1 mutations in zebrafish showed 
NS-like developmental defects, including a craniofacial defects and cardiac malformations. The 
crystal structure of A2M, which is highly homologous to A2ML1, led us to the identification of the 
intramolecular interaction partner of p.Arg802. Mutation of this residue, p.Glu906, induced 
similar developmental defects in zebrafish, strengthening our conclusion that mutations in A2ML1 
cause a disorder clinically related to NS. We showed for the first time, the involvement of an 
extracellular factor in a disorder clinically related to RASopathies, providing potential new leads 
for better understanding of the molecular basis of this family of developmental diseases. 
In Chapter 9, we discuss each previous chapter separately and provide an integrated view on the 




Dit proefschrift beschrijft het gebruik van de zebravis bij de studie van Noonan- (NS) en LEOPARD 
syndromen (LS). In de eerste drie hoofdstukken wordt achtergrondinformatie gegeven voor de 
zes hoofdstukken die daarop volgen. In Hoofdstuk 1 worden gastrulatie en de betrokken signaal-
transductie mechanismen in de vis besproken. Het gebruik van zebravissen om proteïne tyrosine 
fosfatasen (PTP) te bestuderen wordt besproken in Hoofdstuk 2. Er wordt een kort overzicht ge-
geven van eerdere studies naar PTPs die gebruik hebben gemaakt van de zebravis en de genetische 
instrumenten die beschikbaar zijn in de vis worden besproken. Bovendien wordt fosfoproteomica 
besproken als één van de methodes om PTPs in vivo te bestuderen. Hoofdstuk 3 beschrijft de rol 
van PTPN11 (proteïne tyrosine fosfatase, non-receptor type 11), het gen coderend voor SHP2, een 
cytoplasmatische PTP dat essentieel is voor de ontwikkeling van vertebraten. Mutaties in PTPN11 
worden geassocieerd met NS en LS, twee autosomale syndromen met overlappende symptomen. Ver-
rassend is dat NS mutaties leiden tot een ‘actieve’ vorm van SHP2 terwijl LS mutaties leiden tot een 
PTP-defecte vorm van SHP2. NS en LS patiënten vertonen verscheidene symptomen waaronder een 
kort postuur, craniofaciale defecten en hartafwijkingen. Het hart phenotype van NS en LS patiënten 
is vrij verschillend; terwijl NS patiënten vooral pulmonaire stenose (PS) vertonen, is hypertrofische 
cardiomyopathie (HCM) het meest voorkomende defect in LS patiënten.
In Hoofdstuk 4 hebben wij de zebravis als model gebruikt om de rol van Shp2 tijdens de embryonale 
ontwikkeling te bestuderen. We hebben in detail de rol van de twee ptpn11 isovormen (ptpn11a en 
ptpn11b) gekarakteriseerd. We laten zien dat ptpn11a constitutief tot expressie komt en dat ptpn11b 
sterk wordt opgereguleerd tijdens de ontwikkeling. Bovendien zijn de producten van beide ptpn11 
genen, Shp2a en Shp2b, functioneel. Gerichte inactivatie van ptpn11a en ptpn11b laat zien dat homo-
zygote mutanten lethaal zijn op dag 5-6 na fertilisatie (dpf). Ptpn11a-/- ptpn11b-/- embryo’s vertoon-
den verscheidene defecten vanaf 4dpf, waaronder een kortere lichaamsas en craniofaciale defecten, 
wat samen ging met verlaagde hoeveelheden gefosforyleerd Erk op 5dpf. Defecten in de homozygote 
ptpn11a-/- mutanten waren vergelijkbaar, hoewel milder, met defecten in de dubbel mutanten, ter-
wijl de ptpn11b-/- homozygote mutanten geen zichtbare ontwikkelingsdefecten vertoonden, levens-
vatbaar waren en vruchtbaar waren. Ptpn11a-/- ptpn11b-/- mutanten konden gered worden door 
expressie van exogeen ptpn11a en/of ptpn11b, wat impliceert dat Shp2a en Shp2b functioneel gelijk 
zijn.
In Hoofdstuk 5 beschrijven wij, met behulp van fosfoproteomica, de identificatie van Fer kinase als 
een stroomafwaarts eiwit dat betrokken is in de etiologie van NS en LS. Fosfotyrosine immunopre-
cipitatie van lysaten van zebravissen die geïnjecteerd zijn met wild type-, NS- of LS-Shp2, gevolgd 
door massa spectrometrie toonde een vermindering aan in NS en LS van een fosfopeptide wat cor-
respondeert met de tyrosine kinase Fer. Wij hebben laten zien dat Fer tot expressie komt in vroege 
embryo’s en dat verlies van Fer zorgt voor ontwikkelingsdefecten, waaronder convergentie en exten-
sie defecten. Gedeeltelijk verlies van Fer samen met lage expressie van NS en LS varianten van Shp2, 
maar niet met wild type Shp2 zorgde ook voor ontwikkelingsdefecten. In conclusie, het verlies van 
Fer draagt bij aan de NS en LS fenotypes in zebravissen. 
In Hoofdstuk 6 wordt een vergelijkbare aanpak gebruikt met muizenharten waarbij Protein Zero Re-
lated (PZR) als het meest gefosforyleerde eiwit in NS wordt geïdentificeerd. Verlies van PZR leidt tot 
gastrulatie defecten in zebravissen en fenotypes die vergelijkbaar zijn met verlies van Shp2 en met 
NS en LS. PZR is meer gefosforyleerd in diens immuunreceptor tyrosine remmende motieven (ITIMs) 
in verschillende weefsels en wij laten zien dat dit afhankelijk is van Src activering. Co-immuunprecip-
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itatie studies laten zien dat NS en LS Shp2 meer binden aan Src en PZR, waarmee een complex wordt 
gevormd. Bovendien laten wij zien dat de ITIMs, wat bindingsplaatsen zijn voor Shp2, essentieel zijn 
voor de inductie van het convergentie en extensie phenotype in de zebravis. In conclusie, NS en LS 
vormen een complex met Src en PZR wat leidt tot ontwikkelingsdefecten in de zebravis.
In Hoofdstuk 7 hebben wij de rol van de meest voorkomende NS en LS mutaties onderzocht tijdens 
de hartontwikkeling in de zebravis. Foutieve hartontwikkeling is een prominent symptoom van NS 
en LS, echter hoe de Shp2 varianten hartontwikkeling beïnvloeden is nog onduidelijk. Wij laten zien 
dat de hart functie van embryo’s die NS en LS varianten van Shp2 tot expressie brengen, aangetast 
is. De hartafwijkingen bestonden uit verminderde cardiomyocyte migratie, gekoppeld aan vermin-
derde linkswaartse hart verplaatsing. Expressie van lateraliteitsmarkeringen was gerandomiseerd 
in embryo’s die NS en LS varianten van Shp2 tot expressie brachten. Ciliogenese en cilia functie in 
Kupffer’s vesicule was verminderd, wat waarschijnlijk de oorzaak was van de links/rechts asym-
metrie defecten. Mitogeen geactiveerd eiwit kinase (Mapk) signalering was geactiveerd in embryo’s 
die NS en LS Shp2 varianten tot expressie brachten. Remming van Mapk signalering voor de aanvang 
van gastrulatie verminderde de cilia lengte- en hart lateraliteits defecten, wat suggereert dat NS en LS 
Shp2 varianten zorgen voor hyperactivatie van Mapk wat leidt tot verminderde cilia functie in Kup-
pfer’s vesicule wat zorgt voor hartdefecten op latere stadia.
Als laatste hebben wij de rol van Alpha-2-Macroglobulin-Like-1 (A2ML1) in een NS-gerelateerd synd-
room bestudeerd in Hoofdstuk 8. Tot op heden zijn alle bekende mutaties die NS veroorzaken domi-
nant en activeren de RAS/MAPK signaaltransductie route. Echter, in 25% van de gevallen blijft het 
genetische defect onbekend, wat suggereert dat andere factoren dan de standaard RAS/MAPK route 
ook een rol kunnen spelen. In onze studie hebben wij gebruik gemaakt van familie- gebaseerd exoom 
sequencing van een casus-ouder trio en hebben wij een de novo mutatie p.(Arg802His), gevonden 
in A2ML1 wat codeert voor de uitgescheiden protease remmer Alpha-2-Macroglobulin-Like-1. Het 
vervolgens uitlezen van A2ML1 in 155 gevallen met een klinische diagnose van NS leidde tot de iden-
tificatie van verdere mutaties in twee families, p.(Arg802Leu) and p.(Arg592Leu). Functionele karak-
terisatie van deze mutaties in zebravissen toonde NS-achtige ontwikkelingsdefecten aan, waaronder 
craniofaciale defecten en hartafwijkingen. De kristalstructuur van A2M, wat zeer homoloog is aan 
A2ML1, leidde ons tot de identificatie van de intramoleculaire interactiepartner van p.Arg802. Het 
muteren van dit residu, p.Glu906, induceerde vergelijkbare ontwikkelingsdefecten in zebravissen 
wat onze conclusie bevestigt dat mutaties in A2ML1 een stoornis veroorzaakt die klinisch vergelijk-
baar is met NS. Wij laten voor de eerste keer de betrokkenheid van een extracellulaire factor zien in 
een aandoening die klinisch gerelateerd is aan de RASopathies. Hierbij dragen wij potentiële nieuwe 
aanwijzingen aan voor een beter begrip van de moleculaire basis van deze familie van ontwikkel-
ingsstoornissen.
In Hoofdstuk 9 bediscussiëren wij elk vorig hoofdstuk apart en geven wij een overkoepelende blik 
op basis van de bevindingen van dit proefschrift.
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Riassunto in Italiano 
Questa tesi descrive l’uso di Danio Rerio nello studio della sindrome di Noonan-(NS) e di Leopard 
(LS). Nei primi tre capitoli, mettiamo a disposizione un background per i seguenti sei capitoli. Nel 
capitolo 1, discuteremo brevemente e in maniera concisa il processo di gastrulazione in zebrafish e 
i meccanismi di trasduzione del segnale ad essa associati. L’uso di zebrafish per studiare le proteine 
tirosina-fosfatasi “protein tyrosine fosfatase” (PTP) sarà discussa nel capitolo 2. In questo capitolo 
viene fornita  una rassegna sulla letteratura esistente riguardo alla definizione del ruolo delle PTP 
in zebrafish e saranno discusse le diverse metodologie genetiche utilizzate a questo scopo. Inoltre, 
descriveremo in dettaglio l’analisi fosfoproteomica come metodo per studiare PTP in vivo. Nel ca-
pitolo 3 descriveremo il ruolo del gene PTPN11 (proteina tirosina fosfatasi, non-ricettore tipo 11), 
che codifica SHP2, una PTP citoplasmatica essenziale per lo sviluppo dei vertebrati. Le mutazioni in 
PTPN11 sono associate con NS e LS, due patologie autosomiche dominanti con sintomi clinici comuni. 
Le mutazioni NS comportano uno stato più ‘attivo’ di Shp2, mentre mutazioni LS danno origine a una 
proteina con un dominio catalitico difettoso. Pazienti NS e LS presentano vari sintomi, tra cui difetti 
cranio-facciali e anomalie cardiache. È interessante notare che il fenotipo cardiaco dei pazienti NS e 
LS è differente; infatti i pazienti NS sono affetti da stenosi polmonare (PS), mentre la cardiomiopatia 
ipertrofica (HCM) è il difetto cardiaco più comune in LS. 
Nel Capitolo 4 descriveremo l’uso di zebrafish come modello per studiare il ruolo di Shp2 nello svi-
luppo embrionale. Abbiamo caratterizzato in dettaglio il ruolo delle due isoforme PTPN11 presenti in 
zebrafish (ptpn11a e ptpn11b)  dimostrando (concludendo?) che ptpn11a è espresso costitutivamen-
te e che l’espressione ptpn11b è più abbondante negli ultimi stadi di sviluppo embrionale. Inoltre, 
i prodotti di entrambi i geni PTPN11, Shp2a e Shp2b, sono funzionanti. L’inattivazione di ptpn11a 
e ptpn11b comporta la morte dei doppi mutanti ptpn11a-/-ptpn11b-/- entro 5-6 giorni dopo la fe-
condazione (dpf). Gli embrioni di questi doppi mutanti mostrano difetti pleiotropici da 4 dpf in poi, 
tra cui ridotta estensione dell’asse corporeo e difetti cranio-facciali, accompagnata da bassi livelli di 
fosforilazione di Erk a 5 dpf. È interessante notare che i difetti degli omozigoti ptpn11a-/- si sovrap-
pongono ai difetti dei doppi mutanti anche se questi difetti sono più lievi, mentre i singoli mutanti 
ptpn11b-/- non mostrano difetti di sviluppo e sono fertili e vitali. L’espressione esogena di ptpn11a 
e ptpn11b, riduce la severità del fenotipo dei doppi mutanti, indicando ridondanza funzionale tra 
Shp2a e Shp2b. 
Utilizzando approcci di fosfoproteomica, abbiamo identificato la kinasi ? Fer come proteina poten-
zialmente coninvolta a valle del signalling di shp2 e  nell’eziologia di entrambe le sindromi NS e LS 
(capitolo 5). Lisati proteici di embrioni di zebrafish iniettati con mRNA wild type, NS o LS Shp2, se-
guita da spettrometria di massa e arricchimento per proteine fosforilate, ha mostrato una riduzione 
nel picco di un fosfopeptide corrispondente alla tirosina chinasi Fer sia nella NS che nella LS. Abbia-
mo dimostrato che Fer è espresso negli stadi iniziali dello sviluppo embrionale e che la perdita di Fer 
si traduce in difetti di sviluppo, inclusi difetti di convergenza e di estensione. La perdita parziale di 
Fer coopera con la bassa espressione delle varianti NS e LS di Shp2, ma non con l’espressione Shp2 
wild-type. Quindi, la perdita di Fer contribuisce allo sviluppo dei fenotipi NS e LS in zebrafish.
Nel capitolo 6 descriveremo l’uso di un approccio simile a quello poc’anzi descritto ma applicato su 
cuori di topi NS. L’uso di questa metodologia ci ha portato  ad identificare la proteina PZR (protein 
zero related) come iper-fosforilata nella sindrome di Noonan (NS). Inoltre, la perdita di PZR compor-
ta sia difetti gastrulazione in zebrafish che un fenotipo che ricorda quello risultante dalla mancanza 
delle proteine Shp2, NS e LS. PZR risulta essere iper-fosforilata sulle sequenze ITIMs in diversi tessuti 
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e la sua fosforilazione è dipendente dalla attivazione di Src. Studi di co-immunoprecipitazione mo-
strano che NS e LS Shp2 si legano a Src e PZR, costituendo un complesso. Inoltre abbiamo dimostrato 
che le ITIMs sono siti di legame per Shp2 e sono essenziali per l’induzione della convergenza zebrafi-
sh ed estensione fenotipo. Così, NS e LS Shp2 formano un complesso con Src e PZR per indurre difetti 
dello sviluppo in zebrafish. 
Nel capitolo 7 abbiamo studiato il ruolo delle mutazioni più comuni nella NS e nella LS in zebrafish, 
durante lo sviluppo cardiaco. I difetti cardiaci sono un sintomo importante di entrambe le patologie, 
ma ancora non è chiaro come le varianti Shp2 influenzino lo sviluppo cardiaco. Abbiamo dimostrato 
che la funzionalità del cuore è compromessa in embrioni che esprimono NS e LS. Le anomalie car-
diache durante lo sviluppo di zebrafish consistono nella deregolazione della migrazione dei cardio-
miociti, insieme al ridotto movimento del cuore verso sinistra. L’espressione di marcatori specifici di 
lateralità è randomizzata (casuale?) negli embrioni che esprimono NS e LS Shp2. La funzione delle 
cilia nelle vescicole di Kupffer è compromessa, causando probabilmente i difetti di asimmetria sini-
stra / destra. Inoltre il signaling delle Mapk risulta iper-attivato negli embrioni che esprimono NS e LS 
Shp2. È interessante notare che l’inibizione della cascata delle Mapk prima della gastrulazione ripri-
stina la lunghezza delle cilia e annulla parzialmente il difetto cardiaco e di lateralità, suggerendo che 
NS e LS Shp2 possano mediare l’ iperattivazione delle Mapk portando a un’alterata funzione ciliare 
nelle vescicole di Kupffer e al difetto cardiaco successivo. 
Infine nel Capitolo 8, abbiamo studiato il ruolo di Alpha-2-Macroglobulina-Like-1 (A2ML1) nella NS. 
Fino ad oggi, tutte le mutazioni note che causano la NS sono dominanti e comportano un’iperattiva-
zione della via di segnalazione RAS/ MAPK. Tuttavia nel 25% dei casi, la causa genetica di NS rimane 
sconosciuta, suggerendo che altri fattori, oltre quelli coinvolti nella canonica via RAS/MAPK, possa-
no svolgere un ruolo. In questo capitolo, abbiamo utilizzato il sequenziamento dell’esoma (cos’è?) 
basandoci su un trio (??) familiare e abbiamo identificato una mutazione de novo, p. (Arg802His), in 
A2ML1 che codifica per l’inibitore della proteasi alfa-2-Macroglobulina-Like-1. Il successivo sequen-
ziamento di A2ML1 in 155 casi con una diagnosi clinica di NS ha portato all’identificazione di muta-
zioni aggiuntive in due famiglie, p. (Arg802Leu) e p. (Arg592Leu). La caratterizzazione funzionale 
di queste mutazioni A2ML1 umani in zebrafish ha mostrato difetti di sviluppo NS-like, tra cui difetti 
cranio-facciali e malformazioni cardiache. La struttura cristallografica di A2M, altamente omologa 
ad A2ML1, ci ha portato all’identificazione del partner di interazione intramolecolare p.Arg802. La 
mutazione di questo residuo, p.Glu906, induce difetti di sviluppo simili in zebrafish, rafforzando la 
nostra conclusione che le mutazioni in A2ML1 causano una malattia clinicamente correlata alla NS. 
In questa tesi, abbiamo dimostrato per la prima volta, il coinvolgimento di un fattore extracellulare 
in un disturbo clinicamente correlato alle RASopatie, fornendo una migliore comprensione della base 
molecolare di questa famiglia di malattie. 
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A2ML1    Alpha 2 Macroglobulin like 1
C&E        Convergence and Extension
CRISPR  Clustered Regularly Interspaced Short Palindromic Repeat
DFC  Dorsal Forerunner Cell
DORV  Double Outlet Right Ventricle
DPF  Days Post Fertilization
ECM  Extracellular Matrix
ENU  N-ethyl-N-nitrosourea
EVL        Enveloping Layer Cells
FER  Fps/Fes related
HCM       Hypertrophic Cardiomyopathy
HPF         Hours Post Fertilization
ISH  In Situ Hybridization
ITIM      Immunoreceptor Tyrosine-based Inhibitory Motif 
KV          Kupffer’s Vesicle
LEOPARD Lentigines, Electrocardiographic conduction abnormalities, Ocular   
  hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retarded   
  growth, Deafness: Sensorineural
LPM        Lateral Plate Mesoderm
LS           LEOPARD Syndrome
MO  Morpholino
MPZL1  Myelin Protein Zero Like 1
MS  Mass Spectrometry
NIC  Non Injected Control
NS          Noonan Syndrome
PS          Pulmonary Stenosis
PRR        Proline Rich Region
PTK  Protein Tyrosine Kinase
PTP        Protein Tyrosine Phosphatase
PTPN11  Tyrosine-protein phosphatase non-receptor type 11 
PZR        Protein Zero Related
RTK  Receptor Tyrosine Kinase
SFK  Src Family Kinase
SH2        Src Homology 2
SHP2  Src Homology 2-containing protein-tyrosine-phosphatase 2
Spaw      Southpaw
TALEN  Transcription Activator Like Effector Nuclease
TSGI  Target Selected Gene Inactivation
VSD  Ventricle Septal Defect
YSL        Yolk Syncytial Layer 
ZFN  Zinc Finger Nuclease
